

FOIA MARKER

This is not a textual record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

Collection/Record Group: Clinton Presidential Records
Subgroup/Office of Origin: National AIDS Policy Office
Series/Staff Member: Patsy Fleming
Subseries: National AIDS Strategy

OA/ID Number: 9004
FolderID:

Folder Title:
ONAP [Office of National AIDS Policy] Review 7/22/96 [4]

Stack:	Row:	Section:	Shelf:	Position:
S	66	5	10	1

INTERNATIONAL ACTIVITIES

AIDS is a global pandemic. In the United States it is estimated that between ^{600,000} ~~800,000~~ ^{900,000} and ~~1 million~~ people are currently infected with HIV. The World Health Organization (WHO) estimates that 18.5 million adults and over 1.5 million children are currently infected worldwide and there will be 10 to 15 million orphans worldwide attributable to HIV/AIDS by the year 2000. WHO also estimates that two to three million new HIV infections can be expected annually, and by the year 2000, thirty to forty million people will have been infected around the globe.

The pandemic jeopardizes decades of economic and social advances in many developing nations. In Africa and Asia, economic advances are threatened, and in some cases, may be reversed due to the pandemic of HIV and AIDS. Socio-economic studies have shown a decrease in overall domestic savings and investment levels, negative effects on foreign investments, reductions in the volumes of imports and exports, and a reduction in receipts from tourism.²⁸ In many countries, governments will be forced to cope with increasing numbers of cases, weakened health care systems, a deleterious economic impact on the most productive segments of society, and the reduction in the number of healthy men and women able to serve in the government and the military.

At present several Federal Agencies are working at slowing the AIDS epidemic internationally. (See Appendix D.) The Department of State has worked with other Departments, Agencies, and non-governmental organizations to develop a framework to guide U.S. foreign policy in the global efforts against HIV and AIDS. The major areas identified for U.S. leadership are: preventing new infections; reducing the personal, and social impact of the pandemic; and mobilizing and unifying^{ing} national and international efforts. The U.S. Agency for International Development (USAID) also has a leadership role in the global HIV effort through development assistance, research and policy formation. USAID focuses its strategy on developing prevention programs based on proven interventions, addressing social, cultural, regulatory and economic issues related to HIV/AIDS and other sexually transmitted infections, and developing and testing new interventions and methods to prevent transmission and mitigate the impact of the epidemic. The U.S. Information Agency (USIA) supports programs that promote dissemination of U.S. policies and information related to HIV and AIDS; and the Peace Corps trains a portion of its volunteers to directly address HIV-related concerns in their countries of placement. In addition, several Agencies support research overseas, including the National Institutes of Health, the Centers for Disease Control and Prevention, and the Department of Defense (DOD). The DOD is conducting clinical trials of candidate

DOD
or DOD -
do a search

HIV vaccines in Thailand and NIH (working in collaboration with USAID), supports basic scientific studies on social and behavioral aspects of AIDS in developing countries. The results of the studies ultimately will be used to develop interventions to reduce behaviors that place individuals at risk for contracting HIV infection.

Opportunities for Progress

International Leadership. The United States has established a global leadership role in combatting the epidemic. This leadership must continue. The U.S. strongly supports the newly established Joint and Co-sponsored United Nations Programme on AIDS (UNAIDS).²⁹ Moreover, the U.S. is a member of the governing body of UNAIDS.

The U.S. also supports efforts to more effectively make use of available resources as well as to encourage non-traditional donor countries to provide much needed contributions. Supporting UNAIDS ^{and} ~~and~~ its innovative programmatic efforts, and its goal of working to increase the availability of therapeutics (and vaccines when developed) to the residents of developing countries is not only morally correct, but also furthers U.S. interests by promoting economic and social stability worldwide.

Sharing Technology and Bringing Lessons Home. In addition to financing the development of large scale, comprehensive AIDS prevention programs in many countries, USAID has gained valuable insights and lessons from experiences from these countries and is applying them to U.S. populations.

7 Based on the "Lessons without Borders Project" initiative brings
P lessons learned abroad home to inner city and rural areas with problems similar to those experienced overseas. This initiative creates linkages between U.S. community organizations and international projects. The U.S., through its various Agencies will continue to build and strengthen networks that will facilitate leadership, coordination and transnational approaches to AIDS prevention and control programs and AIDS related research; exchange culturally and linguistically appropriate educational and training materials; and demonstrate the bidirectionality of USAID international programs and its potential impact on US-based programs, and U.S. based non-governmental organizations.

Program Coordination. One of the most challenging aspects of the U.S. effort is effective coordination among a host of Agencies with varied missions and activities. The State Department and Agencies such as USAID and USIA are primarily focused on country-specific activities, that include many HIV-related objectives. Other

Agencies, such as NIH and CDC, also support international activities.

These differences in focus present challenges in effectively planning, coordinating, and evaluating the overall U.S. international effort. Therefore, in order to improve this endeavor, the Agencies supporting international activities must develop a mechanism for identifying and coordinating this effort.

TRANSLATION OF RESEARCH INTO PRACTICE

An important element in our fight against AIDS is ensuring that hard won research advances are translated into practice (i.e., ensuring that new knowledge is incorporated into the standard practice of clinicians, service providers, and health educators caring for persons living with HIV). The increasing presence of HIV in every community necessitates that all health care providers become knowledgeable about assessing risk, promoting prevention, and caring for persons with HIV.

Improving the translation of research advances into daily clinical practice will require an ongoing collaborative effort on the part of the Federal government, individual health care providers, medical schools, professional organizations, international organizations, health centers and hospitals, and other parts of the private sector.

Information dissemination activities fall under the missions of several Agencies. (See Appendix E.) The National Institutes of Health (NIH) supports a broad range of efforts including a "Clinical Alerts" mechanism for the dissemination of clinical trials results to health professionals, the media, and the general public. DHHS supports and directs the International HIV/AIDS

Clinical Conference Call series⁵ which disseminates critical, state-of-the-art clinical care information to primary care providers via live worldwide audio tele-conferencing. NIH also supports publicly available computerized databases such as AIDSDRUGS, AIDSTRIALS, and AIDSLINE. In addition the toll-free 1-800 TRIALS-A AIDS Clinical Trials Information Service (ACTIS) is co-sponsored by NIH, CDC, and FDA. The Centers for Disease Control and Prevention (CDC) disseminates information through hotlines such as its toll-free 1-800-HIV-0440 HIV/AIDS Treatment Information Service (ATIS) and the AIDS Information Clearinghouse.

The CDC also issues guidelines for health professionals through its^S *Morbidity and Mortality Weekly Report*; such guidelines have included The U.S. Public Health Service Recommendations for HIV Counseling and Voluntary Testing for Pregnant Women. The Agency for Health Care Policy and Research (AHCPR) has published a series of HIV-related clinical practice guidelines for clinicians and companion pamphlets for their patients; an example of these materials is clinician guidelines for the evaluation and management of early HIV infection. The Health Resources and Services Administration has also developed guidances for its CARE Act grantees, funds an AIDS warmline that responds to questions from clinicians across the country, and directs a nationwide system of AIDS Education and Training Centers that provide state of the art

HIV clinical information to health care providers.

Opportunities for Progress

Due in part to Federally-sponsored information dissemination activities, dramatic changes in the way HIV is treated have taken place over the last 15 years. However, despite these successes, there are still areas for improvement. For example, an AHCPR-supported study indicated that primary care physicians may miss significant HIV-related symptoms during patient examinations.³⁰ Other research indicates that a disturbing number of clinicians do not use universal precautions in the course of routine patient care.³¹

We are also at a stage in the epidemic where research advances are coming frequently. In the case of the NIH study that demonstrated it is possible to block perinatal transmission by administering a specific AZT regimen to the mother and baby, it became clear that this scientific breakthrough required a change in the standard of care and action by a number of Federal Agencies. This change also required the development of new testing and counseling guidelines to reflect the new options available to women. And it meant that for patients enrolled in Medicaid and Medicare to receive access to this therapeutic regimen, a policy change on the part of the Health

Care Financing Administration (HCFA) was required.

State of the Art Guidelines. One of the most difficult tasks for clinicians and patients is interpreting the patchwork of data and articles regarding treatments and converting it into a therapeutic strategy for their patients. With every research breakthrough, this task becomes more difficult. It is essential that practical information for practicing clinicians and their patients be provided in a timely manner.

The Federal government currently supports a number mechanisms for periodically assessing advances in clinical care. It is essential that these assessment efforts continue and that crucial information ^{be} ~~is~~ widely disseminated. This will require collaboration with industry, government, and professional groups.

Coordination of Federal Activities. Enhancing coordination of information dissemination activities among Public Health Service Agencies is an important priority. Within the DHHS, the Office of HIV/AIDS Policy (OHAP) has the lead responsibility for coordinating the HIV-related activities of the Public Health Service Agencies. Ensuring that information about a research breakthrough is easily available, reaches the appropriate persons and organizations, and that policies and standard-of-care practices for Federally-

sponsored programs are modified to reflect the new standard, requires a continued high level of cooperation and coordination among Public Health Service Agencies.

Improved information dissemination efforts are also needed in the area of primary prevention models. As noted in the prevention section, models of effective prevention interventions have been developed, but often this valuable information is not reaching those persons developing, implementing, and evaluating prevention programs. Here again, the Public Health Service must take the lead in ensuring that information that can be used to stem the tide of new infections reaches those who can make a difference.

TRANSLATION OF RESEARCH INTO PRACTICE

An important element in our fight against AIDS is ensuring that hard won research advances are translated into practice (i.e., ensuring that new knowledge is incorporated into the standard practice of clinicians, service providers, and health educators caring for persons living with HIV). The increasing presence of HIV in every community necessitates that all health care providers become knowledgeable about assessing risk, promoting prevention, and caring for persons with HIV.

Improving the translation of research advances into daily clinical practice will require an ongoing collaborative effort on the part of the Federal government, individual health care providers, medical schools, professional organizations, international organizations, health centers and hospitals, and other parts of the private sector.

Information dissemination activities fall under the missions of several Agencies. (See Appendix E.) The National Institutes of Health (NIH) supports a broad range of efforts including a "Clinical Alerts" mechanism for the dissemination of clinical trials results to health professionals, the media, and the general public. DHHS supports and directs the International HIV/AIDS

Clinical Conference Call series which disseminates critical, state-of-the-art clinical care information to primary care providers via live worldwide audio tele-conferencing. NIH also supports publicly available computerized databases such as AIDSDRUGS, AIDSTRIALS, and AIDSLINE. In addition the toll-free 1-800 TRIALS-A AIDS Clinical Trials Information Service (ACTIS) is co-sponsored by NIH, CDC, and FDA. The Centers for Disease Control and Prevention (CDC) disseminates information through hotlines such as its toll-free 1-800-HIV-0440 HIV/AIDS Treatment Information Service (ATIS) and the AIDS Information Clearinghouse.

The CDC also issues guidelines for health professionals through its *Morbidity and Mortality Weekly Report*; such guidelines have included The U.S. Public Health Service Recommendations for HIV Counseling and Voluntary Testing for Pregnant Women. The Agency for Health Care Policy and Research (AHCPR) has published a series of HIV-related clinical practice guidelines for clinicians and companion pamphlets for their patients; an example of these materials is clinician guidelines for the evaluation and management of early HIV infection. The Health Resources and Services Administration has also developed guidances for its CARE Act grantees, funds an AIDS warmline that responds to questions from clinicians across the country, and directs a nationwide system of AIDS Education and Training Centers that provide state of the art

HIV clinical information to health care providers.

Opportunities for Progress

Due in part to Federally-sponsored information dissemination activities, dramatic changes in the way HIV is treated have taken place over the last 15 years. However, despite these successes, there are still areas for improvement. For example, an AHCPR-supported study indicated that primary care physicians may miss significant HIV-related symptoms during patient examinations.³⁰ Other research indicates that a disturbing number of clinicians do not use universal precautions in the course of routine patient care.³¹

We are also at a stage in the epidemic where research advances are coming frequently. In the case of the NIH study that demonstrated it is possible to block perinatal transmission by administering a specific AZT regimen to the mother and baby, it became clear that this scientific breakthrough required a change in the standard of care and action by a number of Federal Agencies. This change also required the development of new testing and counseling guidelines to reflect the new options available to women. And it meant that for patients enrolled in Medicaid and Medicare to receive access to this therapeutic regimen, a policy change on the part of the Health

Care Financing Administration (HCFA) was required.

State of the Art Guidelines. One of the most difficult tasks for clinicians and patients is interpreting the patchwork of data and articles regarding treatments and converting it into a therapeutic strategy for their patients. With every research breakthrough, this task becomes more difficult. It is essential that practical information for practicing clinicians and their patients be provided in a timely manner.

The Federal government currently supports a number of mechanisms for periodically assessing advances in clinical care. It is essential that these assessment efforts continue and that crucial information is widely disseminated. This will require collaboration with industry, government, and professional groups.

Coordination of Federal Activities. Enhancing coordination of information dissemination activities among Public Health Service Agencies is an important priority. Within the DHHS, the Office of HIV/AIDS Policy (OHAP) has the lead responsibility for coordinating the HIV-related activities of the Public Health Service Agencies. Ensuring that information about a research breakthrough is easily available, reaches the appropriate persons and organizations, and that policies and standard-of-care practices for Federally-

sponsored programs are modified to reflect the new standard, requires a continued high level of cooperation and coordination among Public Health Service Agencies.

Improved information dissemination efforts are also needed in the area of primary prevention models. As noted in the prevention section, models of effective prevention interventions have been developed, but often this valuable information is not reaching those persons developing, implementing, and evaluating prevention programs. Here again, the Public Health Service must take the lead in ensuring that information that can be used to stem the tide of new infections reaches those who can make a difference.

CIVIL RIGHTS

One of the Nation's common goals is to ensure that services provided to persons living with HIV caring, ethical, and in accordance with legal standards. Discrimination based on HIV status is illegal and morally wrong.

Discrimination undermines the Nation's efforts to prevent and treat HIV infection and bring the epidemic under control. Because of fear of discrimination and stigma, many people do not voluntarily seek testing for HIV, remain unaware of their HIV status, consequently do not take advantage of care that could help them live longer, healthier lives. In addition, opportunities to educate people are lost. Discrimination can also wrongfully deny persons access to housing, insurance, employment, and health care.

The Federal government and some States have enacted laws that protect persons with HIV from discrimination on the basis of their infection. Many of the more common legal issues faced by people living with HIV and AIDS, such as family law issues, estate planning, landlord/tenant problems are regulated by State law.

The primary source of Federal statutory protection for people living with HIV is the Americans with Disabilities Act of 1990

(ADA). Title I of the ADA prohibits discrimination against qualified disabled individuals in employment settings. The Equal Employment Opportunity Commission (EEOC) is responsible for enforcing Title I. Title II of the ADA prohibits discrimination on the basis of disability with regard to public services while Title III prohibits discrimination on the basis of disability in public accommodations. The Department of Justice (DOJ) is responsible for enforcing Titles II and III. In addition, the Department of Health and Human Service's (DHHS) Office of Civil Rights (OCR) is responsible for implementing portions of the ADA, including investigating and resolving Title II complaints of discrimination by health care and social service programs.

Federal Agencies and recipients of Federal funds are prohibited from discriminating against people with disabilities under Section 504 the Rehabilitation Act of 1973. The DHHS' Office of Civil Rights is also responsible for enforcing Section 504 as it pertains to recipients of DHHS funds such as hospitals, nursing homes, and social service agencies. The Health Care Financing Administration (HCFA) also enforces regulations regarding the treatment of HIV-infected persons.

Opportunities for Progress

Enforcement of Federal Laws. The Federal government has aggressively and successfully prosecuted private sector violations of the ADA. These efforts will continue. Under this provision the government has been extremely successful in prosecuting a range of cases, including those against clinicians who have refused to care for HIV-positive patients and employers who have dismissed persons based on their actual or perceived HIV status. In addition to ongoing efforts, a joint Department of Justice and Health and Human Services program will seek to combat nursing home discrimination against persons living with AIDS.

Federal Policies. The Federal government must also actively work to remedy any of its own existing discriminatory policies. The Director of the Office of National AIDS Policy is working with Federal Agencies to ensure that HIV testing programs follow the recommendations of public health professionals. The Administration will also continue to oppose Congressional attempts to force discharge of infected military personnel who are still able to serve their country.

Leadership. The United States has made progress in fighting discrimination. However, the enactment of laws is insufficient to end discrimination. As a Nation we need to be vigilant and vocal in our efforts to fight discrimination. This is a responsibility

that must be shared among Federal Agencies, States, communities,
and the citizens of this country.

Footnotes

1. *Morbidity and Mortality Weekly Report*. U.S. Department of Health and Human Services, Public Health Service. November 24, 1995, vol. 44, No. 46.
2. Communication, Department of Labor.
3. For 5 years of care after initial heart attack. Source: *American Journal of Cardiology*, 1990.
4. Depending on stage diagnosed -- early or late. Source: Swartz & Rollins, *Business and Health*, 1985, 85, 24-6.
5. *Journal of the American Medical Association*, July 28, 1993. Add page number/complete reference.
6. The Public Health Service Agencies within DHHS with responsibility for a range of activities and programs associated with the HIV epidemic are: the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Health Resources and Services Administration (HRSA), the Agency for Health Care Policy and Research (AHCPR), the Food and Drug Administration (FDA), and the Indian Health Service (IHS). Information regarding these agencies can be found in the Appendices.
7. Public Health Service Plan for the Prevention and Control of Acquired Immune Deficiency Syndrome (AIDS), Public Health Reports 100:453-455, September-October, 1985.
8. Coolfont Report. A PHS plan for the Prevention and Control of AIDS and the AIDS Virus. Public Health Reports 101:341-348, July-August 1986.
9. Report of the Second Public Health Service AIDS Prevention and Control Conference. Public Health Reports. Vol. 103 Supplement No.1 (Revised). 1988.
10. The Public Health Service Strategic Plan to Combat HIV & AIDS in the United States. U.S. Department of Health and Human Services. 1992.

11. AIDS: An Expanding Tragedy. The Final Report of the National Commission on AIDS. Washington, DC. 1993.
12. This section will address primary prevention activities. Other aspects of prevention, such as secondary prevention (i.e., preventing complications of HIV infection), development of topical microbicides, the behavioral components of vaccine research, and international prevention activities will be discussed in the following research, care and services, and international activities sections.
13. External Review of HIV Prevention Strategies by the CDC Advisory Committee on the Prevention of HIV Infection. U.S. Department of Health and Human Services, Public Health Service. June 1994.
14. Information on NIH-supported behavioral and epidemiological research relevant to primary prevention can be found in Appendix B: Research.
15. *AIDS and Behavior: An Integrated Approach*. Judith D. Auerbach, Christina Wypijewska, and H. Keith H. Brodie, Editors. Institute of Medicine, National Academy Press, Washington, D.C., 1994. p.79.
16. *AIDS and Behavior: An Integrated Approach*. Judith D. Auerbach, Christian Wypijewska, and H. Keith H. Brodie, Editors. Institute of Medicine. National Academy Press. Washington, DC. 1994.
17. *AIDS and Behavior: An Integrated Approach*. Judith D. Auerbach, Christian Wypijewska, and H. Keith H. Brodie, Editors. Institute of Medicine. National Academy Press. Washington, DC. 1994.
18. JAMA article used in PRIM&R speech
19. Don C. Des Jarlais, Holly Hagan, Samuel R. Friedman, Patricia Friedmann, David Goldberg, Martin Frischer, Steven Green, Kerstin Tunving, Bengt Ljungberg, Alex Wodak, Michael Ross, David Purchase, Margaret E. Millson, Ted Myers. Maintaining Low HIV Seroprevalence in Populations of Injecting Drug Users. JAMA, October 18, 1995 -- Vol. 274, No. 15. pp 1226-1231.
20. Heiner Grosskurth, Frankc Mosha, James Todd, Extra Mwijarubi, Arnould Clokke, Kesheni Senkoro, Philippe Mayaud, John Changalucha, Angus Nicoll, Gina ka-Gina, James Newell, Kokuugonza Mugeye, David Mabey, Richard Hayes. Impact of Improved Treatment of Sexually Transmitted Diseases on HIV Infection in Rural Tanzania: Randomized Controlled Trial. The Lancet, Vol. 346, August 26, 1995.

21. Maria Wawer, Science. 9.08.95, vol. 269, No. 5229
22. Personal communication from CDC Division TB Elimination.
23. Epidemiology of Tuberculosis, Self-Study Module on Tuberculosis, Module Number 2, Division of Tuberculosis, Nation Center for HIV, STD, and TB Prevention, the Centers for Disease Control and Prevention.
24. This section focus primarily on biomedical and health services research. Discussion of behavioral and social science research is presented in the Prevention section.
25. Alan B. Stone, and Penelope J. Hitchcock. Vaginal Microbicides for Preventing the Transmission of HIV. AIDS 1994, 8 (suppl 1):S285-S293.
26. The accelerated approval regulation permits companies to seek approval of drugs for serious or life-threatening diseases when the drug provides meaningful therapeutic benefit over existing therapies. Under these procedures, the FDA may approve drugs based on surrogate endpoints, such as CD4+ cell counts that reasonably predict that a drug provides clinical benefit. The company is then required to confirm this clinical benefit through additional human studies to be completed after marketing approval. The accelerated approval regulation provides for removal of the drug from the market if further studies do not confirm the clinical benefit of the therapy.
27. Housing and the HIV/AIDS Epidemic: Recommendations for Action. National Commission on AIDS. Washington, D.C. July 1992.
28. *HIV/AIDS Policy Guidance*. U.S. Agency for International Development. September 1995.
29. Until recently, the United Nations' response to HIV/AIDS was carried out primarily by the World Health Organization's Global Programme on AIDS. On January 1, 1996 the U.N. launched UNAIDS, co-sponsored by six U.N. agencies to strengthen coordination and focus support for HIV/AIDS activities at the global and country levels. UNAIDS has established three mutually reinforcing roles: to be a major source of policy development and research; provide technical support; and be an advocate for comprehensive, multisectoral responses to the pandemic.
30. Douglas S. Paauw, Marjorie D. Wenrich, J. Randall Curtis, Jan D. Carline, Paul G. Ramsey. Ability of Primary Care Physicians to Recognize Physical Finding Associated with HIV Infection. *JAMA*. 1995; 274:1380-1382.

31. Colombotos, J., Messeri, P., McConnell, M.B., et al: Physicians, Nurses, and AIDS: Findings From a National Study. Rockville, MD: Agency for Health Care Policy and Research; 1995. Grant No. HS06359. (NTIS Publication PB95-129185)

***The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96***

Agency: Department of Defense

Goal: Preservation of an effective fighting force through prevention of HIV infection.

Objective 1: Prevent HIV infection in service members.

Reduce the number of new active duty HIV infection by 20 percent by 1997 based on a 1995 baseline figure of 204 persons for all services.

Action Steps: Provide basic information on HIV transmission and risk reduction for new recruits, civilian work force members, and officers;

Require education and general military training on methods of transmission and approaches for avoiding transmission, including barrier methods, avoidance of intravenous drug use, and use of universal precautions;

Provide training for personnel, instructors, and peer educators; and

Support train the trainer courses to develop multidisciplinary teams from medical, dental, nursing, and public health corps for promoting HIV and AIDS education.

Objective 2: Ensure safety of the Armed Services Blood Program Office (ASBPO).

Action Steps: Advise service personnel with serologic evidence of HIV infection or repeated ELISA reactivity, but Western Blot negative or indeterminate, to refrain from donating blood.

Employ ASBPO "Look Back Program" to trace contacts of identified positive donors who serconvert after blood donation -- trace and contact blood recipients.

FY 95: Approximately \$500,000

FY 96: Approximately \$500,000

FY 97: Approximately \$500,000

Populations Served: Active duty service members and their eligible family members, health care providers and those at risk of exposure to body fluids, and recipients of ASBPO blood products.

Constituency Involvement: Active duty force, affiliated civilian

workforce, and the health care and public health communities.

Unmet Need: None

***The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96***

Agency: Department of Education

Goal: To disseminate information on Department of Education (ED) Programs in coordination with other Federal agencies.

Objective 1: Fund AIDS prevention initiatives as part of the overall grant budget through the comprehensive school health program.

Action Steps: Coordinate and share information with CDC-sponsored National AIDS Clearing House;

Include information related to school-based comprehensive health programs (ED funded) in the Comprehensive Health Information Database (HHS).

Descriptions: A broad range of programs are supported; for example, including the Foundation For Children With AIDS, Duke University Medical Center, and University of CA Disability Statistics Rehabilitation Research and Training Center.

FY 95: Part of overall operating budget.

FY 96: Part of overall operating budget.

FY 97: Part of overall operating budget.

Populations Served: Elementary and secondary students, teachers and parents through health education curricular, preservice, and inservice training and parental involvement programs.

Constituency Involvement: The majority of ED programs are developed at local level and therefore there is little involvement of constituency groups at the Federal level.

Unmet Need: Many groups are unaware that resources are available to assist them. Increased funding would assist in improved information dissemination.

Objective 2: Fund AIDS prevention information dissemination efforts, underscoring the link between drug and alcohol use and HIV risk behaviors, as part of the overall program plan for Safe and Drug-Free Schools National Programs.

Action Steps: Using existing survey data, identify informational gaps;

Coordinate with the CDC on the School Health Information Planning Program (SHIPPP);

*The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96*

Identify public and private agencies and groups that have developed HIV-related materials appropriate for school-based programs;

Catalog and distribute information on these resources;

Establish process to inform schools about resources available to address HIV/AIDS education and prevention;

Provide schools with information on Federal resources;

Prepare publication on the relationship between HIV/AIDS to drug use;

Meet with the National Coordinating Committee and the Interagency Committee on School Health to assist in identifying areas of need and publicizing the availability of resources.

Descriptions: Identify and disseminate information and information resources.

FY 95: Part of overall operating budget.

FY 96: Part of overall operating budget.

FY 97: Part of overall operating budget.

Populations Served: Elementary and secondary students, teachers and parents through health education curricular, preservice, and inservice training and parental involvement programs.

Constituency Involvement: The majority of ED programs are developed at local level and therefore there is little involvement of constituency groups at the Federal level.

Unmet Need: Many groups are unaware that resources are available to assist them. Increased funding would assist in improved information dissemination.

***The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96***

Agency: Department of Health and Human Services, the Agency for Health Care Policy and Research

Goal: To provide national estimates of the cost and use of HIV-related prevention services.

Objective 1: To examine the effects of an in-home computer information and support system on health care costs and quality of life.

Action Steps: Half of three hundred patients with advanced HIV infection are provided with in-home computer system; the other half receive no intervention. Effects of this system are assessed with respect use of prophylactic treatments, early detection of infections, and quality of life.

Descriptions: Demonstrating Computer Support Impact on AIDS Patients

FY 95: \$704,655

FY 96: \$56,453

FY 97: \$0

Populations Served: 300 volunteers with advanced HIV infection.

Constituency Involvement: Persons with HIV

Unmet Need: None.

Objective 2: Evaluate the cost-effectiveness of alternative strategies for preventing HIV-related opportunistic infections.

Action Steps: Embed clinical and cost data from randomized trials and observational cohorts into a comprehensive decision-analytic, cost-effectiveness model.

Descriptions: Cost-Effectiveness of Preventing AIDS Complications.

FY 95: \$346,420

FY 96: \$21,020

FY 97: \$0

Populations Served: Persons with HIV.

Constituency Involvement: N/A

Unmet Need: None.

Agency: Department of Health and Human Services, the Centers for Disease Control and Prevention

Goal: To more accurately monitor the HIV epidemic and provide data to assess and direct prevention programs by strengthening existing systems and develop new surveillance systems.

Objectives: Implement projects that evaluate and expand the uses of HIV infection and AIDS case surveillance and sero-surveillance data so that these data systems can more effectively guide public health policy and provide relevant information necessary to direct and evaluate prevention activities.

Improve understanding of the natural history of HIV infection as well as the risk factors and protective factors for sexual, drug-related, perinatal, and healthcare worker related HIV transmission in order to develop more effective prevention strategies for all affected populations.

Action Steps: Evaluate HIV infection reporting systems (named, anonymous, unique identifier) used nationally for their ability to monitor the epidemic, provide linkages to medical and social services, and to assess their impact on a person's decision to be tested;

Characterize high risk behaviors of persons with evidence of recent HIV infection such as persons with documented HIV seroconversion, high CD4+ counts, or diagnosis of HIV infection in adolescents;

Assess the impact of public health guidelines and recommendations and prevention efforts;

Characterize persons co-infected with TB and HIV;

Evaluate ways to improve the completeness and quality of risk ascertainment on persons reported with HIV and AIDS;

Identify and characterize previously unreported AIDS cases among deaths investigated by local medical examiners to assess the impact of under-diagnosis of AIDS cases on AIDS surveillance among disadvantaged populations that often do not receive adequate health care;

Test the efficiency of new techniques for reporting HIV and AIDS surveillance data from health care providers and laboratories to health departments;

The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96

Collect additional data on persons reported through HIV/AIDS surveillance which may be important for the planning and evaluation of prevention and care programs, such as social/economic status, levels of disabilities, drug use history, sex behavior history, utilization of HIV testing and medical care services, and reproductive history in women;

Assess the interrelationship of behaviors, HIV markers and surrogates, and their potential role in surveillance systems;

Assess the interaction of socioeconomic, behavioral, and biologic factors in HIV transmission;

Determine the role of female-specific biological factors that are linked to acquisition and transmission of HIV infection and that influence the course of HIV disease;

Determine factors contributing to the efficiency of sexual transmission of HIV;

Assess the risk of transmission of HIV and TB from HIV-infected health-care worker to patient and vice versa;

Develop systems to monitor the emergence of multidrug-resistant TB in the HIV infected;

Continue to develop improved methods for projecting or modeling the HIV epidemic;

Develop methods to differentiate HIV-specific antibodies generated in participants in HIV vaccine trials from those generated in response to HIV infection;

Develop methods to identify potential cases of HCW-to-patient transmission;

Expand HIV reporting systems to collect information about primary and secondary HIV prevention services needed and received by HIV-positive clients (in collaboration with HRSA);

Work with providers and users of lab services to develop & implement systems which provide assurance that the capacity and quality requirements for HIV testing are met;

Work with international partners to study TB, implement vaccine trials, enhance clinical management, assess prevention efficacy, and improve program management of HIV/AIDS.

***The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96***

Develop methods to evaluate the use of HIV infection and AIDS surveillance systems to assess early intervention strategies.

Descriptions: Many of the activities in the above-cited action steps are carried out through cooperative agreements with state and local health departments. In addition, specialized projects and studies also serve to focus attention on these activities, these include: Evaluation of HIV Infection Reporting Systems Project, Recent HIV Infection Projects, Surveillance to Evaluate Prevention Projects, Adult Spectrum of Disease Project, the TB Project, Mode of Transmission Validation Project, the Medical Examiner Study, and the Enhancement of AIDS Surveillance Efficiency Project.

FY 95: \$141,046,000

FY 96: \$139,668,000

FY 97: \$139,778,000

Populations Served: All major racial, ethnic, and risk groups.

Constituency Involvement: There is regular consultation with national, state, and local public health officials and many other relevant organizations such as HIV-related community-based organizations.

Unmet Need: The current system does not provide for adequate surveillance of risk behaviors that contribute to HIV transmission, nor does it provide an accurate means for monitoring HIV incidence.

***The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96***

Agency: Department of Health and Human Services, the Centers for Disease Control and Prevention

Goal: To increase the public understanding of, involvement in, and support for HIV prevention.

Objectives: Provide leadership in HIV and STD prevention by (1) establishing sustained and active national agenda through the media; (2) promoting credible messages based on science through credible channels; and (3) encouraging and supporting prevention efforts at the local level.

Establish a collaboration of partners composed of national, State, and local organizations to facilitate (1) diffusing social marketing principles applied to HIV and STD prevention at the local level; (2) identifying and promoting mechanisms to exchange technology and information; and (3) developing guidelines for applying social marketing principles to local HIV and STD prevention.

Apply social marketing principles at the local level for the purpose of (1) demonstrating the participatory social marketing process (i.e., skills and resources needed to effectively engage the community); (2) measuring the effects of behavior-based social marketing interventions; and, (3) documenting the lessons learned.

Facilitate the application of prevention marketing principles in CDC-funded community planning efforts by (1) promoting guidelines for consideration of these principles at the local level for prevention interventions and (2) providing interactive technical assistance on social marketing technology principles (or prevention marketing) to public health agencies as well as HIV Prevention Community Planning Groups.

Promote HIV prevention as a relevant issue in business settings.

Provide and promote a network of resources and referrals to assist in implementing the Business Responds to AIDS (BRTA) Comprehensive HIV/AIDS Workplace Program.

Market the comprehensive workplace HIV/AIDS program to business.

Establish and execute a research agenda to formulate and assess strategies and resources to advance the knowledge of effective workplace HIV programs.

Action Steps: Monitor changes in public knowledge about how HIV

is and is not transmitted;

Develop methodologies to measure community mobilization or changes in institutional behavior in relation to mass media public information and education programs;

Develop new mass media messages, in collaboration with the public health systems and with international, national, state, and local private sector organizations and agencies;

Expand the relationship between CDC and the entertainment industry to improve messages and role modeling for HIV prevention;

Develop communication interventions with appropriate organizations to ensure that consistent, accurate HIV prevention information is provided to the public;

Develop community coalitions for HIV prevention;

Coordinate and disseminate information messages through the media that explain new scientific findings and policies concurrent with the release of new scientific information;

Develop leadership of health/education officials to effectively deliver HIV prevention messages through partnerships;

Evaluate the role of communications in changing individual knowledge, community norms, and individual behavior through establishment of model programs;

Expand the relationship between CDC and academic experts in mass communications to develop methods for measuring the impact of mass media on individual and community behaviors;

Develop ways of measuring the mobilization of community groups, i.e., changes in community norms, capacity;

Monitor business policies and employee education programs regarding HIV/AIDS;

Implement a BRTA initiative to develop HIV prevention and service programs for the workplace and the community;

Sponsor and participate in national meetings of businesses and religious, civic, medical, social, and voluntary agencies which conduct HIV prevention and service programs.

Descriptions: Many of the activities cited above are carried out at local demonstration sites and in coordination with community planning efforts. In addition, specialized projects and studies also serve to focus attention on these activities, these include projects entitled: National Health Communications, Prevention Collaborative Partners, the CDC National AIDS Clearinghouse, and the CDC National AIDS Hotline, and the Prevention Marketing Initiative.

Also, linkage efforts with business, labor, and community groups have received special attention. The Business Responds to AIDS (BRTA) and Labor Responds to AIDS (LRTA) programs have focused on issues such as: HIV/AIDS workplace policies, supervisor and labor leader training, employee education, employee family education, and community service and volunteerism. Partnerships have also been forged among a variety of communities including business, labor, religious, voluntary and the media. And, national and regional minority organizations have also been sought out in forging these important linkages.

FY 95: \$45,960,000

FY 96: \$45,512,000

FY 97: \$45,647,000

Populations Served: All segments of the population including all major racial and ethnic groups, young persons (18-25), persons engaging in behaviors that place them at risk for HIV infection, and business and labor leaders including their employees and families.

Constituency Involvement: Regular consultation with leaders from over 200 prevention collaborative partners composed of national, state, and local organizations and over 50 business and labor partners.

Unmet Need: There is a need for more effective use of social marketing principles in HIV prevention programs, further implementation of strategies to promote adoption of BRTA and LRTA comprehensive programs. There is also an increased need for family education materials, more effective materials to encourage abstinence and other prevention behaviors, and more HIV prevention materials for use by religious communities.

***The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96***

Agency: Department of Health and Human Services, the Centers for Disease Control and Prevention

Goal: To prevent risk behaviors that can cause HIV infection and related health problems in school age children and college age youth through implementation of comprehensive school health education programs.

Objectives: Increase by 15 percent the proportion of school districts that require age-appropriate HIV education at each grade level, K-12, especially at grades 9-12, preferably as part of comprehensive school health education.

Increase by 15 percent the proportion of colleges and universities that provide HIV education for students and staff, preferably as part of an institution-wide health promotion program.

Decrease by 10 percent at each grade level the proportion of 9th to 12th grade students who report they have engaged in sexual intercourse.

Among 9th to 12th grade students who report they have engaged in sexual intercourse, decrease by 10 percent the proportion who report they have engaged in sexual intercourse during the past 3 months.

Among 9th to 12th grade students who report they have engaged in sexual intercourse during the past 3 months, increase by 10 percent the proportion who report they used a condom at last intercourse.

Decrease by 10 percent the proportion of 9th to 12th grade students who report they have injected illicit drugs.

Action Steps: Monitor state-level policy and program requirements that support effective HIV education within comprehensive school health education (CSHEs);

Monitor district-level policy and program requirements that support effective HIV education within comprehensive school health education programs;

Monitor the prevalence of behaviors that cause HIV infection and related health problems among school and college youth;

Implement and revise as necessary, CDC guidelines for effective school health education to prevent the spread of HIV infection;

Enhance the capacity of state and local educational agencies to develop and implement effective HIV education within CSHEs;

Enhance the capacity of colleges and universities to provide HIV education for students and staff, preferably as part of an institution-wide health promotion program;

Ensure the integration of education to prevent HIV infection, other STDs and the use of alcohol and other drugs among youth;

Strengthen the capabilities of state and local departments of education and health to collaboratively help schools, colleges and universities implement effective HIV education programs for youth;

Increase the effectiveness of HIV education for youth served by state and local departments of education and college and universities through the efforts of selected national organizations;

Enhance the capacity of state and local agencies to help prevent HIV infection and HIV-related problems among youth through the efforts of training and demonstration centers established for state and local departments of education;

Establish teacher training coordinators in every interested state to help teachers provide effective HIV education within a CSHE;

Identify and disseminate, through training and demonstration centers and through teacher training directors, HIV education programs that have been shown to be effective in reducing behaviors that cause HIV infection and related health problems;

Synthesize and apply the results of research to increase the effectiveness of HIV prevention education for youth;

Conduct formative evaluations of state and local departments of education policies, curricula, teacher training, and school efforts to prevent behaviors that cause HIV infection and related health problems;

Develop a standardized report for each state to profile the nature of priority health problems and risk behaviors among youth in that state and school efforts to prevent these problems and behaviors;

Conduct evaluations of the effectiveness of existing school-based interventions to reduce behaviors that result in HIV infection

and related health problems;

Develop state-of-the-art school-based interventions and evaluate their effectiveness in reducing behaviors that result in HIV and related health problems; and

Conduct and apply meta-evaluations of existing research data about the effectiveness of school-based interventions in reducing health risks behaviors among adolescents.

Descriptions: Funding and technical assistance for state and local educational agencies is provided through several avenues including national non-governmental organizations, colleges and universities, and teacher training sites. There is also support for youth surveys and projects to reach out-of-school youth.

FY 95: \$48,205,000

FY 96: \$47,735,000

FY 97: \$47,771,000

Populations Served: Young persons engaging in behaviors that place them at risk for acquiring HIV through sexual exposure, including all major racial and ethnic groups. All school- and college-aged youth regardless of school enrollment status.

Constituency Involvement: Consultation with a wide range of constituency groups was established to: (1) improve existing programmatic efforts; (2) improve assistance and resources provided by CDC; and, (3) explore strategies that the Nation might take to improve the health status of young people. These groups include representatives from: (1) every state education agency, District of Columbia, and six territorial education agencies; (2) national nongovernmental health or education organizations, 3) colleges and universities, 4) state public health departments, as well as young people themselves. Meetings included an annual constituency meeting, quarterly training programs, and communication through an electronic bulletin board and network.

Unmet Need: Not all youth are accessible through existing institutional-based efforts, and currently not all states monitor youth health-risk behaviors.

***The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96***

Agency: Department of Health and Human Services, the Centers for Disease Control and Prevention

Goal: To prevent or reduce behaviors or practices which place individuals at risk of HIV infection, and for HIV positive individuals, place others at risk.

Objectives: At least 90 percent of individuals with known HIV infection will be abstinent or will have used a condom at last sexual intercourse, and at least 50 percent of individuals who have engaged in high-risk sexual behaviors within the past 12 months will be abstinent, in a mutually monogamous relationship, or have used a condom at last sexual intercourse.

At least 75 percent of injecting drug users will have stopped injecting drugs or used sterile or decontaminated injection equipment at last injection.

At least 80 percent of the health care and public safety workplaces will implement programs and procedures for preventing HIV transmission at work sites.

Reduce unintended pregnancies to no more than 40 percent of pregnancies among women with or at risk for HIV infection.

The number of individuals donating blood and found to be infected with HIV at the time of donation will decrease by 50 percent through self-deferral.

Among selected populations of youth in high-risk situations, increase by 10 percent the proportion who report they used a condom at last sexual intercourse.

Action Steps: Collaborate with prevention partners to assess risk behaviors and practices in selected communities;

Identify barriers to implementation of HIV prevention programs at community, state, and national levels;

Collaborate with selected communities in developing and implementing a model behavioral intervention program that comprehensively addresses community needs and uses available community resources and prevention partners in selected sites;

Design, develop, and test effective community-level interventions to change risk behaviors through altering community norms and values to support healthy behaviors;

*The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96*

Expand the community's capacity to plan, implement, and evaluate culturally competent and linguistically specific HIV prevention guidelines and programs tailored to the needs of specific populations;

Enhance the capacity of CDC staff to plan, administer, and evaluate behavioral change strategies and community-based interventions to provide public health leadership and assist our prevention partners in designing and managing effective strategies for HIV prevention programs;

Enhance the capacity of local health departments and other relevant community agencies to collaboratively provide effective HIV education for youth in high-risk situations;

Establish scientifically-based evaluation components for HIV prevention activities; and

Use evaluation of components to design or refine HIV prevention programs and/or redirect HIV prevention resources.

Descriptions: Several mechanisms are employed for achieving the goals and objectives cited above. These include cooperative agreements with state and local health departments, in addition to direct funding of community-based organizations, national organizations, and national minority organizations. HIV intervention research studies are also supported.

FY 95: \$185,625,000

FY 96: \$183,814,000

FY 97: \$203,958,000

Populations Served: All major racial and ethnic groups in addition to persons engaging in behaviors that place them at risk for acquiring HIV.

Constituency Involvement: A major avenue for constituency involvement is the HIV Prevention Community Planning Process. Through this mechanism, state and local health departments form community planning groups to assist in developing HIV prevention plans. In addition, there is regular and extensive consultation with representatives from state and local health departments, community planning groups, and national organizations.

Unmet Need: There is currently a lack of behavioral risk surveillance data for program planning and evaluation purposes. There is also a need to develop a more effective application of behavioral science findings to HIV prevention programs. And

*The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96*

there is a special need to develop and maintain prevention efforts that target high risk women, youth and gay men of color.

***The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96***

Agency: The Department of Health and Human Services, the Centers for Disease Control and Prevention

Goal: To increase individual knowledge of serostatus and strengthen systems for successful referral to early intervention services.

Objectives: At least 85 percent of the estimated 800,000 to 1,000,000 HIV-infected individuals will know their HIV serostatus.

At least 90 percent of health care sites receiving public funds and serving at-risk persons will provide appropriate HIV counseling and testing services.

At least 80 percent of known HIV infected individuals, either directly or through referral, will receive primary and secondary prevention services.

Action Steps: Working with governmental and nongovernmental partners, enhance community-level assessments of needed primary & secondary prevention services;

Identify opportunities for common HIV prevention data collection and development of uniform data sets;

Integrate HIV prevention services into standards of care for the diagnosis and treatment of HIV disease;

In collaboration with the FDA, develop, test, and implement rapid HIV testing procedures;

Strengthen the capacity of state, and local health departments to provide partner notification services to private health care providers offering HIV counseling & testing;

Develop alternative methods to provide HIV counseling and testing services;

Work with professional groups, hospitals, and state health departments to ensure that health care workers receive adequate training on primary and secondary HIV prevention (in collaboration with HRSA);

Study the impact of discrimination as a barrier to prevention services;

Assist publicly funded counseling and testing sites establish

selection criteria and systems for monitoring the quality of referral laboratories;

Interview persons newly diagnosed with HIV infection to identify missed opportunities for earlier diagnosis and CD4+ testing;

Conduct a study of incident AIDS cases to determine what services HIV-positive clients are receiving over time to identify service gaps (in collaboration with HRSA); and

Provide guidelines and training to HIV counselors to improve the quality of counseling.

Descriptions: Counseling, testing, referral partner notification programs are supported as part of cooperative agreements with state and local health departments.

FY 95: \$168,995,000

FY 96: \$167,351,000

FY 97: \$181,027,000

Populations Served: All major racial and ethnic groups and persons engaging in behaviors that place them at risk for acquiring HIV.

Constituency Involvement: A major avenue for constituency involvement is the HIV Prevention Community Planning Process. Through this mechanism, state and local health departments form community planning groups to assist in developing HIV prevention plans. In addition, there is regular and extensive consultation with representatives from state and local health departments, community planning groups, and national organizations.

Unmet Needs: There is a need for more effective long-term intervention programs for HIV positive individuals in addition to a lack of resources for supporting comprehensive referral and data monitoring systems. Also, there is a need to determine the best balance between CTRPN programs and other HIV prevention strategies.

***The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96***

Agency: Department of Health and Human Services, the Food and Drug Administration

Goal: To reduce transfusion-transmitted HIV infection.

Objective: Ensure supply and safety of the national blood supply.

Action Steps: Establish policies, expedite review of product applications, conduct approval inspections, oversee surveillance, and support enforcement activities.

Descriptions: Encourage high risk donors to exclude themselves; update list of unsuitable donors; quarantine and test blood; investigate incidents to identify, and rectify common errors in blood banks.

FY 95: \$17,458,000

FY 96: \$17,458,000

FY 97: \$17,458,000

Populations Served: All persons who may receive blood or blood products.

Constituency Involvement: The FDA depends on scientific advisory committees to provide independent expert advice to the agency in its evaluation of regulated products. These committees are composed of representatives from academia, research, government, industry, and patient advocates.

Unmet Need: With the passage of Prescription Drug Use Fee Act of 1992, the FDA has been able to expeditiously review HIV/AIDS related therapeutic applications. With the continuation of the provisions in the Act, the FDA will be able to continue expeditious reviews.

***The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96***

Agency: Department of Health and Human Services, the Health Care Financing Administration

Goal: To reduce perinatal transmission among Medicaid-eligible women.

Objectives: Develop and implement a campaign to inform HIV positive women in selected pilot areas about the benefits of AZT in FY 95.

Expand pilot project to one State in all regions in FY 96.

Expand project to include all States in FY 97.

Action Steps: Develop, obtain, and distribute brochures and other materials describing current guidelines for the use of AZT during pregnancy for preventing perinatal transmission, and Medicaid eligibility and coverage to Medicaid eligible women.

Descriptions: Establish a consumer-oriented educational campaign in key states with high HIV prevalence rates among women.

FY 95: \$50,000 (Federal share)

FY 96: \$60,000 (Federal share)

FY 97: \$185,000 (Federal share, subject to availability of funds)

Populations Served: HIV positive women eligible for Medicaid coverage.

Constituency Involvement: Significant consultation with high-risk pregnant women and their advocates.

Unmet Need: The pilot project will not initially include women of unknown or negative HIV serostatus.

*The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96*

Agency: Department of Health and Human Services, the Health Resources and Services Administration

Goal: To reduce the perinatal transmission of HIV.

Objective: Enhance provider capacity to provide appropriate services for women at the community level.

Improve provider capacity for outreach, counseling, testing and care for women of childbearing age for early identification and linkage to care for pregnant women.

Enhance providers' abilities to provide AZT for HIV positive pregnant women.

Ensure funding and dissemination of innovative models of care that evaluate all of the major care and service goals listed in this plan: effectively educated providers, increased access to and quality of care, reduction of perinatal transmission of HIV.

Action Steps: Establish the Women's Initiative for HIV Care for Women and Reduction of Perinatal Transmission (WIN);

Establish ongoing WIN Steering Committee;

Provide technical assistance to grantees;

Conduct centralized training for all WIN sites with follow-up local training;

Collaborate with Association of Maternal & Child Health Programs (AMCHP) to develop local guidelines;

Establish MCHB working group to coordinate HIV risk reduction related efforts across programs;

Distribute counseling and testing guidance, AHCPR consumer brochure and video, and other PHS documents to MCHB community;

Review currently funded SPNS projects to identify gaps in project coverage for future Requests for Applications (RFAs); and

Evaluate sites.

Descriptions: Enhance outreach for HIV counseling and testing.

Improve service linkages for women of childbearing age in an ongoing care system and to reduce perinatal HIV transmission.

*The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96*

PHS 076 Implementation Plan.

FY 95: \$1,520,000

FY 96: \$1,800,000

FY 97: \$????????

Populations Served: CARE Act grantees. Adolescent and adult women and their infants, with special attention for pregnant women in addition to MCH and HIV providers.

Constituency Involvement: Health care providers, evaluation researchers, communication experts, and patient advocates. There is also consumer participation in WIN steering committee and projects' advisory board in addition to linkages with other HRSA grantees including those from RWCA and SPNS programs.

Unmet Need: Funds needed to provide more services in order to reach more women and enhance evaluation efforts and improve technical assistance and training.

In particular, it is critical to fund services (e.g., outreach, case finding, case management) that better link women of childbearing age with counseling and testing services and, after testing, with comprehensive medical, social, and support services and long-term followup for themselves and their families. Training non-HIV providers, particularly primary care, family practice, ob/gyn, and MCH providers, to perform women-sensitive counseling and testing, to deliver appropriate primary care for women with HIV, and to provide appropriate referrals for these women is another critical need. Funding is also needed for peer-support programs for these women and their families. While it should be our assumption that all women are at risk for HIV, it is important to recognize that certain groups of women (e.g., substance abusers, partners of substance abusers) are at special risk and need additional services in order to enter and remain in care.

***The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96***

Agency: Department of Health and Human Services, the Indian Health Service

Goal: To reduce the number of new infections among Federally recognized American Indians and Alaska Natives.

Objective 1: Maintain surveillance of HIV infection in American Indians and Alaska Natives.

Action Steps: Maintain timely and complete case reporting to appropriate local, state and national entities and the Indian Health Service (IHS) AIDS Prevention Activities Office.

Descriptions: Area AIDS Coordinators will be responsible for reporting.

FY 95: \$912,000

FY 96: \$912,000

FY 97: \$

Populations Served: Federally recognized American Indians and Alaska Natives.

Constituency Involvement: Local and National Indian Health Advisory Boards.

Unmet Need: ???

Objective 2: Maintain training and information activities to provide health education and risk reduction messages.

Action Steps: Teach empowerment skills at the individual and community level that will enhance the individual's ability to actualize assimilated knowledge as behavior change.

Descriptions: The changed behavior includes adjustments of beliefs and the formation of AIDS community-based task forces at the local level.

FY 95: \$2,321,000

FY 96: \$2,321,000

FY 97: \$

Populations Served: American Indians and Alaska Natives population, tribal leaders, women, youth, individuals practicing high risk behavior, and IHS/tribal health care workers

The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96

Constituency Involvement: Local and National Indian Health
Advisory Boards.

Unmet Need: ???

Agency: Department of Health and Human Services, National Institutes of Health

Goal: To support behavioral and social science research for the purpose of furthering understanding of behaviors associated with HIV transmission in addition to developing and improving HIV prevention interventions, and, to support natural history and epidemiological research to improve the understanding of HIV transmission, disease progression, and the risk factors associated with HIV infection and AIDS.

The NIH's efforts in these areas can be found under these goals in Appendix B: Research.

***The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96***

Agency: Department of Health and Human Services, Office of Population Affairs

Goal: To reduce the number of new HIV infections.

Objective: Provide counseling, education, and HIV testing as needed to Title X program clinics.

Action Steps: Include HIV/AIDS education in all clinic education programs.

Include HIV/AIDS prevention in STD screening programs.

Provide HIV testing or referral for testing to all Title X clients who request testing.

Descriptions: Title X Program

FY 95: NA -- HIV services integrated into overall budget.

FY 96: NA -- HIV services integrated into overall budget.

FY 97: NA -- HIV services integrated into overall budget.

Populations Served: The Title X program provides family planning and related reproductive health services to approximately 4.5 million clients annually through a network of 4,500 clinics. Clients are predominantly young women; most are members of low-income families, and 30 percent are adolescents and 2/3 are below age 25.

Constituency Involvement: For non-profit grantees, clients participate on boards of directors. For all grantees, clients participate on committees approving all information and education materials.

Unmet Need: The Title X program reaches an estimated 50 percent of potential clients. Expansion of program would provide a concomitant expansion in HIV/AIDS prevention activities, since these are provided as an integral part of the reproductive health services in Title X programs.

***The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96***

Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration

Goal: To reduce the number of new HIV infections.

Objective 1: Demonstrate the effectiveness of incorporating HIV/AIDS prevention curricula into ongoing substance abuse prevention programs.

Demonstrate the differential effectiveness of incorporating HIV/AIDS prevention curricula into ongoing substance prevention programs.

Action Steps: Supplementation of high risk youth grants for alcohol, tobacco and other drugs (ATOD) prevention for the purpose of including HIV/AIDS prevention strategies in their present activities;

Develop program to empower youth with skills, knowledge, and beliefs for HIV prevention;

Demonstrate effective strategies to prevent ATOD use and abuse among high risk youth; and

Include developmentally and culturally appropriate HIV/AIDS education and prevention approaches.

Descriptions: High Risk Youth Program.

FY 95: \$1,000,000

FY 96: \$0

FY 97: [REDACTED]

Populations Served: High risk youth or youth at risk for ATOD, adolescent females, and youth at risk for AOD-related violent behavior.

Constituency Involvement: Families of youth, youth service workers, and the communities that support youth at risk for ATOD abuse.

Unmet Need: Presently this initiative reaches only 25 percent of high risk youth grantees. Supplementing all grantees would provide greater opportunity for services integration and evaluation.

Objective 2: Apply a community-designed, community-focused approach to the prevention of HIV/AIDS in a culturally

appropriate manner, specifically targeting communities of high seroprevalence.

Reduce ATOD use.

Action Steps: Supplementation of all community partnerships and community coalitions providing communities with the opportunity to design targeted HIV/AIDS messages emphasizing the direct relationship between the use of ATOD and HIV/AIDS; and

Solicit neighboring communities in program implementation.

Descriptions: Demonstration sites and community training in the use of HIV/AIDS curriculum.

FY 95: \$0

FY 96: \$5,000,000

FY 97: [REDACTED]

Populations Served: High risk neighborhoods and communities, including youth, families, and community organizations.

Constituency Involvement: All community members.

Unmet Need: Supplementing all community coalition grantees and partnerships would provide greater opportunity for services integration and evaluation.

Objective 3: Improve training of Faculty Development Program (FDP) grantees.

Action Steps: Supplement all FDP grantees for the purpose of improving teaching skills related to integration ATOD and HIV/AIDS prevention; and

Improve training regarding professional/client interaction.

Descriptions: Supplementation of Faculty Development Program (FDP) grantees.

FY 95: \$0

FY 96: \$650,000

FY 97: [REDACTED]

Populations Served: General public.

Constituency Involvement: Health professional institutions, consumers, and community service providers.

Unmet Need: Additional resources could provide further education and training and thereby reach more health professionals.

***The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96***

Agency: Department of Housing and Urban Development

Goal: To reduce the number of new infections among residents of public and subsidized housing.

Objective: Provide primary prevention programs to public housing residents at risk for HIV infection. Coordinate meetings of the state and local agencies responsible for the prevention program services.

Action Steps: Forge local partnerships and improve coordination of existing resources.

Descriptions: HIV/AIDS Prevention in Public Housing Demonstration Program.

FY 95: \$0 (Activities carried out within existing HUD personnel resources.)

FY 96: \$0

FY 97: \$0

Populations Served: Children and adults in public housing in five targeted cities.

Constituency Involvement: Input received through local planning groups.

Unmet Need: The initial demonstration program reached sites in five cities. An increase in resources would enable HUD to meet increasing demand for services and permit expansion to include other public and subsidized housing efforts.

Agency: Department of Justice

Goal: To reduce the risk of infection to INS detainees who are at risk.

Objective: Educate detainees believed to be at risk regarding HIV/AIDS and thereby reduce the risk of transmission and new infections.

Action Steps: Upon obtaining informed consent, test detainees suspected of or diagnosed with HIV/AIDS or test upon detainee request and provide pre- and post-test counseling to detainees deemed at risk.

Descriptions: Provide limited testing and counseling.

FY 95: Part of overall operating budget.

FY 96: Part of overall operating budget.

FY 97: Part of overall operating budget.

Populations Served: INS Detainees.

Constituent Involvement: None.

Unmet Need: None.

***The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96***

Agency: Department of Justice

Goal: To reduce the risk of employee infection and avoid possible worksite performance problems.

Objective: Educate Bureau of Prisons (BOP) staff, Drug Enforcement Agency (DEA) employees, Federal Bureau of Investigation (FBI) employees, Immigration and Naturalization Service (INS) employees, and U.S. Marshals Service (USMS) regarding HIV/AIDS transmission and thereby reduce the risk of infection. Educate all Justice Department employees about HIV/AIDS in the workplace.

Action Steps: For Bureau of Prison (BOP) staff provide:

- annual HIV information update and infectious disease training to all staff;

- produce inmate and staff HIV educational videos; and

- participate at least quarterly with HRSA in audio conferences on HIV issues.

For DOJ employees in occupations that possess a heightened possibility for exposure to HIV or other bloodborne pathogens, including employees of the DEA, FBI, INS, and USMS provide:

- general training and field office training;

- annual bloodborne pathogen training to all personnel as mandated by OSHA (discussion of HIV/AIDS is included in this training); and

- an annual update on the bloodborne pathogens training as necessary to discuss new information or changes in the use of safety equipment, etc.

For all Department employees, the Justice Management Division (JMD) provided:

- instructional materials to be used in a one time general training;

- and technical assistance to other DOJ components.

Descriptions: DOJ staff prevention training programs.

FY 95: Part of overall operating budget.

*The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96*

FY 96: Part of overall operating budget.

FY 97: Part of overall operating budget.

Populations Served: DOJ employees.

Constituency Involvement: None.

Unmet Need: Additional resources for field office training for USMS and FBI.

*The National Strategy for HIV and AIDS, Appendix A: Prevention
Draft for ONAP Review: 7.22.96*

Agency: Department of Veterans Affairs

Goal: To prevent transmission of HIV infection through education of employees and patients.

Objective 1: Train and maintain cadre of professional staff to conduct HIV transmission and prevention education for patients and conduct pre- and post-test HIV antibody test counseling.

Action Steps: Establish national training program to educate 2 professional staff from every VA medical center to conduct patient education and pre- and post-test counseling.

Maintain on-going training program on limited basis to address turnover of staff and maintain cadre of counselors/patient educators.

Objective 2: Educate and maintain cadre of knowledgeable staff to teach all staff in VA health-care facilities on prevention and transmission of HIV infection.

Action Steps: Develop a national "train the trainer" education program to educate selected staff from every VA Medical Center on how to organize and conduct staff educational activities on HIV transmission and prevention.

Update training materials/revise strategies to maintain knowledgeable base of trainers for every facility.

Objective 3: Integrate HIV prevention education in addiction treatment programs.

Action Steps: Conduct national training program for professional staff in addiction treatment programs and Vet Centers on how to integrate HIV prevention education for patients in their treatment areas.

Objective 4: Stimulate innovative approaches to HIV/AIDS education at the local level (VA medical centers and communities).

Action Steps: Award educational demonstration grants to HIV/AIDS education proposals on competitive basis.

Facilitate system-wide dissemination of completed projects through annual publication and national quarterly newsletters.

Objective 5: Maintain education and information support systems.

Action Steps: Continue AIDS awareness and education programs through national system of regional education centers and individual facility programs.

Through library system, continue purchase of appropriate private and Federal sector videos, publications, posters, and other materials.

Objective 6: Prevent transmission of HIV in health-care setting.

Action Steps: Ensure on-going implementation of CDC recommendations on universal precautions, via policy.

Ensure continuing implementation of OSHA rule on protection of health-care workers against bloodborne pathogens via policy.

Provide national training program on interdisciplinary team training for staff from infection control, employee health, safety in all VAMCs to implement OSHA rule.

Descriptions: Prevention activities including education and universal precautions.

FY 95: \$31,000,000 *

FY 96: \$31,000,000 *

FY 97: \$31,000,000 *

* Figures are based on the estimated resource expenditures for universal precautions and education and are part of the general Medical Care Budget. FY 1996 and FY 1997 estimates are based on the resource levels contained in the President's budget.)

Populations Served: Eligible veterans through local medical centers and facilities, local VA health-care and support staff, veteran patients and families, general public.

Constituency Involvement: VA medical centers and health-care facilities, and local communities.

Unmet Need: Advances in treatment through research and/or changes in prevention activities may require re-assessment of funding levels.

Agency: Corporation for National Service

Goal: To offer HIV/AIDS education programs and other services with volunteers from the Learn and Serve America project.

Objective: Support HIV-related Learn and Serve America projects.

Action Steps: Continue programs for youth in elementary school or high school to volunteer in community service activities, such as peer education in HIV/AIDS prevention.

Continue to award higher education grants directly to colleges and universities which provide service opportunities on HIV/AIDS prevention.

Program Description: Examples of higher education programs include Robert Wood Johnson Medical School and the University of San Diego where students provide education on HIV/AIDS to homeless and other high risk populations.

FY 95: Part of overall operating cost.

FY 96: Part of overall operating cost.

FY 97: Part of overall operating cost.

Populations Served: Persons living with HIV and AIDS and others who could benefit from HIV/AIDS education.

Constituency Involved: The Learn and Serve America program and students across the country.

Unmet Needs: Without these programs, students would not have an opportunity to serve their communities in HIV/AIDS related projects.

*The National Strategy for HIV and AIDS, Appendix B: Research
Draft for ONAP Review: 7.22.96*

Agency: Department of Commerce

Goal: To foster, serve, and promote the Nation's economic development and technological advancement, including encouraging HIV-related advances and innovation through the Department's collaborative efforts with the global business community.

Objective: Support activities which can assist in forwarding AIDS research by expanding the role of public-private partnerships in developing a vaccine and therapeutics.

Action Steps: Through the Advanced Technology Program (ATP), promote advances in biotechnology and provide funding to small and start-up research and development companies;

Support the Patent and Trademark Office's (PTO) AIDS-related patent database, developed in partnership with the National Science Foundation;

Through the National Technical Information Service, disseminate HIV-related training and technical materials;

Through data collection and analysis programs conducted by the Bureau of the Census and the Bureau of Economic Analysis, provide data for decision-making regarding the distribution of funds and other resources for private and public health initiatives, including HIV-related research, treatment, and service programs;

Through scientific standards, methodologies and technologies developed through the programs of the National Institute of Standards and Technology, set standards for laboratory procedures and equipment calibration at research facilities, including those conducting HIV-related research; and

Through the Patent and Trademark Office Biotechnology Examining Groups, review applications for a range of proposed HIV-related patents.

Descriptions: Advance Technology Program, Patent and Trademark Office reviews, National Technical Information Service, Bureau of the Census, and the National Institute of Standards and Technology.

FY 95: Part of overall operating budget

FY 96: Part of overall operating budget

FY 97: Part of overall operating budget

Populations Served: Start-up companies, biotechnology and

pharmaceutical companies, academic institutions, and researchers.

Constituency Involvement: The Department supports public-private partnerships to encourage innovative research.

Unmet Need: An increase in support for valuable programs such as ATP and the Patent and Trademark Office's innovative AIDS-related patent database would enhance Department of Commerce's ability to serve both public and private sectors.

*The National Strategy for HIV and AIDS, Appendix B: Research
Draft for ONAP Review: 7.22.96*

Agency: Department of Defense

Goal: To carry out state-of-the-art research on the prevention and treatment of HIV infection to promote medical readiness in U.S. military forces.

Objective: Support the development of a safe and effective HIV vaccine.

Support the development of new biochemical and genetic strategies to slow HIV disease progression

Support natural history studies for the purpose of evaluating the efficacy of intervention strategies.

Action Steps: Define the global molecular epidemiology of HIV to assist with candidate vaccine selection;

Explore novel vaccine technologies;

Conduct vaccine trials in endemic areas;

Assess the immune response and efficacy of vaccine candidates;

Evaluate potential therapies for treatment of HIV infection and potential for immune reconstitution;

Evaluate prevalence of drug resistance, develop rapid genetic assay for resistant mutants, and methods for genetic targeting of novel therapies *in vivo*;

Participate in national surveillance of AZT resistance;

Develop a comprehensive panel of immunologic, virologic, and functional parameters for management of HIV infection; and

Support natural history studies and specimen repositories.

Descriptions: Vaccine, therapeutic, and epidemiological research, including vaccine design, development and testing in the U.S. and overseas locations; epidemiologic studies of vaccine field studies; and reduction or conclusion of drug treatment and behavior studies.

FY 95: \$37,000,000

FY 96: \$26,600,000

FY 97: \$9,611,000

Populations Served: Active duty personnel.

Constituency Involvement: Clinicians, researchers, and active duty personnel.

Unmet Need: Increased resources would permit more aggressive research on promising therapies and vaccine candidates.

Agency: Department of Energy

Goal: To provide infrastructure support for physical chemical research, termed structural biology, including indirect support for HIV-related research.

Objective: In collaboration with other Federal agencies, provide access to sophisticated equipment and specially trained scientific personnel.

Action Steps: In collaboration with all relevant agencies (NIH, NSF, DOE) and the scientists they support, provide continued essential support for structural chemistry and biology facilities. Provide both the academic and the industrial community access to the facilities for further studies on the structural biology of HIV.

Descriptions: The National Synchrotron Light Source at Brookhaven National Laboratory includes a Department of Energy supported x-ray beam line extensively used by structural biologists studying virus structure, including the structure of HIV. In addition, through its National Laboratory system, DOE provides user facilities at other synchrotron light sources and at neutron beam facilities, which can be used by researchers to characterize the structural configuration of intact HIV, and HIV's biochemical components, often in complexes with inhibitors. These studies assist in the development of novel therapies, as well as advance our understanding of the pathogenesis and fundamental biology of HIV growth.

FY 95: Part of DOE's general operating budget.

FY 96: Part of DOE's general operating budget.

FY 97: Part of DOE's general operating budget.

Populations Served: The scientific community.

Constituency Involvement: Access to resources through peer review.

Unmet Need: Stable funding, guaranteed access for scientists to the facilities for the foreseeable future.

*The National Strategy for HIV and AIDS, Appendix B: Research
Draft for ONAP Review: 7.22.96*

Agency: Department of Health and Human Services, Agency for Health Care Policy and Research

Goal: To provide national estimates of the cost and use of HIV-related medical and non-medical services.

Objective 1: To provide comprehensive information on unmet needs for service and barriers to accessing services.

To examine effects of different systems of organizing and delivering care on outcomes such as cost, utilization, survival, patient satisfaction, and quality of life.

To examine effects of patient characteristics (including gender, race/ethnicity, substance abuse, mental health, socioeconomic status, insurance coverage) on outcomes such as service utilization, unmet service needs, and costs.

To provide data on service utilization and costs for a representative sample of rural residents with HIV infection.

To examine patterns of transition between different types of provider (e.g., private physician to public clinic) and the relationship of such transitions to changes in clinical status, employment, and insurance coverage.

Action Steps: This study will be the first to obtain a true national random sample of people with HIV infection receiving treatment. Approximately 3200 adult patients in urban and rural areas will be enrolled. Study will be co-sponsored by HRSA, NIMH, NIDR, NIA, NIDA, and the Robert Wood Johnson Foundation.

Descriptions: HIV Costs and Service Utilization Study (HCSUS)

FY 95: \$4,150,657

FY 96: \$3,468,114

FY 97: \$3,131,582

Populations Served: HIV-infected individuals receiving treatment.

Constituency Involvement: Community Advisory Board, comprising members of infected and affected groups, has been established.

Unmet Need: Insufficient resources for a national probability sample of pediatric HIV-infected patients. Insufficient resources for a sample of HIV-infected adolescents.

Objective 2: To examine health care utilization among

participants in the NIH-sponsored Women's Interagency HIV Study (WIHS).

Action Steps: Supplement the WIHS by adding a health services research component.

Collect and analyze utilization data on women with HIV infection (in addition to the detailed clinical data obtained in the core study.)

Descriptions: Women's Interagency HIV Study (WIHS)

FY 95: \$60,000

FY 96: \$0

FY 97: \$0

Populations Served: Women with HIV infection participating in the WIHS.

Constituency Involvement: A broad representation of researchers and patient advocates had input in the development of the WIHS.

Unmet Need: None.

Objective 3: To examine factors affecting health care utilization among participants in the NIH-sponsored Multicenter AIDS Cohort Study (MACS).

Action Steps: Supplement the MACS by adding a health services research component.

Collect and analyze utilization data on men with HIV infection (in addition to the detailed clinical data obtained in the core study.)

Descriptions: Multicenter AIDS Cohort Study (MACS)

FY 95: \$65,000

FY 96: \$0

FY 97: \$0

Populations Served: Homosexual and bisexual men participating in the MACS in four urban areas.

Constituency Involvement: A broad representation of researchers and patient advocates had input in the development of the MACS.

Unmet Need: None

Objective 4: To examine health care utilization among participants in the CDC-sponsored HIV Epidemiological Research Study (HERS).

Action Steps: Supplement the HERS by adding a health services research component.

Collect and analyze utilization data on women with HIV infection (in addition to the detailed clinical data obtained in the core study.)

Descriptions: HIV Epidemiological Research Study (HERS)

FY 95: \$50,000

FY 96: \$50,000

FY 97: \$50,000

Populations Served: Women with HIV infection participating in the HERS.

Constituency Involvement: A broad representation of researchers and patient advocates had input in the development of the HERS.

Unmet Need: None.

Objective 5: To provide longitudinal data on utilization of inpatient, outpatient, home care, pharmaceutical, and other services, and to estimate their associated costs.

To examine the impact of a Medicaid Home and Community-Based waiver on service utilization, costs, functional status, and survival.

To examine any substitutions of formal for informal home care.

Action Steps: Conduct interviews with participants in New Jersey Medicaid Waiver program.

Abstract data from Medicaid claims.

Descriptions: Health Care Costs and Utilization in AIDS Home Care.

FY 95: \$295,918

FY 96: \$39,456

FY 97: \$0

Populations Served: Medicaid recipients with AIDS in New Jersey.

*The National Strategy for HIV and AIDS, Appendix B: Research
Draft for ONAP Review: 7.22.96*

Constituency Involvement: Persons with AIDS residing at home or in community facilities.

Unmet Need: None.

Objective 6: To examine types of ambulatory care providers used to treat HIV infection, patterns of transitions between ambulatory provider types, and service utilization and costs for pediatric HIV patients.

Action Steps: Analyze Medicaid claims and eligibility data from New York State Medicaid files.

Descriptions: Ambulatory Care for HIV/AIDS, Models and Outcomes.

FY 95: \$0

FY 96: \$0

FY 97: \$0

Populations Served: New York State Medicaid recipients.

Constituency Involvement: N/A

Unmet Need: None.

Objective 7: To assess the impact of antiretroviral, antimicrobial, and prophylactic treatment on the natural history of HIV infection, and the effect of pharmaceutical therapies on service utilization, costs, and clinical outcomes.

Action Steps: Develop clinical database linked to Medicaid claims data.

Descriptions: Outcomes of Pharmaceutical Therapy in HIV Disease.

FY 95: \$527,497

FY 96: \$479,952

FY 97: \$505,000

Populations Served: HIV-infected population in Maryland.

Constituency Involvement: N/A

Unmet Need: None.

Objective 8: To study issues of costs and quality of care, with a focus on women and children, examine trends and variation in adherence to scientifically-based clinical guidelines, and study

predictors of variation in treatment, by patient, physician, and practice setting characteristics.

Action Steps: Analyze Medicaid claims and eligibility data, supplemented with AIDS Registry data.

Descriptions: Quality and Costs of Care for HIV Infected Medicaid Patients.

FY 95: \$0

FY 96: \$0

FY 97: \$0

Populations Served: New Jersey Medicaid recipients.

Constituency Involvement: N/A

Unmet Need: None.

Objective 9: To develop an econometric framework for the simultaneous study of health care usage and survival, and synthetic estimates of per-person lifetime costs of HIV disease for various groups of HIV-infected individuals.

Action Steps: Formulate statistical models and associated computer software.

Descriptions: Developing Econometric Models to Estimate AIDS Costs.

FY 95: \$248,126

FY 96: \$8,003

FY 97: \$0

Populations Served: Participants in the AIDS Costs and Service Utilization Survey, with potential extensions to all persons with HIV disease.

Constituency Involvement: N/A

Unmet Need: None.

Objective 10: To identify personal and institutional factors that shape physicians' willingness to care for HIV-infected patients.

Action Steps: Conduct the third in a series of interviews with physicians, who are currently in their sixth post-graduate year.

*The National Strategy for HIV and AIDS, Appendix B: Research
Draft for ONAP Review: 7.22.96*

Descriptions: Determinants of Physicians' AIDS-Related Practice Behavior

FY 95: \$0

FY 96: \$0

FY 97: \$0

Populations Served: Persons with AIDS

Constituency Involvement: Physicians

Unmet Need: None.

Objective 11: Continuing work previously completed with AHCPR support, compare outcomes of inpatient care for AIDS provided by dedicated AIDS units versus scattered-bed approaches.

Action Steps: Expand upon original comparative multi-site observational study of 20 hospitals.

Descriptions: Outcomes of Hospital Dedicated AIDS Units

FY 95: \$180,649

FY 96: \$214,708

FY 97: \$0

Populations Served: 1300 patients receiving services in study hospitals.

Constituency Involvement: N/A

Unmet Need: None.

Objective 12: Obtain and analyze data on inpatient hospital utilization by people with HIV infection.

Action Steps: Assemble and will analyze database of hospital discharge data from all hospitals in 12 States.

Descriptions: Hospital Cost and Utilization Project

FY 95: \$500,000

FY 96: \$0

FY 97: \$500,000

Populations Served: Patients with AIDS receiving inpatient care in hospitals in 12 states.

Constituency Involvement: N/A

Unmet Need: None.

*The National Strategy for HIV and AIDS, Appendix B: Research
Draft for ONAP Review: 7.22.96*

Agency: Department of Health and Human Services, the Food and Drug Administration

Goal: To ensure the safety and effectiveness of HIV-related preventive and therapeutic vaccines.

Objective: Expedite regulatory review of promising products for preventive and therapeutic vaccines.

Action Steps: Expand partnership between FDA and its counterparts from outside organizations involved in vaccine development.

Descriptions: Encourage early consultation with sponsoring companies, develop guidance documents, exchange information, and work with other agencies and international organizations. Facilitate scientific review by FDA advisory committees.

FY 95: \$11,863,000

FY 96: \$11,863,000

FY 97: \$11,863,000

Populations Served: All persons who may benefit from approved preventive and therapeutic vaccines.

Constituency Involvement: The FDA depends on scientific advisory committees to provide independent expert advice to the agency in its evaluation of regulated products. These committees are composed of representatives from academia, research, government, industry, and patient advocates.

Unmet Need: With the passage of Prescription Drug Use Fee Act of 1992, the FDA has been able to expeditiously review HIV/AIDS related therapeutic applications. With the continuation of the provisions in the Act, the FDA will be able to continue expeditious reviews.

*The National Strategy for HIV and AIDS, Appendix B: Research
Draft for ONAP Review: 7.22.96*

Agency: Department of Health and Human Services, the Food and Drug Administration

Goal: To ensure the effectiveness of test methodologies for HIV detection and measurement.

Objective: Expedite improved test methodologies (such as diagnostic reagents and test kits) for HIV detection, confirmation, and viral load measurement.

Action Steps: Ensure timely and efficient pre- and postmarket review.

Descriptions: Encourage early consultation with sponsor and develop guidance documents. Facilitate scientific review of drugs and biologics by FDA advisory committees.

FY 95: \$8,732,000

FY 96: \$8,732,000

FY 97: \$8,732,000

Populations Served: All persons who may benefit from approved test methodologies for HIV detection and measurement.

Constituency Involvement: The FDA depends on scientific advisory committees to provide independent expert advice to the agency in its evaluation of regulated products. These committees are composed of representatives from academia, research, government, industry, and patient advocates.

Unmet Need: With the passage of Prescription Drug Use Fee Act of 1992, the FDA has been able to expeditiously review HIV/AIDS related therapeutic applications. With the continuation of the provisions in the Act, the FDA will be able to continue expeditious reviews.

*The National Strategy for HIV and AIDS, Appendix B: Research
Draft for ONAP Review: 7.22.96*

Agency: Department of Health and Human Services, the Food and Drug Administration

Goal: To ensure the safety and effectiveness of HIV-related medical devices.

Objective: Expedited access and approval of safe and effective medical devices.

Action Steps: Encourage quality application and data submissions to ensure timely and efficient pre- and postmarket review.

Descriptions: Conduct meetings with sponsors on study design; produce guidance documents. Facilitate scientific review of drugs and biologics by FDA advisory committees.

FY 95: \$9,457,000

FY 96: \$9,457,000

FY 97: \$9,457,000

Populations Served: All persons who may benefit from approved HIV-related medical devices.

Constituency Involvement: The FDA depends on scientific advisory committees to provide independent expert advice to the agency in its evaluation of regulated products. These committees are composed of representatives from academia, research, government, industry, and patient advocates.

Unmet Need: The FDA depends on scientific advisory committees to provide independent expert advice to the agency in its evaluation of regulated products. These committees are composed of representatives from academia, research, government, industry, and patient advocates.

The National Strategy for HIV and AIDS, Appendix B: Research
Draft for ONAP Review: 7.22.96

Agency: Department of Health and Human Services, the National Institutes of Health

Goal: To support natural history and epidemiological research to improve the understanding of HIV transmission, disease progression, and the risk factors associated with HIV infection and AIDS.

Objective 1: Develop and assess intervention strategies to reduce or prevent HIV transmission in both domestic and international settings.

Action Steps: Develop and maintain the infrastructures to define populations in the United States and throughout the world with incidence and prevalence suitable for vaccine and other intervention trials (e.g. microbicides, barriers, treatment, behavioral) for preventing HIV transmission.

Support development and evaluation of improved, acceptable, effective physical and chemical barrier methods and conduct research on existing barrier methods to prevent sexual transmission of HIV and STDs.

Develop strategies and conduct studies to evaluate vaccines, drugs, and other interventions such as caesarian sections, vaginal cleansing, breast-feeding practices, nutritional interventions, and other approaches that prevent perinatal transmission.

Develop and assess the efficacy of strategies that may decrease transmission of HIV among drug users.

Develop and evaluate biological and behavioral interventions to control STDs as cofactors in HIV transmission.

Develop strategies that enhance safe sex behaviors and provide information on safe and effective contraceptive choices for at-risk women.

Develop methods to prevent infection in hard-to-reach gay male populations such as young, substance-using, and minority gay and bisexual men.

Develop methods of accessing hard-to-reach populations to identify factors that contribute to recruitment (and retention) into prevention and intervention activities.

Evaluate access to, acceptability of, and compliance with

interventions such as AZT for perinatal transmission, condoms, and virucides.

Evaluate improved procedures for screening, monitoring, and inactivating HIV and other retroviruses in the blood supply; and develop and evaluate alternatives to blood transfusion.

Assess the impact of drug and alcohol abuse and mental health impairment on efficacy of behavior modification interventions directed at sexual transmission.

Develop effective drug treatment strategies for addiction, particularly focused on heroin and cocaine use.

Description: The development of biologically based interventions to interrupt transmission is an essential component of a comprehensive HIV prevention strategy that also includes behavioral intervention strategies as well as efforts to develop a vaccine(s). International studies should be supported with the goal of developing prevention strategies that can be used to reduce HIV transmission in the United States. Research is ongoing in these areas.

Epidemiologic studies, including vaccine preparedness research, provide opportunities for intervention research in defined cohorts of well-characterized populations. Strategies that employ therapies, devices, and other approaches, such as needle/syringe exchange programs using HIV seroconversion end points, are useful approaches for providing epidemiologic causation and evaluating effectiveness in preventing or reducing HIV transmission.

In addition, despite the fact that the blood supply in the United States is safer than it has ever been, it is important to develop even better methods for maintaining and improving its safety.

Objective 2: Characterize the risk factors and mechanisms of HIV transmission in both domestic and international populations, with the goal of preventing transmission.

Action Steps: Evaluate HIV transmission in relationship to: viral factors such as virus load in the blood and at mucosal sites, characteristics of HIV (genotype and phenotype), and pre-existing infection with other agents; host factors such as contraceptives, pregnancy, menstrual cycle, substance abuse, and nutritional, immunologic and genetic determinants; local factors including intercurrent STDs, exogenous irritants, oral and anogenital inflammation, mucosal immunity, circumcision and cervical

ecotopy.

Further define the timing and mechanisms and risk factors in perinatal transmission, including breast-feeding.

Study mechanisms of resistance to HIV infection in persons who remain uninfected despite perinatal, sexual or parental exposure.

Define the determinants of high-risk behavior for transmission through drug use and sexual practices.

Characterize the dynamics of HIV transmission in epidemiologic studies of at-risk groups, including evaluation of sexual and drug-using networks, social and geographic mixing patterns, and turnover rates of at-risk populations.

Characterize the transmission and host immune responses of related retroviruses.

Description: Understanding the role of risk factors and mechanisms of HIV transmission is critical to the development of biologically and behaviorally based strategies to interrupt transmission of HIV. Epidemiologic studies provide important biological and behavioral information including the role of cofactors that may reduce or enhance transmissibility.

Objective 3: Elucidate the progression of HIV infection, from its earliest stages through long-term sequelae, with the goal of understanding, preventing, and treating those factors.

Action Steps: Use epidemiologic studies to identify pathogenic mechanisms and cofactors for disease progression and disease-specific outcomes in well-defined subsets of individuals, individuals, including those with different rates of progression.

Conduct epidemiologic studies to understand the initiation and progression of early HIV infection, according to route of exposure, viral dose, viral genotype and phenotype, and host response, and how these early events influence disease progression.

Use epidemiologic studies to investigate the influence of viral genotype and phenotype on transmission efficacy and disease progression.

Use epidemiologic studies to evaluate the extent of dissemination of drug-resistant strains of HIV and its impact on pathogenesis.

Study the natural history of related retroviruses to elucidate retroviral pathogenesis.

Elucidate the mechanisms of HIV-associated carcinogenesis to improve strategies for early diagnosis and intervention.

Study HIV-infected children to determine: (1) mechanisms that contribute to impaired growth and neurodevelopment; (2) impact on childhood infectious diseases and the safety and efficacy of immunization; (3) impact on childhood psychosocial development, and (4) childhood-specific complications.

Evaluate the interaction of hormonal factors (including pregnancy, contraceptives, and hormonal replacement therapy) and HIV disease progression.

Study the progression of HIV-related disease in adolescents who have acquired their diseases as a result of drug use and/or sexual activity.

Study the natural history of HIV infection in the nervous system, including cognitive impairment, dementia, and neuropathy.

Describe the full spectrum of HIV-related diseases in HIV-infected populations.

Maintain and effectively utilize national specimen repositories for HIV-related studies.

Description: Epidemiologic studies provide a critical knowledge and resource base for more basic investigations of HIV pathogenesis. A better understanding of the diversity of HIV-related disease outcomes, cofactors for progression, and predictors of disease progression will be important in furthering attempts to develop HIV vaccines and more effective therapeutic interventions against HIV and its sequelae.

Objective 4: Undertake epidemiologic research to reduce or prevent the occurrence of opportunistic illness in HIV-infected persons.

Action Steps: Study the impact of HIV infection on the emergence of new human pathogens and the impact of HIV infection on the reemergence of infectious diseases domestically and internationally.

Identify risk factors for the acquisition of opportunistic pathogens.

Study the determinants of the continuing occurrence of preventable opportunistic illnesses.

Study the role of transmissible and other preventable exposures in the etiology of AIDS-associated cancers and other outcomes.

Description: Most morbidity and mortality in HIV-infected persons result from the occurrence of opportunistic illnesses, including both infections and malignancies. Strategies to prevent these illnesses include prevention of exposure to the etiologic agents, prevention of disease in those who are exposed, and prevention of disease recurrence. Additional epidemiologic data are needed to design more effective strategies to prevent the occurrence of these opportunistic illnesses.

Objective 5: Develop and evaluate new laboratory assays, behavioral methods, and statistical techniques for epidemiologic studies.

Action Steps: Promote development and evaluation of virologic and immunologic assays to elucidate mechanisms of HIV transmission and disease.

Develop new survey and interview techniques to better measure HIV risk behaviors.

Develop new biostatistical techniques, including mathematical models, to better characterize transmission dynamics and disease progression.

Develop innovative approaches for record linkages to study HIV-associated diseases and mortality.

Characterize the epidemiologic features of emerging HIV variants, including drug-resistant strains, diverse genotypes, and newly recognized geographic distribution.

Description: Epidemiologically defined populations contain well-characterized cohorts that can provide insights into HIV transmission, including resistance and susceptibility to infection and infectiousness, and into progression of HIV-related disease, from early infection through long-term sequelae, including cancer and neurocognitive impairment. The application of innovative biomedical research and behavioral strategies to such populations will greatly increase understanding at the biological level and will help to identify strategies for prevention of transmission and for clinical management of patients.

*The National Strategy for HIV and AIDS, Appendix B: Research
Draft for ONAP Review: 7.22.96*

FY 95: \$192,624,000

FY 96: \$205,812,000

FY 97: \$203,285,000

Populations Served: All populations.

Constituency Involvement: Researchers, clinicians, community and patient representatives, and NIH-affiliated advisory councils and committees.

Unmet Needs: The NIH FY 1996 Plan and Budget Estimate for Scientific Opportunities in HIV-Related Research identified areas for further productive research in this area in the amount of \$33,986,000 over the FY 97 figure.

Agency: Department of Health and Human Services, the National Institutes of Health

Goal: To support etiology and pathogenesis research to improve the understanding of the causes and progression of HIV disease.

Objective 1: Delineate the cellular and molecular mechanisms associated with the viral immunopathogenesis of HIV-related immune dysfunction.

Action Steps: Delineate the direct and indirect mechanisms underlying HIV-induced depletion and dysfunction of target cells/tissues.

Define the virologic (load, phenotype, and genotype), immunologic (specific and nonspecific), pharmacologic, and environmental factors that contribute to disease progression and non progression.

Delineate the mechanisms of virally triggered immunopathogenesis, including immune activation, induction of nonresponsiveness, and production of host factors, including cytokines, in pathogenesis.

Delineate the molecular mechanisms by which virus-encoded genes, gene products, and cellular factors regulate HIV replication and influence pathogenesis, with special emphasis on the use of primary virus isolates and cells.

Delineate the mechanisms of host genetic factors that mediate resistance or sensitivity to infection and influence disease progression.

Delineate the physiology and HIV-related pathophysiology of primary and secondary lymphoid organs, including hematopoietic precursor cells and their microenvironment.

Study the mechanisms of HIV infection that uniquely influence the developing immune system.

Further develop and utilize experimental models to examine the pathogenesis of lentiviral infections.

Establish and expand programs to facilitate access to and sharing of key patient samples, animal model resources, laboratory reagents, information databases, and quantitative virologic and immunologic assays.

Description: Basic scientific information regarding the cellular

and molecular mechanisms that underlie HIV-related immune dysfunction and viral pathogenesis is critical to all areas of AIDS research.

Objective 2: Delineate the molecular and cellular mechanisms of transmission and establishment of infection and their impact on disease progression.

Action Steps: Define the cellular and immune mechanisms that inhibit/enhance the early events in establishing HIV infection.

Determine the impact of early events in the establishment of HIV infection on the clinical course of the disease.

Determine the roles of specific and nonspecific mucosal and systemic immunity and other host factors that inhibit/enhance HIV transmission.

Determine the cell or tissue type that serves as the portal of entry of HIV and the impact of STDs and other pathogenic processes that influence HIV transmission.

Determine the role of viral phenotype/genotype and load on transmission of cell-free and cell-associated virus.

Elucidate unique aspects of HIV transmission and disease progression in under-researched populations.

Determine the mechanisms of vertical HIV transmission.

Description: The mechanisms of HIV transmission and the early events in the establishment of infection, and their relationship to disease progression, need to be better understood.

Objective 3: Elucidate the etiologic factors and cofactors in the pathogenesis of AIDS-associated disease states. Enhance a bidirectional flow between basic and clinical observations and intervention programs on HIV-related complications and foster interdisciplinary collaborations.

Description: Knowledge of AIDS-associated disease pathogenesis is urgently needed.

Sub-Objective 3a: Elucidate the etiologic factors, cofactors, and mechanisms in the pathogenesis of HIV-related malignancies.

Description: Knowledge about the origins and pathogenesis of HIV-related cancers is urgently needed.

Action Steps: Elucidate the role of HIV infection, immune dysfunction, and interactions with potential cofactors in the development of HIV-associated malignancies.

Identify the characteristics of the host that predispose to development of malignant disease, including genetic, hormonal, and growth factors and immunologic characteristics.

Identify the pathogenic contributions of oncogenes, suppressor genes, carcinogens, and non-HIV viral and other microbial genes and proteins to HIV-associated malignancies; correlate these molecular factors with epidemiologic studies.

Establish and expand programs to facilitate development and sharing of *in vivo* animal models and patient specimens for HIV-associated malignancies.

Sub-objective 3b: Elucidate the pathogenic mechanisms involved in HIV-associated neurological disease and neurobehavioral dysfunction.

Description: The damage that leads to both central and peripheral nervous system dysfunction must be better understood through studies of HIV-associated neuropathogenesis.

Action Steps: Investigate the characteristics of lentiviruses that invade the nervous system and the mechanisms by which these viruses cause nervous system impairment.

Study the effects of neurotrophins and immunoregulatory and proinflammatory cytokines on both host and viral gene expression.

Employ animal models of CNS-lentivirus infection that are crucial to understanding neuropathophysiology.

Delineate the role of OIs and drug treatment in neurologic complications of AIDS, including CNS dysfunction and peripheral neuropathies.

Investigate biological and environmental factors that may affect nervous system function in the context of HIV-1 infection, emphasizing the role of psychoactive drug use.

Study mechanisms of HIV infection that uniquely influence the developing nervous system.

Develop technologies for correlative structural-functional analysis of progressive HIV-associated neurological and

behavioral disorders and the progression of CNS disease.

Sub-objective: Elucidate the pathogenic mechanisms of HIV-related opportunistic infections.

Description: It is critical to understand the pathogenic mechanisms responsible for the development of HIV-associated OIs.

Actions Steps: Elucidate the mechanisms of immune function that mediate protection against OIs.

Study the effects of OIs on immune dysfunction and HIV disease progression.

Conduct studies of the basic biology and pathogenic mechanisms of opportunistic pathogens and their interactions with the host.

Develop *in vitro* techniques and animal models to propagate the opportunistic pathogens associated with HIV disease.

Develop and validate diagnostic assays for the reliable and rapid identification of HIV-associated OIs.

Identify biologic markers that are correlative for susceptibility and disease progression for HIV-associated OIs.

Identify and elucidate the genetic and environmental risk factors associated with susceptibility to and development and progression of OIs.

Sub-objective 3c: Elucidate the etiology and pathogenesis of HIV-related disorders: gastrointestinal, renal, endocrine, cardiovascular, cutaneous, hematologic, oral, pulmonary, and other diseases.

Description: It is critical to understand various other organ/tissue-specific complications of HIV infection.

Action Steps: Investigate the etiologic and pathogenic mechanisms of HIV-associated gastrointestinal disease.

Identify the etiologic and pathogenic mechanisms of HIV-associated nephropathy.

Elucidate the etiology and pathogenesis of endocrine dysfunction and the role of alteration in the endocrine/immune axis in progression of HIV disease.

***The National Strategy for HIV and AIDS, Appendix B: Research
Draft for ONAP Review: 7.22.96***

Elucidate the etiology and pathogenesis of HIV-related autoimmune disorders and cardiovascular, cutaneous, hematologic, oral, pulmonary, and other organ/tissue-specific disorders.

FY 95: \$344,303,000

FY 96: \$382,903,000

FY 97: \$400,182,000

Populations Served: All populations.

Constituency Involvement: Researchers, clinicians, community and patient representatives, and NIH-affiliated advisory councils and committees.

Unmet Needs: The NIH FY 1996 Plan and Budget Estimate for Scientific Opportunities in HIV-Related Research identified areas for further productive research in this area in the amount of \$20,801,000 over the FY 97 figure.

Agency: Department of Health and Human services, the National Institutes of Health

Goal: To support preclinical and clinical research for the purpose of developing new therapies and improving treatments for HIV infection, HIV-associated conditions, and HIV prevention.

Objective 1: Improve understanding of the structure and function of molecular targets in order to develop improved assays for such targets; conduct screening, discovery, and preclinical development of novel anti-HIV agents and strategies (such as gene transfer technology and interruption of transmission) directed to the virus and/or host cell; and foster activity by and in collaboration with industry.

Description: Identify and develop novel anti-HIV therapies, particularly those therapies that impact at different stages of the life cycle of the virus.

Action Steps: Identify and characterize promising targets for anti-HIV therapy and extend knowledge of their mechanisms of action, develop relevant assays for identifying drugs active against those targets, and develop new compounds active at those targets, with emphasis placed on identifying agents active at novel targets other than reverse transcriptase inhibitors; emphasize agents that can effectively cross the blood-brain barrier.

Complete preclinical development, in cooperation with industry when appropriate, of promising new compounds and combinations of compounds and novel natural products, including assessment of toxicity, immunologic effects, pharmacokinetics, teratogenicity, and fertility in animal models and development of analytical method and chemical formulations.

Continue and accelerate domestic and international collection screening of large numbers of natural and synthesized compounds for anti-HIV activity in the AIDS Drug Screen, with a particular emphasis on the detection of agents that act at unique steps of the HIV life cycle with the intent of identifying lead compounds that can be modified for increased potency and other attributes (such as bioavailability and central nervous system penetration); develop and screen combinatorial libraries.

Emphasize basic and applied research to advance cross-NIH development of gene therapy; support development of preclinical laboratories to advance gene therapies; advance gene therapies, including new strategies for streamlining or eliminating ex vivo

manipulation of cells; develop more efficient and safe viral and nonviral gene delivery vectors; target tissue cells and subcellular compartments; develop effective antiviral genes; standardize evaluation of different gene therapies singly and in combination; and develop suitable lentivirus animal models for in vivo efficacy and safety studies.

Determine the high-resolution molecular structures for several of the HIV proteins and apply these structures to the rational design of drugs as part of the targeted drug development program; determine generalizable and effective approaches for the use of macromolecular structure in designing drugs to combat HIV infection and AIDS; make resolved structures available in publicly accessible data bases.

Increase understanding of the mechanisms and limitations of drug resistance; study the effect of various agents on HIV replication and viral variation; evaluate early markers of resistance; evaluate the activity of anti-HIV drugs in various cell types (including macrophages) and in various stages of the cell cycle.

Develop new compounds capable of inhibiting the sexual transmission of HIV, such as topical microbicides (which may inhibit HIV and STDs associated with enhanced HIV transmission), HIV-specific viricides, and systemic agents.

Develop formulations that would be suitable for infants and children for both existing and experimental agents.

Evaluate transplacental passage of antiretroviral and other agents as well as the effects of these drugs on placental function and on the embryo/fetus in animal models.

Objective 2: Conduct clinical trials and develop new trial methodologies for the treatment of HIV infection. Trials should be designed in order to rapidly develop new therapeutic strategies, optimize clinical efficacy and proper use of available modalities, define factors that affect the success of therapeutic strategies (including the role of resistance), and advance our understanding of disease pathogenesis and progression.

Description: Trials to evaluate new antiretroviral therapies alone and in combination will provide important information regarding resistance and synergistic effects of drugs that may eventually prolong the disease-free state and survival in HIV-infected individuals.

Action Steps: Support and improve clinical trials of potential therapeutic agents and combinations of agents in studies to determine pharmacokinetics and bioavailability and evaluate anti-HIV combinations that are non-cross-resistant, synergistic, and toxicity-sparing and that may delay development of drug-resistant HIV strains; enhance collaboration between and within ICDs to facilitate opportunities for clinical trials.

Implement the development and evaluation of virologic, immunologic, and clinical markers to assess drug activity and determine the prognostic value of surrogate markers in response to therapeutic interventions.

Support research and development of clinical trials methodology and study design so that appropriate pathways are taken rapidly to evaluate the activity, clinical efficacy, and ultimate acceptability of new agents and approaches that translate into clinical use.

Increase the understanding of the pathogenesis of HIV disease based on the evaluation of antiretroviral agents in clinical trials; establish effective mechanisms to evaluate therapeutic interventions and elucidate the pathogenesis of acute/early HIV infection.

Foster collaboration and better interactions with industry in drug development and evaluation efforts.

Evaluate safety, toxicity, and pharmacokinetics of retroviral agents provided to pregnant women, including transplacental passage of the agent, safety to the fetus/infant, and pharmacokinetics of drug elimination in the newborn. (Also noteworthy, assess the potential efficacy and feasibility of obstetric interventions to prevent vertical transmissions, such as cesarean deliveries and other aspects of intrapartum care.)

Enhance utilization of GCRCs for the conduct of single and multi-institutional clinical trials.

Develop and validate quality-of-life parameters included in patient assessments of clinical trials.

Support research on the effectiveness of pharmacologic (including compliance with therapies and STD prevention) and non-pharmacologic including psychosocial) interventions (including nutritional factors and adherence improvement).

Investigate possible interactions between therapies for HIV-related disease and other substances that HIV-infected individuals might use, such as drug-abuse treatment medications, oral contraceptives or other prescription drugs, nonprescription drugs, alternative or complementary therapies, or drugs of abuse.

Coordinate studies to encourage co-enrollment of patients on all trials where appropriate (co-enrollment would not only allow for better utilization of limited resources but also enable assessment of concomitant medications and their interactions, improving the efficiency of the primary study).

Develop a coordinated plan to evaluate long-term therapeutic strategies, e.g., develop plans for long-term followup, enroll patients in sequential randomized trials once they have reached an end point in their initial trial.

Support clinical trials to evaluate the safety and pharmacokinetics of existing and experimental agents for use in treating HIV-infected infants and children; evaluate the effects of puberty on the pharmacokinetics of antiretroviral agents and other drugs for the treatment/prophylaxis of HIV infection and the pharmacokinetics of drugs in adolescents.

Evaluate potential late toxic effects of antiretroviral therapy given to infants and children.

Objective 3: Develop and evaluate strategies that will enhance, restore, and/or maintain the immune systems of HIV-infected individuals and extend our understanding of immunopathogenesis.

Description: Essential to HIV research efforts are studies directed toward finding therapies that can restore, enhance, or maintain the integrity of the immune system.

Action Steps: Evaluate therapeutic approaches that test specific hypotheses of HIV immunopathogenesis,

Develop and validate new methods for evaluating immune function in the context of clinical trials.

Continue and accelerate the testing of cytokines, modulators of cytokines, and other immunomodulating agents either singly or in combination with antiretroviral agents for the purpose of reconstituting the deficient immune systems of HIV-infected individuals.

Develop and evaluate various approaches of active and passive

immunotherapy for both HIV infection and its sequelae.

Develop a program of reconstituting the immune systems of HIV-infected individuals by administration of cellular elements in an autologous, syngeneic, or allogeneic fashion, including use of expanded peripheral blood T cells, bone marrow transplantation, thymic transplantation, cord blood, stem cells, and/or xenogeneic transplantation.

Develop new therapeutic strategies based on gene therapy approaches to protect hematopoietic stem cells and thereby reconstitute the immune system with HIV-resistant lymphoid, monocytic and other cellular compartments.

Use structural biologic techniques to determine the structures of various cytokines and cytokine receptors as potential targets for HIV therapies.

Increase collaboration of ICDs by joint funding of projects to facilitate the conduct of immune-based therapeutic trials and to enhance pathogenesis-related research in HIV-infected individuals.

Foster collaboration and better interactions with industry in developing and evaluating immunorestorative/immune-enhancing agents.

Define the mechanisms of immunomodulating agents and proceed with preclinical studies of the most promising agents.

Objective 4: Discover, develop, and evaluate potential agents for prevention and treatment of HIV-associated OIS and other infections modified by HIV infection.

Description: Opportunistic infections (PIs) are the most common cause of morbidity and mortality in HIV-infected individuals. Continuing to develop and evaluate therapies for preventing and treating OIs is essential for decreasing morbidity and improving survival.

Action Steps: Support basic research on OIs in order to increase fundamental knowledge and to identify new therapeutic targets and strategies and understand how pathogens contribute to morbidity. Determine the high resolution molecular structures for OI proteins and apply these structures to the rational design of drugs as part of the targeted drug development program and determine generalizable and effective approaches for the use of macromolecular structure in designing drugs to combat OIs

associated with AIDS.

Support discovery and preclinical programs to develop therapies especially targeting cryptosporidia, microsporidia, JC virus, HPV, and azole-resistant fungal organisms, with emphasis on bioavailable agents with favorable pharmacokinetics. Develop *in vitro* culture systems for OIs such as *Pneumocystis carinii* (PCP).

Further conduct clinical trials for the prophylaxis and treatment of HIV-associated OIs in HIV-infected individuals. Important OIs include *Mycobacterium tuberculosis* infection (TB), *Mycobacterium avium* complex, cytomegalovirus infection, cryptosporidiosis, microsporidiosis, cryptococcal disease, azole-resistant fungal infection, toxoplasmosis, PCP, acyclovir-resistant herpes infections, progressive multifocal leukoencephalopathy (PML), bacterial infections, and other infections whose course is affected by HIV. Evaluate immune-based therapies as adjuncts for treating OIs.

Determine the optimal strategies and combinations of agents to prevent and treat multiple OIs (by simultaneous prophylaxis of multiple opportunistic pathogens) and determine their effects in combination with antiretroviral agents. Strategies need to focus on the subgroups at increased risk, time of initiation, compliance, pharmacologic interactions, toxicities and adverse reactions (e.g. trimethoprim sulfamethoxazole reactions), and minimizing development of resistance; studies should include quality-of-life assessments and cost-benefit analyses.

Develop and utilize animal models for preclinical efficacy, pharmacokinetics, and safety testing of potential agents for OIs, including mutagenicity and teratogenicity.

Develop clinically useful assays for the rapid diagnosis of disease, treatment response, and sensitivity testing of OIs, especially TB, MAI, enterics, and infections produced by CMV, fungi, *Toxoplasma*, and JC virus, including use of specimens in existing repositories.

Determine the role and capability of preexisting immunity (both induced and natural) to control OIs and the ability of HIV-infected individuals to respond to vaccination throughout the course of infection and disease; assess possible interaction of vaccination and HIV replication.

Explore the bidirectional interactions between OIs and HIV infection including possible impact of opportunistic pathogens on the clinical expression and acceleration of HIV disease and vice

versa.

Support clinical trials to evaluate the safety and pharmacokinetics of existing and experimental agents for use in preventing and treating OIs in HIV-infected infants, children, and pregnant women.

Objective 5: Develop, evaluate, and implement strategies for interrupting vertical transmission of HIV from mother to child and extend out understanding of perinatal transmission and the pathogenesis of early infection (treatment of children will be addressed in other objectives).

Description: Vertical transmission of HIV from mother to child is the predominant mode of transmission for pediatric HIV infection. The identification, development, and testing of interventions should be based on the pathogenesis of transmission.

Action Steps: Support the rapid translation of basic research observations to strategies for the interruption of vertical transmission; apply the results of clinical trials to the investigation of pathogenesis and to clinical practice.

Support national and international collaborative studies to retrospectively and prospectively evaluate potential obstetric factors associated with vertical transmission including non-protocol use of antiretroviral agents.

Develop and evaluate strategies for interrupting the vertical transmission of HIV from pregnant women to their offspring that are simpler and less costly than the current AZT regimen and derive information on pathogenesis of transmission from the study of these strategies. Such strategies include antiviral agents, anti-HIV immunoglobulin, monoclonal antibodies, vitamin supplementation (e.g. vitamin A), HIV vaccines, adjuvants, virucides, and other intrapartum interventions alone and in combination.

Evaluate the safety, toxicity, pharmacokinetics, and antiretroviral activity of anti-HIV agents in pregnant women and newborns; explore the use of highly active agents that may develop resistance rapidly and could be used in this setting.

Assess the potential efficacy and feasibility of obstetric interventions to prevent vertical transmissions, such as cesarean deliveries and other aspects of intrapartum care.

Develop and improve sensitive and specific diagnostic parameters

that are accessible and cost-effective to permit early differentiation of HIV infection status in children born to HIV-infected mothers.

Investigate the role of the placenta in transmission of anti-HIV drugs from mother to fetus.

Expand the obstetrical and pediatric infrastructure for the conduct of perinatal trials through collaborative efforts, particularly in the international setting.

Support the long-term followup of women and children who participate in perinatal trials to evaluate potential distant effects of antiretroviral agents and/or biologicals.

Evaluate the risk of vertical transmission of drug-resistant virus.

Evaluate incorporation of ACTG 076 AZT regimen into clinical practice in the United States.

Evaluate therapeutic strategies for treating infants during acquisition of HIV to determine whether disease progression can be significantly altered.

Objective 6: Discover, develop, and evaluate improved strategies for the treatment and prevention of HIV-associated malignancies and extend our understanding of the risk factors for and pathogenesis of such malignancies.

Description: HIV-associated malignancies have a significant impact on morbidity and mortality, and some are expected to become increasingly common as survival with severe immune dysfunction is prolonged and as the demographics of HIV infection change. The development of methods to identify persons at high risk for subsequent malignancy, and the identification, development, and clinical testing of new therapeutic strategies for these malignancies are essential.

Action Steps: Support basic research on HIV-associated malignancies to increase fundamental knowledge of the etiology, pathogenesis, and biology of these neoplasms; develop preclinical models for testing potential therapeutic strategies.

Identify novel mechanisms and targets (e.g. cytokines, angiogenesis, viral or hormonal cofactors) for treatment and prevention of HIV-associated tumors, including Kaposi's sarcoma (KS), non-Hodgkin's lymphoma, HPV-associated malignancies, and

others, and develop new therapeutic strategies on the basis of these findings.

Use structural biologic and biochemical information to rationally design drugs to inhibit specific pathogenic factors of HIV-associated malignancies.

Develop *in vivo* models (SCID/nude mouse) for pathogenesis and drug sensitivity testing.

Develop *in vitro* models of KS as well as assays for angiogenesis inhibitors.

Encourage the develop and coordinate the conduct of clinical trials that concurrently evaluate antiretroviral and anti-OI therapeutic strategies directed against the malignancy in order to assess the effects of such treatment on the malignancy as well as on the underlying HIV infection, immune function, and clinical course.

Continue and expand screening, discovery and development of novel therapeutic agents with activity against HIV-associated malignancies (e.g. agents with better CNS penetration, agents with better safety profiles).

Develop trials to optimize existing therapies for malignancies in HIV-infected patients, including therapeutic adjuncts such as hematopoietic colony-stimulating factors and supportive care; develop and validate quality-of-life assessments.

Encourage collaborative studies to develop mechanisms for early identification of patients at high risk for malignancy and to develop and assess interventional strategies to reduce or prevent the development of malignancies.

Improve diagnostic methods for early diagnosis of malignancies and for early detection of recurrent cancer.

Improve collaboration between various adult and pediatric cooperative groups conducting clinical trials of HIV-associated malignancies and ICDs and industry to accelerate trials completion and approval of active agents.

Foster prompt referral of patients (co-registration) from antiretroviral trials to trials for AIDS-related malignancies.

Objective 7: Develop strategies for assessing, preventing, and treating central and peripheral nervous system dysfunction in the

course of HIV infection.

Description: Nervous system impairment, including AIDS-related cognitive/motor dysfunction (formerly AIDS dementia complex), and peripheral nerve/spinal cord dysfunction are serious sequelae of HIV disease.

Action Steps: Develop novel strategies and agents that are active against putative pathways of HIV-induced CNS dysfunction, e.g inhibitors of quinolinic acid, excitatory neurotransmitters, gp160/120, and other potential neurotoxins.

Implement studies related to the delineation of mechanisms responsible for impaired neurocognitive development in children born to HIV-infected mothers, and develop strategies directed at the prevention and treatment of this complication of HIV infection; utilize insights from the impaired state to better understand the course of normal neurocognitive development.

Implement clinical trials addressing nervous system complications of HIV infection and incorporate neurologic and neuropsychological assessments into other HIV-related clinical trials.

Develop therapeutic agents and/or delivery systems that are capable of crossing the blood-brain barrier and develop carriers that capitalize on different mechanisms to deliver drug to the CNS and are active against HIV infection; assess the safety of these different preparations; develop an understanding of physical and physiological mechanisms involved in penetration of the blood-brain barrier, and possibly develop agents that could conceivably block HIV entry into the CNS.

Better delineate etiologies of peripheral neuropathy in HIV infection, and develop strategies to prevent and treat this complication.

Develop and utilize *in vitro* and animal models of CNS impairment and AIDS-related cognitive/motor dysfunction to further identify agents that can reverse HIV neuropathogenesis.

Implement assessments and approaches for the diagnosis of HIV-related dementia in clinical studies; improve implementation of standardized adult, adolescent, and pediatric neuropsychologic and neurologic assessment batteries in clinical studies and evaluate treatment-induced changes in neurocognitive impairment in a linguistically and culturally sensitive context.

Develop alternative methods for detecting and assessing response to treatment of central and peripheral nervous system dysfunction including brain structural, spectroscopic, and functional imaging (for dementia); develop quantitative summary testing and examination of cutaneous nerve fibers in neuropathy.

Objective 8: Develop and evaluate therapies for the treatment and prevention of serious HIV-associated complications, especially

wasting syndrome and growth failure, as well as other disorders including hematologic, dermatologic, renal, metabolic, pulmonary, and oral manifestations.

Description: Important clinical sequelae of HIV infection include wasting syndrome, growth failure, metabolic disorders, dermatologic disorders, ITP, nephropathy, oral diseases, and other symptoms and serious complications. Drugs and strategies that can treat these sequelae are needed to ameliorate these conditions.

Action Steps: Develop and evaluate therapeutic strategies for preventing and ameliorating the various sequelae of HIV infection (listed above in the Description) and increasing understanding of their pathogenesis.

Develop and validate quality-of-life parameters for adults and children for the various sequelae of HIV infection (listed above in the Description).

Develop and evaluate therapeutic strategies for alleviating the various symptoms of unclear etiology in HIV-infected persons (listed above in the Description) and improving the quality of life.

FY 95: \$462,929,000

FY 96: \$472,944,000

FY 97: \$470,042,000

Populations Served: All populations.

Constituency Involvement: Researchers, clinicians, community and patient representatives, and NIH-affiliated advisory councils and committees.

Unmet Needs: The NIH FY 1996 Plan and Budget Estimate for Scientific Opportunities in HIV-Related Research identified areas for further productive research in this area in the amount of \$75,363,000 over the FY 97 figure.

Agency: Department of Health and Human Services, the National Institutes of Health

Goal: To support basic and clinical vaccine research for the purpose of developing a preventive HIV vaccine.

Objective 1: Increase scientific knowledge of host defense mechanisms leading to protection against HIV infection and disease.

Description: More basic knowledge is needed to define protective immune responses to HIV in order to facilitate the development of vaccines and other immunologic strategies to prevent and control HIV infection.

Action Steps: Develop animal models that are practical and as much as possible are representative of the spectrum of HIV infections and AIDS; models should be amenable to use in evaluating protection by vaccines and, where this can be demonstrated, determining the correlates of protective immunity.

Determine the mechanisms of immunologically mediated control of infection with HIV and other related retroviruses, including the role of specific and nonspecific immunity in inhibiting viral replication.

Additional basic knowledge is needed to determine:

- factors, including persistence of antigens, that favor establishment of memory and development of long-term protective immunity;
- the heterogeneity of specific responses to an immunogen within distinct compartments of the immune system;
- factors that promote development of particular effector cell types;
- mechanisms resulting from exposure to HIV that interfere with induction or propagation of vaccine-induced effector responses;
- mechanisms of virus neutralization.

Study acutely infected individuals, exposed/uninfected humans (and other primates), and rapid/nonprogressors to determine viral and host factors that impact amounts of circulating virus and disease course; ensure that plasma, PBMC, biopsy, autopsy, and

other key patient and animal samples, including CNS samples, are accessible to qualified laboratories.

Define and characterize viral B cell and T cell epitopes that induce protective immunity; understand their structure and antigenicity and determine whether and how their immunogenicity can be exploited in vaccine development; and define epitopes in which substitutions cannot be tolerated by the virus.

Determine whether infection with one strain of HIV or related retroviruses confers protection against subsequent infection with a second strain; determine the protective mechanism and timing.

Understand how and why HIV and related lentiviruses evade or escape from humoral and cellular arms of the immune response.

Explore strategies to elucidate the obligate mechanisms for protective immunity against HIV, including amplification of selected responses by passive transfer of Ab or immune cells and subtraction by deletion of selected components of the immune system.

Study chronic infection with attenuated viruses, such as SIV variants shown to induce strong protection against virulent SIV strains in macaques, to understand what properties of the virus and the immune system are responsible for lack of disease induction and protection from challenge with wild-type virus.

Explore the molecular epidemiology and serology of HIV-1 populations relevant to vaccine trials and collect clinical material from these populations for scientific analysis. Acquire epidemiological information to assist in interpretation of these analyses.

Develop quantitative measures of HIV concentration in bodily fluids to determine whether there is a relationship between HIV concentration and transmission and to determine the effect of concurrent STDs on HIV shedding.

Objective 2: Apply findings from basic, epidemiologic, and clinical research to the design and evaluation of vaccine strategies in laboratory studies and animal models, and foster collaboration with industry in the research and development of candidate vaccines.

Description: The identification of viral antigens and vaccine delivery methods that elicit long-lasting protective immune responses against a broad range of HIV isolates will facilitate

development of effective vaccines.

Action Steps: Support the design and development of potential vaccines, including vaccines composed of:

- whole-killed HIV and genetically engineered, noninfectious HIV mutants that lack the viral RNA genome or have a defect in a critical gene necessary for replication but contain an array of HIV genes for expression of antigenic proteins;
- live, recombinant viral and bacterial vectors engineered to express one or more HIV proteins;
- naturally occurring and genetically engineered, live-attenuated strains of HIV;
- synthetic peptide candidates capable of inducing and boosting both cellular and humoral immunity;
- DNA coding for viral proteins;
- agents that stimulate mucosal immune responses;
- a combination of the above agents and preparations;
- other novel agents and preparations.

Evaluate the efficacy of vaccine strategies in animal models of HIV and related lentiviruses. To accomplish this:

- test vaccine strategies in animal models that most closely mimic the HIV infection in humans;
- determine the effect of vaccine formulation and regimen as well as the nature, timing, and route of vaccine challenge on the characteristics and effectiveness of the vaccine-induced immune response;
- define the impact of different vaccine approaches on kinetics of immune responses, kinetics and localization of viral replication, disease progression, and biologic characteristics of breakthrough virus including transmissibility;
- conduct long-term followup of vaccinated animals that become chronically infected to determine the impact of vaccination on disease progression;

- develop assays to distinguish between infection and serological responses due to immunization.

Support design and development of methods to improve or modulate immune responses (qualitatively or quantitatively), including:

- novel adjuvants and presentation methods;
- vaccines incorporating cytokines or other biologically active molecules;
- establishment of physical or biological reservoirs for long-term antigen presentation;
- other novel strategies.

Encourage development of candidate vaccines of suitable antigenic types and possessing stability and route of administration

characteristics appropriate for international as well as domestic use.

Characterize and evaluate the potential negative side effects of candidate vaccines, including production antibodies enhancing neurotoxicity and oncogenicity.

Develop better *in vitro* methodologies to measure immune responses to primary viral isolates.

Develop infrastructure, and address scientific, legal, and regulatory issues to foster and encourage participation by, and collaboration with, industry and other agencies in the research, development, production, and clinical testing of candidate vaccines.

Objective 3: Select candidate vaccines or concepts suitable for Phase I and Phase II trials and conduct these trials.

Description: Suitable candidate vaccines need to be selected and evaluated in Phase I and Phase II trials to determine safety and immunogenicity.

Action Steps: Support the conduct of Phase I and Phase II coordinated clinical trial that will determine long-term and short-term safety and compare immunologic responses to preventive vaccine candidates; include a broad range of humoral, cell-mediated, and mucosal immune parameters;

Develop a mechanism to evaluate the suitability of vaccine candidates for entry into Phase I and Phase II trials; evaluation criteria should include originality and intrinsic value of the concept and animal model data.

Develop strategies at the local and national levels to reduce social and economic risk to volunteers in Phase I and Phase II trials to facilitate broad participation.

Design and conduct Phase II trials using promising HIV vaccines that are also genetically or immunologically related to HIV isolates circulating in the proposed trial population and of an appropriate size to facilitate decisions regarding efficacy trials. Analyze immune responses in vaccines and appropriate controls. Isolate and characterize virus and follow clinical course and immune responses of vaccines who become HIV-infected.

Study viral isolates from participants in HIV vaccine trials and selected controls to explore the possible effects of vaccination on the characteristics of transmitted viruses.

Conduct behavioral research on trial participants to establish whether their risk behavior has been influenced by participation in a vaccine trial, with emphasis on individuals who become infected while participating.

Closely coordinate the evaluation of research findings on prophylactic AIDS vaccines with preclinical research and immunotherapeutic interventions.

Objective 4: Identify mechanisms of protective immunity to HIV in newborns and infants and support the development of safe and effective immunologic strategies for preventing or controlling HIV infection in this population.

Description: Distinct approaches and infrastructure are needed to achieve protection of newborns and infants because of the unique nature of their immune responses and modes of exposure to HIV.

Action Steps: Determine what viral, immunologic, and nonimmunologic host factors influence transmission of HIV-1 from mother to infant;

- Compare virus isolates that are and are not transmitted from mother to infant;
- Seek maternal and infant immune responses that might prevent transmission to infants.

Develop and maintain domestic and international infrastructure necessary to enroll mothers and infants in prospective long-term followup vaccine trials and other interventions.

Determine the safety and immunogenicity of various HIV vaccines and adjuvants in relevant animal models of maternal-fetal and maternal-infant transmission to evaluate safety, immunogenicity, and efficacy of candidate vaccines.

Select and evaluate antibody and/or cellular preparations in passive or passive/active HIV prevention studies.

Establish criteria for advancement of candidates in Phase I, Phase II, and Phase III clinical trials in children.

Conduct Phase I, Phase II, and Phase III clinical trials in children for the most promising candidates that meet established criteria.

Objective 5: Identify appropriate domestic and international population and develop infrastructure and collaborations with government, communities, and industry necessary for ensuring adequate performance of Phase III efficacy trials.

Description: Preparation for HIV vaccine efficacy trials requires development of an infrastructure and a series of studies and planning activities to ensure their feasibility.

Action Steps: Develop domestic and international sites with access to populations at high risk for acquiring HIV infection, where vaccine or other prevention research activities may be feasible.

Establish linkages with communities or community organizations where efficacy trials might be conducted to optimize education, recruitment, and followup activities and to help address community concerns related to AIDS vaccine efficacy trials.

For international trials, work closely with national (host) governmental and regulatory authorities, collaborating institutions, vaccine manufacturer(s), and the World Health Organization to plan and conduct vaccine efficacy trials adhering to the highest ethical and scientific standards.

Carry out appropriate epidemiologic studies that determine the risk profiles and infection rates of various populations in the United States and worldwide in order to identify those groups most likely to be the participants in vaccine trials.

Maintain the necessary laboratory infrastructure at designated sites for conducting domestic and international vaccine efficacy trials.

Acquire and analyze HIV isolates from recent seroconverters representative of potential efficacy trial populations so that genetic and antigenic information about virus circulating in the population can be obtained.

Evaluate other biomedical and behavioral interventions that could prove of benefit in decreasing the incidence of HIV infection in the populations identified for future vaccine efficacy trials and assess their potential impact on the evaluation of vaccine efficacy.

Conduct behavioral research in populations at high risk for HIV infection to determine, for example, appropriate risk-reduction interventions and to estimate risk behavior and recruitment, adherence, and retention strategies pertinent to the design and execution of a successful efficacy trial, especially for populations that have been historically underrepresented in clinical trials.

Determine possible adverse social, economic, or legal consequences of participation in clinical trials, and develop strategies for mitigating potential harm.

Determine optimal methods of achieving informed consent for vaccine efficacy trials.

Prepare for adequate long-term followup of individuals participating in vaccine clinical trials where it will be necessary to determine the longevity of immune response, the correlates of immune protection, long-term safety, the impact of participation on risk-taking behavior, and the possible positive or negative effects of vaccine immunization against disease progression and HIV transmission.

Encourage linkage between vaccine preparedness studies in high-risk populations and other research activities including research on TB and STDs; and integrate research on vaccines against opportunistic infections as appropriate.

Objective 6: Select suitable vaccine candidates and support efficacy trials when appropriate criteria are met.

Description: Conduct HIV vaccine efficacy trials of the most promising candidate vaccines in well-characterized, high-risk

populations to identify effective vaccines for the control of HIV infection.

Action Steps: Establish criteria with concurrence of an advisory group that has the requisite scientific, public health, government and community expertise.

Conduct large-scale efficacy trials of preventive vaccine candidates that have proven promising, safe, and immunogenic in Phase II trials and that meet appropriate criteria;

- Evaluate HIV vaccine candidate efficacy against infection and disease;
- Evaluate additional virologic, immunologic, and behavioral outcomes, particularly correlates of protective immunity.
- Ensure that trials are conducted with the highest regard for social and ethical standards.

FY 95: \$100,399,000

FY 96: \$109,533,000

FY 97: \$116,132,000

Populations Served: All populations.

Constituency Involvement: Researchers, clinicians, community and patient representatives, and NIH-affiliated advisory councils and committees.

Unmet Needs: The NIH FY 1996 Plan and Budget Estimate for Scientific Opportunities in HIV-Related Research identified areas for further productive research in this area in the amount of \$38,639,000 over the FY 97 figure.

The National Strategy for HIV and AIDS, Appendix B: Research
Draft for ONAP Review: 7.22.96

Agency: Department of Health and Human Services, the National Institutes of Health

Goal: To support behavioral and social science research for the purpose of furthering understanding of behaviors associated with HIV transmission in addition to developing and improving HIV prevention interventions.

Objective 1: Support research to develop and evaluate social and behavioral interventions at the societal, community, organizational, and individual levels to reduce HIV transmission by reducing HIV-related risk behaviors and increasing protective behaviors. Multi-site and cross-national studies are encouraged.

Description: Studies have demonstrated that HIV-related risk behaviors can be measured and modified. In response to the evolving epidemic, an expanded HIV prevention research agenda is called for on what works, for whom, where, for how long, and at what cost.

Action Steps: Develop and evaluate the effectiveness and cost-effectiveness of demographically and culturally appropriate behavioral and social interventions in different domestic and international settings and populations to reduce high-risk HIV-related behaviors and HIV transmission (e.g. through safer sexual practices, increased use of condoms and other barrier methods, use of sterile injection equipment, and reduction of high-risk drug-related behaviors).

Support research on a range of HIV prevention strategies in a variety of settings for both emerging populations and groups that continue to be at high risk for HIV.

Support research to increase the effectiveness and cost-effectiveness of drug abuse, mental health, and alcoholism treatment, including the development of new pharmacotherapies, to reduce HIV-related risk behavior in different settings and populations.

Support research (including multi-site and cross national studies) on comprehensive interventions that integrate various HIV and STD prevention and family planning approaches.

Support research to improve the access to, delivery of, evaluation, and cost-effectiveness of services that reduce HIV risk behaviors and transmission.

Design and test interventions to increase recruitment, retention,

and adherence to protocols for HIV prevention research, including prophylactic vaccines.

Support research to improve the transfer of effective interventions to and from community planning processes.

Objective 2: Support basic research to strengthen the understanding of determinants and processes that influence HIV-related risk behaviors and the consequences of HIV disease.

Description: Understanding the basic factors influencing behavior and behavior change at the societal, community, organizational, and individual levels is necessary for the development of interventions to prevent the transmission of HIV and to ameliorate its adverse consequences. Research is needed to define the behavioral, psychological, cognitive, and social consequences of HIV infection, disease progression, and treatment.

Action Steps: Develop models of behavior and behavior change that integrate biological, psychological, and social perspectives to explain and predict the acquisition, change, and maintenance of HIV-related behaviors among individuals and groups in various settings.

Study the social, structural, and cultural factors such as class, ethnicity, sexual identification, age, and gender that influence HIV-related behavior, affect access and delivery of care, and determine intervention strategies.

Study the development and maintenance of HIV-related risk and preventive behaviors in specific social contexts such as the sexual dyad, peer groups, social and drug-using networks, families, and communities.

Conduct research on decision-making processes, which may include disclosure of one's HIV-status, choice of treatment options, and adoption of protective behaviors.

Support research to understand the processes of how communities become involved in HIV intervention research.

Identify the behavioral, psychological, cognitive, and social consequences of HIV disease for HIV-seropositive individuals, their support systems (e.g. partners, family members, and other care givers), and their communities.

Support studies in animal models in behavior and behavior change

relevant to HIV infection and prevention.

Conduct research that identifies the social and behavioral factors affecting recruitment, retention, and adherence in clinical trials.

Conduct research on the barriers to preventive actions based on lack of trust and misinterpretations of meaning of information related to HIV.

Objective 3: Support research for the discovery, development, and evaluation of strategies for preventing or minimizing the negative physical, psychological, cognitive, and social consequences of HIV, including stigmatization of persons with or at-risk for HIV infection. Support research strategies for promoting effective health care utilization among persons with HIV infection.

Description: Enhancement of the quality of life of seropositive individuals and facilitation of HIV treatment require further research on interventions to affect the physical, behavioral, psychological, cognitive, and social consequences of HIV infection, disease progression, and treatment. Research is also needed to improve delivery of care to diverse population groups.

Action Steps: Develop and evaluate interventions for promoting quality of life and to delay or prevent physical, behavioral, psychological, cognitive, and social consequences.

Promote research to identify and remove barriers to effective health care utilization among persons with or at-risk of HIV infection, including access, engagement, followup, and adherence to health and social services across the care continuum (e.g. testing and counseling, health care-seeking behavior, adherence, case management, and home/hospice care). This strategy may entail developing and testing innovative models of treatment delivery for HIV disease at all illness stages.

Develop and evaluate interventions for promoting increased recruitment, adherence, and retention, especially in underrepresented populations, in HIV treatment and clinical trials.

Test models of care-giving for people living with HIV disease, their significant others, extended family members, and care providers.

Develop and evaluate interventions for preventing social

stigmatization of persons with or at-risk of HIV infection and AIDS in different settings (e.g. workplaces, schools, health care facilities, and prisons).

Objective 4: Support research to advance innovative quantitative and qualitative methodologies to enhance HIV behavioral and social science research.

Description: Behavioral and social science methods have greatly advanced our understanding of HIV transmission and health maintenance. Further refinement of established methods and rapid development of emerging technologies are essential to continued improvement of our knowledge of HIV-related behaviors; our understanding of linkages between HIV-related risk behaviors, transmission, and disease progression; and the evaluation of interventions.

Action Steps: Develop improved qualitative and quantitative methodologies for studying behavioral and social factors associated with HIV, including improved methods for validating self-report data, improved measurement tools for surveys, and the measurement of change over time.

Develop improved sampling strategies for subpopulations and culturally and linguistically sensitive and appropriate research instruments.

Develop improved methods and techniques for dealing with subject attrition and missing data.

Encourage secondary data analysis by developing techniques to protect confidentiality and by using of meta-analysis.

Develop and refine techniques for measuring social networks associated with HIV.

Develop and refine research techniques for measuring responses by organizations to HIV and for characterizing organizations working in the HIV field.

Encourage studies that will support multi-site studies and cross-national comparisons.

Develop and refine mathematical models for linking behavior change interventions with reduction in HIV transmission.

FY 95: \$170,984,000

FY 96: \$174,077,000

*The National Strategy for HIV and AIDS, Appendix B: Research
Draft for ONAP Review: 7.22.96*

FY 97: \$180,238,000

Populations Served: All populations.

Constituency Involvement: Researchers, clinicians, community and patient representatives, and NIH-affiliated advisory councils and committees.

Unmet Needs: The NIH FY 1996 Plan and Budget Estimate for Scientific Opportunities in HIV-Related Research identified areas for further productive research in this area in the amount of \$25,655,000 over the FY 97 figure.

*The National Strategy for HIV and AIDS, Appendix B: Research
Draft for ONAP Review: 7.22.96*

Agency: Department of Health and Human Services, the National Institutes of Health

Goal: To support training and infrastructure development programs for the purpose of improving the training and resources available to HIV researchers.

Objective 1: provide both domestic and international training in biomedical and behavioral research on HIV.

Description: Meeting the needs of research on HIV/AIDS requires recruiting and training basic, clinical, and behavioral scientists in the United States and abroad in the many disciplines necessary to carry out this diverse scientific agenda.

Action Steps: Increase predoctoral and postdoctoral training, as well as advanced research training, in a range of AIDS-related disciplines to a level comparable (about 3 percent of the budget) to that of other training programs within NIH.

Sponsor an annual AIDS Fellows Meeting to promote collaboration and information dissemination.

Increase training of scientists and clinical investigators in basic AIDS research to better link basic and clinical pathogenesis research.

Stimulate predoctoral and postdoctoral training in prevention, behavior change, and adherence and compliance to treatment.

Promote training of biomedical and behavioral scientists in the use of high-performance computing systems for HIV-related research.

Expand training and research capacity to deal with the epidemic of tuberculosis (TB), including multiple drug resistance associated with HIV infection.

Increase participation in the Fogarty International Center (FIC)-sponsored international training and research programs and expand these programs by recruiting trainees from additional countries in Asia and Latin America, with the long-term goal of providing AIDS-related training for leading health scientists from all developing countries.

Develop new grant mechanisms to link U.S. AIDS research scientists and institutions with leading AIDS research

scientists and institutions in foreign countries.

Expand both predoctoral and postdoctoral training in structural biology.

Expand the NIH AIDS Loan Repayment Program to bring scientists and physicians to the NIH to expand the cadre of trained intramural researchers.

Expand both pre- and post-doctoral domestic and international AIDS-related training in epidemiology, biostatistics, and behavioral methodologies.

Establish and expand appropriate career training programs for laboratory investigators, clinical investigators, and translational scientists (i.e. making the transition from bench to patient).

Enhance training of investigators in applied immunobiology.

Support training of basic investigators, clinical investigators, and translational investigators for OI research.

Support training of basic investigators, clinical investigators, and translational scientists for research on malignancies in HIV-infected patients.

Collaborate with other PHS agencies in the development of training regarding HIV prevention, treatment, research, and education for health care providers, AIDS service providers, and health educators.

Objective 2: Establish appropriate infrastructure for the conduct of HIV research domestically and internationally.

Description: The conduct of HIV research in the United States and abroad requires establishment of infrastructure to carry out this research program, including facilities and instrumentation, computers, data communications, laboratories, and animal colonies.

Action Steps: Provide additional facilities to study animal models of pediatric AIDS.

Foster animal models to study HIV-related malignancies.

Continue the Research Facilities Infrastructure Program (RFI) and

*The National Strategy for HIV and AIDS, Appendix B: Research
Draft for ONAP Review: 7.22.96*

General Clinical Research Centers (GCRC) Program.

Expand the use of the National Research and Education Network (NREN) for national and international collaboration and data communications.

Provide for expansion of breeding facilities to ensure the adequate supply of species of emerging importance, e.g. *M. nemestrina*.

Provide NCRR animal model support tied to needs of basic research grants.

Provide for the long-term support of advanced in-country research and research infrastructure in those developing countries participating in efficacy trials of candidate HIV vaccines and other priority intervention research.

Develop and support animal models predictive of human behavior, specifically, models of non-human primate behavior of impaired impulse control and risk-taking.

Provide additional laboratory and biocontainment facilities for primate research.

Increase support for the Internet connections program at health sciences centers and hospitals for research and patient care.

Establish and support repositories of samples obtained from individuals with HIV infection for current and future studies.

Increase support for screening the development of HIV macaque monkey models.

Develop and support Regional Primate Research Center (RPRC) expertise in molecular immunology, peptide biochemistry, and pharmacology.

Provide for the establishment of specific pathogen-free (SPF) non-human primate programs at all the RPRCs.

Provide further support for the development of SPF macaque colonies.

FY 95: \$46,483,000

FY 96: \$44,643,000

FY 97: \$44,335,000

Populations Served: All populations.

Constituency Involvement: Researchers, clinicians, community and patient representatives, and NIH-affiliated advisory councils and committees.

Unmet Needs: The NIH FY 1996 Plan and Budget Estimate for Scientific Opportunities in HIV-Related Research identified areas for further productive research in this area in the amount of \$14,368,000 over the FY 97 figure.

*The National Strategy for HIV and AIDS, Appendix B: Research
Draft for ONAP Review: 7.22.96*

Agency: Department of Justice

Goal: To estimate the prevalence of HIV/AIDS among the corrections and parole population and to monitor the HIV/AIDS-related policies of Federal, State, and local correctional agencies.

Objective: Data collection and dissemination of periodic reports.

Action Steps: Conduct surveys of federal, state and local prisons and inmates and publish results in periodic reports.

Descriptions: When published, the 1995 Survey on Probation, the 1996 Survey of Inmates in Local Jails, and the 1997 Survey of State and Local Federal Inmates in Adult Correctional Facilities will contain estimates of HIV prevalence among probationers and inmates, and characteristics of this HIV positive population.

Publication of reports describing findings of multi-year project, "HIV Education in Lockups and Booking Facilities."

1994 Survey of HIV/AIDS in Correctional Facilities.

Publication of 1996 report "HIV/AIDS and STDs in Juvenile Facilities."

Census of prison, survey of jail and prison inmates and probationers, and study examining research on prevention programs directed towards persons whose behavior makes them vulnerable to HIV infection.

FY 95: Part of overall operating budget.

FY 96: Part of overall operating budget.

FY 97: Part of overall operating budget.

Populations Served: Department of Justice, corrections administrators, and public.

Constituency Involvement: None.

Unmet Need: Funding for research into requirements for effective management of HIV positive inmates.

Funding to conduct surveys of individual facilities and increase surveys of the juvenile system, and to conduct additional work in the areas of prevention and education.

Agency: Department of Veterans Affairs

Goal: To utilize the unique resource of the VA-served patient population to further biomedical, health services, and rehabilitation research on HIV and AIDS.

Objective 1: Support AIDS-related research as a high priority area within the VA-served patient population utilizing the unique resources.

Action Steps: Fund research with high technical and scientific merit.

Continue to fund AIDS-related research through existing funding mechanisms, i.e., investigator-initiated studies, cooperative studies, and research centers.

Collaborate with other federal departments and agencies in initiating and conducting AIDS relevant research (including joint funding of projects), thereby making the unique resources of VA available to collaborating investigators.

Provide applicants for research support with feedback on the technical and scientific quality of their proposals.

Objective 2: Develop and maintain AIDS Research Centers to stimulate and emphasize importance of HIV/AIDS research in VA's unique population.

Action Steps: Establish AIDS Research Centers based on competitive proposal basis.

Objective 3: Encourage collaboration with other Federal departments and agencies in initiating and conducting AIDS-related research.

Action Steps: Facilitate investigator requested funding by NIH, other Federal agencies.

Support participation in community trials on individual investigator and medical center basis.

Objective 4: Disseminate research findings.

Action Steps: Publish and present findings of research in peer reviewed journals, and at national and international conferences.

Description: Research activities.

*The National Strategy for HIV and AIDS, Appendix B: Research
Draft for ONAP Review: 7.22.96*

FY 95: \$ 5,400,000 *

FY 96: \$ 5,700,000 *

FY 97: \$ 5,700,000 *

(* Estimated expenditures for HIV/AIDS research are part of the general Medical and Prosthetics Research budgets. FY 1996 and FY 1007 estimates are based on the resource levels contained in the President's budget.)

Populations Served: Veteran patients, general public, researchers.

Constituency Involvement: Veteran patients, scientific community, general public at large.

Unmet Need: Increased funding would enhance ability to involve VA's unique population in research and thereby increasing patients' access to research and the research knowledge base.

*The National Strategy for HIV and AIDS, Appendix B: Research
Draft for ONAP Review: 7.22.96*

Agency: Department of the Treasury

Goal: Through tax code policies, provide incentives for privately-sponsored research, including HIV-related research.

Objective: Encourage private sector investment in medical research, including HIV-related research.

Action Steps: Support the revenue neutral extension of the Research and Experimentation Tax Credit and the Orphan Drug Tax Credit.

Descriptions: Research and Experimentation (R&E) Tax Credit and Orphan Drug Tax Credit.

FY 95: Not applicable.

FY 96: Not applicable.

FY 97: Not applicable.

Populations Served: Private sector entities supporting research.

Constituency Involvement: The National AIDS Drug Development Task Force, comprised of industry and government representatives and patient advocates, supported these policies.

Unmet Need: ???

National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96

Agency: Department of Defense

Goal: To provide state-of-the-art patient-centered comprehensive care for all eligible service members throughout the asymptomatic and symptomatic phases of HIV and AIDS.

Objective: Provide immediate evaluation and continuity of care for service members who become HIV positive.

Through contact tracing, identify persons at risk and provide consultation and evaluation. Refer to care as appropriate.

Provide continuation of employment until no longer physically fit for duty.

Action Steps: Conduct periodic screening of active duty personnel;

For HIV positive personnel, provide comprehensive evaluation, treatment, and care;

Restrict assignment to continental U.S., Alaska, Hawaii, or Puerto Rico to assure continuity of medical care; and

Educate health care staff on best clinical practice for persons living with HIV.

Descriptions: Comprehensive state-of-the-art clinical care.

FY 95: \$2,000,000 to \$3,000,000

FY 96: \$2,000,000 to \$3,000,000

FY 97: \$2,000,000 to \$3,000,000

Populations Served: HIV positive active duty personnel.

Constituency Involvement: Clinicians, active duty personnel, military health providers, manpower and personnel administration staff.

Unmet Need: None.

Agency: Department of Health and Human Services, the Administration for Children and Families

Goal: To meet the social and support service needs of children, youth, and families with or at risk for HIV/AIDS.

Objective 1: Stabilize the crisis situation and provide needed services to runaway and homeless youth.

Action Steps: Provide shelter and immediate services including diagnostic medical services and education and prevention related to HIV/AIDS.

Descriptions: Runaway and Homeless Youth Program.

FY 95: NA -- HIV services integrated into overall budget.

FY 96: NA -- HIV services integrated into overall budget.

FY 97: NA -- HIV services integrated into overall budget.

Populations Served: Runaway and homeless youth at risk for HIV.

Constituency Involvement: A network of more than 500 grantees, both public and private.

Unmet Need: More services and resources need to be available, particularly in the areas of education and prevention.

Objective 2: Provide foster care and adoption services to abused, neglected, or otherwise needy children including those with HIV/AIDS.

Action Steps: Provide diagnostic and treatment services, counseling for children, parents, extended family, foster and adoptive parents, and others relevant to HIV/AIDS.

Descriptions: Child Welfare Services Program.

FY 95: NA -- HIV services integrated into overall budget.

FY 96: NA -- HIV services integrated into overall budget.

FY 97: NA -- HIV services integrated into overall budget.

Populations Served: Children in foster care and those placed in adoption, their parents, and extended families.

Constituency Involvement: National, professional, advocacy, and service organizations such as the Child Welfare League of America, American Public Welfare Association, National Association of Social Workers, and 56 State/Territorial grantees.

***National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96***

Unmet Need: More services and resources need to be available.

Objective 3: Support health and social services for abandoned infants and young children who have been drug-exposed and/or have HIV/AIDS.

Action Steps: Provide foster care, health services, counseling and other social services.

Descriptions: Abandoned Infants Assistance Program.

FY 95: NA -- HIV services integrated into overall budget.

FY 96: NA -- HIV services integrated into overall budget.

FY 97: NA -- HIV services integrated into overall budget.

Populations Served: Abandoned infants and young children who have been drug-exposed and/or have HIV/AIDS.

Constituency Involvement: Public and private providers of these services, grantees, and national resource agencies.

Unmet Need: Resources to serve geographic areas of unmet needs.

Objective 4: The Head Start Program provides comprehensive child development services to children, including those with HIV/AIDS, their parents, and families.

Action Steps: Services to Head Start families may include prevention and education, identification, and intervention related to HIV/AIDS; children with HIV/AIDS are enrolled in the on-going Head Start program.

Descriptions: Head Start Program.

FY 95: NA -- HIV services integrated into overall budget.

FY 96: NA -- HIV services integrated into overall budget.

FY 97: NA -- HIV services integrated into overall budget.

Populations Served: Low income pre-schoolers and their families, including pregnant women.

Constituency Involvement: National Head Start Association and related early childhood development organizations, such as National Association for the Education of Young Children.

Unmet Need: Increased resources will make services available to more children.

Objective 5: Support the independence, productivity, and integration into the community of persons with developmental disabilities.

Action Steps: Twenty-seven of the current 51 grantees operate Pediatric HIV/AIDS Clinics in or associated with the university.

Descriptions: University Affiliated Program

FY 95: NA -- HIV services integrated into overall budget.

FY 96: NA -- HIV services integrated into overall budget.

FY 97: NA -- HIV services integrated into overall budget.

Populations Served: Developmentally disabled persons, including those with HIV/AIDS.

Constituency Involvement: National network of grantees; national advocacy organizations related to HIV/AIDS and developmental disabilities.

Unmet Need: Although a university pediatric AIDS clinic is located in each state, not all patients have access to the services.

National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96

Agency: Department of Health and Human Services, the Health Care Financing Administration

Goal: To provide primary health care to Medicaid-eligible HIV positive persons.

Objective: Provide quality primary health to Medicaid-eligible HIV positive persons.

Action Steps: Assess state compliance with Medicaid program standards. Review and evaluate waiver applications. Encourage compliance with changes in the standard-of-care.

Description: Medicaid primary health care services.

FY 95: \$1,640,000,000 (Federal share)

FY 96: \$1,800,000,000 (Federal share)

FY 97: \$1,970,000,000 (Federal share)

Populations Served: HIV positive Medicaid-eligible persons.

Constituency Involvement: Information and activities routinely discussed with external groups at meetings and conferences.

Unmet Need: Since Medicaid is an entitlement program any unmet need is a result of State budgeting limitations.

Agency: Department of Health and Human Services, the Health Care Financing Administration

Goal: To provide quality home health care for HIV positive Medicaid and Medicare beneficiaries.

Objective: Provide quality standards for appropriate home health care services and treatment of HIV disease.

Action Steps: Identify current home health care practices through literature review and survey of best practices.

Descriptions: Develop and implement quality standards for appropriate home health care for HIV positive beneficiaries in partnership with private sector organizations and PHS agencies;

Develop directives in implementation of developed guidelines.

FY 95: \$25,000 (Conferences and materials)

FY 96: NA

FY 97: NA

Populations Served: HIV positive Medicaid and Medicare beneficiaries receiving home health care.

Constituency Involvement: Significant constituent consultation throughout course of project development.

Unmet Need: Implementation of directives dependent on nature and resources of each project partner.

National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96

Agency: Department of Health and Human Services, the Health Resources and Services Administration

Goal: To increase the number of competent primary care providers willing to care for HIV positive persons.

Objective: To increase the number of health care providers who are effectively educated and motivated to counsel, diagnose, treat, and manage individuals with HIV infection.

Action Steps: Support didactic and clinical training activities for primary health care providers in collaboration with Federal, state, and local HIV care programs;

Disseminate state-of-the art HIV information to providers; and

Develop and coordinate distribution of HIV provider materials.

Descriptions: A significant source of training takes place under the guidance of AIDS Education and Training Centers. In addition there are quarterly interactive conference calls with experts and providers, the National HIV Telephone Consultation Service (Warmline), phone consultation services, newsletters, bulletins, and provider guides for HIV priority areas (i.e., guidance for clinicians regarding the use of AZT for the prevention of perinatal transmission).

FY 95: \$16,287,000

FY 96: \$12,000,000

FY 97: \$16,287,000

Populations Served: Health care providers and people living with HIV disease.

Constituency Involvement: Faculty, staff, advisory committees, training panels, persons living with AIDS, and academic faculty.

Unmet Need: Not enough adequately trained health care providers to meet patients demand, and, inadequate resources to meet provider training needs.

National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96

Agency: Department of Health and Human Services, the Health Resources and Services Administration

Goal: To reduce barriers to obtaining dental care for HIV positive persons.

Objective: Increase the number of dental practitioners who provide care to HIV positive patients.

Assist dental schools in meeting uncompensated costs associated in providing oral health care to HIV positive patients.

Action Steps: Provide reimbursement to dental schools of uncompensated costs incurred in treating patients with HIV.

Descriptions: The AIDS Dental Reimbursement Program is designed to reimburse accredited dental schools and post doctoral dental programs for the documented uncompensated costs incurred from providing oral health treatments to HIV positive patients.

FY 95: \$6,937,000

FY 96: \$6,937,000

FY 97: \$6,937,000

Populations Served: Children and adults living with HIV.

Constituency Involvement: American Association of Dental Schools, American Association of Hospital Dentists, and the American Dental Association.

Unmet Need: Uncompensated costs that dental schools and hospitals incur are much more than the dollars available under the AIDS Dental Reimbursement Program.

***National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96***

Agency: Department of Health and Human Services, the Health Resources and Services Administration

Goal: To increase access to care and improve quality of life for persons living with HIV and AIDS.

Objectives: Through the Ryan White Comprehensive AIDS Resources Emergency (Care) Act (RWCA), improve accessibility and quality of care for all persons living with HIV.

Develop comprehensive and participatory planning processes at the state and local levels to guide funding allocation decisions.

Increase patient access to clinical research.

Establish quality guidelines and evaluate program effectiveness.

Action Steps: Support comprehensive outpatient, ambulatory health and support services, case management, and inpatient case management services that prevent unnecessary hospitalization or expedite discharge (RWCA Title I);

Support consortia to improve the quality and availability of health care, including home and community-based services, continuation of health insurance, purchase of AIDS drugs, direct provision of care for individuals and families living with HIV and AIDS (RWCA Title II);

Develop a minimum drug formulary for federally-assisted AIDS Drug Assistance Programs (ADAP --RWCA Title IV);

Support outpatient early intervention services for low-income medically underserved people in existing primary health care systems (RWCA Title III);

Support comprehensive care services for affected women, infants children, and youth in a comprehensive community-based, family-centered system of care (RWCA Title IV);

Support initial development of care systems linked to research for children, youth and women in 7 new communities;

Enhance linkages between care providers and sites where research is conducted;

Provide leadership, training, and technical assistance;

Convene youth and family leadership conferences and distribute

findings;

Develop, distribute, and train providers on quality indicators and quality assurance guidelines for the clinical management of HIV disease;

Develop guidance for grantees in developing local strategies for changes in the standard-of-care; and

Evaluate program effectiveness through development of common evaluation criteria of CARE Act grants that address program delivery and program outcomes and establishment of evaluation measures that are unique to each Title.

Descriptions: Provide RWCA-supported services through individual grantees and service organizations. In addition to these broad-based efforts, support a variety of focused initiatives such as the adolescent research and clinical network and a cooperative agreement with Institute of Family-Centered Care to provide training and technical assistance to youth and families.

FY 95: RWCA Title I: \$356,500,000
 RWCA Title II: \$198,147,000
 RWCA Title III: \$ 52,318,000
 RWCA Title IV: \$ 26,000,000

FY 96: RWCA Title I: \$391,700,000
 RWCA Title II: \$260,847,000
 RWCA Title III: \$ 56,918,000
 RWCA Title IV: \$ 29,000,000

FY 97: RWCA Title I: \$423,943,000
 RWCA Title II: \$284,954,000
 RWCA Title III: \$ 64,568,000
 RWCA Title IV: \$ 34,000,000

Populations Served: HIV positive individuals and their family members, low income persons with HIV/AIDS, pregnant women living with HIV/AIDS, neonates and children born to HIV positive women. In addition, RWCA grantees and planning councils receive technical assistance in conducting and evaluating their programs.

Constituency Involvement: The input and guidance of PLWAs and affected communities is gathered through a variety of avenues. Constituents are represented on the HRSA AIDS Advisory Committee, RWCA planning councils, with the input of broad-based local representation, guide local prioritization of RWCA funds.

The development of evaluation measures is a participatory process whereby local groups assist in the development of self-assessment tools. Local participants have early and ongoing involvement in all phases of data collection design, planning, and implementation.

In addition, focus groups, workshops, and discussion groups of PLWAs, providers of HIV care, State and local officials, researchers, and national groups such as the Pediatric AIDS Foundation and the National Positive Youth Alliance review proposed policies, program directives, and planning and evaluation activities to ensure constituency input.

Unmet Need: Access to mental health and substance abuse services. Funds for existing projects are inadequate to meet rapidly growing caseloads and increased demand care and training. Meeting these will require collaborative efforts with NIMH and SAMSHA in addition to expanding programs in general and especially for adolescents such as mental health, substance abuse, and family case management services. For the RWCA Title IV, funds were available for only one third of grant applicants in FY 1995. There is also a need for increased access to 1% evaluation funds for service-related evaluations.

Moreover, 24 states lack comprehensive care systems for children, youth, women; funding of approximately \$1.8 million would support new planning and initial development projects in these states.

For frontline providers who may receive funding from several Federal Agencies, there is a need for improved coordination within and between Agencies. In addition, for example, to the lack of adequate resources for technical assistance and evaluation, there is also a need for improved planning and coordination of these activities between the various CARE activities and between Federal agencies.

National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96

Agency: Department of Health and Human Services, the Health Resources and Services Administration

Goal: To develop and evaluate innovative models of comprehensive managed care for persons living with HIV.

Objective 1: Develop models of comprehensive managed care networks that enroll a broad spectrum of primary care and psychosocial providers within the HIV continuum of care, and that provide patients and their families access to services.

Action Steps: Develop innovative models and disseminate results of evaluation.

Descriptions: Special Projects of National Significance (SPNS).

FY 95: \$2,092,302

FY 96: \$4,000,000

FY 97: \$????????

Populations Served: Persons living with HIV and their families.

Constituency Involvement: Primary care providers, community-based organizations, state and local health officials, Ryan White planning bodies, and persons living with HIV.

Unmet Need: There is a need for more effective linkages among community providers and financially stable medical sites.

Objective 2: Ensure that services provided under SPNS program are fully evaluated for both utilization and impacts and increase the evaluation capacity within community-based providers' organizations.

Action Steps: Increase emphasis on evaluation;

Increase the representation of evaluation researchers on review groups; and

Provide technical support for evaluation activities.

Descriptions: Evaluation of Special Projects of National Significance

FY 95: \$2,000,000

FY 96: \$4,000,000

FY 97: \$??????

Populations Served: SPNS grantees.

Constituency Involvement: Health care providers, evaluation researchers, and patient advocates.

Unmet Need: There is a need to develop more effective linkages between providers and evaluation researchers.

National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96

Agency: Department of Health and Human Services, the Substance Abuse and Mental Health Services Administration

Goal: To provide a range of high quality mental health services to people affected by or living with HIV and AIDS.

Objective 1: To change risk behaviors and prevent further HIV transmission, evaluate the effectiveness and efficiency of the different approaches or models used for organizing and providing those services, and determine the outcome of those services on the quality of life of the individuals served.

Action Steps: Increase compliance with medical treatment and enhance access to existing services;

Disseminate information about successful service models;

Develop and rigorously evaluate models for replication and integration into HIV/AIDS delivery systems; and

Increase productive work capacity as result of receiving services.

Descriptions: HIV/AIDS Mental Health Services Demonstration Program.

FY 95: \$1,500,000 (With \$1,400,000 from NIH and \$1,500,000 from HRSA)

FY 96: \$1,500,000 (With \$1,400,000 from NIH and \$1,500,000 from HRSA)

FY 97:

Populations Served: People living with or affected by HIV/AIDS including injection drug users, sex partners of injection drug users, sex workers, gay or bisexual men, and racial and ethnic minority populations.

Constituency Involvement: Health professionals, consumers, and community service providers.

Unmet Need: This collaborative effort has successfully enhanced the services rendered by providing comprehensive services to the populations served. However, additional financial resources could include other agencies, i.e. HUD, AHCPR in providing the client population with a spectrum of services relating to diverse needs.

Objective 2: To demonstrate the efficacy of outreach as an

intervention for facilitating access to substance abuse treatment for high risk and hard to reach substance abusers.

To demonstrate that comprehensive HIV outreach interventions affect behavior changes in diverse populations.

Action Steps: Identify chronic, hardcore, drug users and their sex and/or needle-sharing partners;

Facilitate entry into substance abuse treatment;

Provide a range of services including medical and diagnostic services for HIV, STDs, and TB;

Employ information-sharing, skills and other prophylactic means to affect behavior change; and

Evaluate program effectiveness.

Descriptions: HIV/AIDS Community Outreach Program.

FY 95: \$7,500,000

FY 96: \$7,500,000

FY 97:

Populations Served: Chronic, hard core substance abusers and their sex and/or needle-sharing partners, including those individuals who have severe drug problems, frequently inject heroin and/or cocaine and/or are poly drug users. There is also emphasis within various racial and ethnic groups, women, residents of public housing projects, and homeless individuals.

Constituency Involvement: Health professionals, consumers, and community service providers.

Unmet Need: Additional resources for medical treatment of HIV/AIDS, STDs, TB and other medical services would provide greater access to care through integration of substance abuse and medical care services.

National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96

Agency: Department of Health and Human Services, the Substance Abuse and Mental Health Services Administration

Goal: To improve HIV/AIDS training of clinicians.

Objective 1: Enhance mental health professionals' prevention and treatment efforts by training mental health care providers and other health care workers.

Action Steps: Assess neuropsychiatric/psychosocial aspects of HIV/AIDS to prevent the spread of HIV infection;

Establish linkages with health care providers;

Include alcohol and other drug (AOD) related HIV prevention in all training curriculums;

Train mental health professionals who serve people with serious mental illness;

Provide training about pre and post HIV antibody counseling and testing, physiological aspects of HIV/AIDS, in addition to culturally sensitive, linguistically and gender appropriate interventions and methodologies;

Address managed care and training issues; and

Evaluate the effectiveness of training techniques.

Descriptions: AIDS Health Care Worker Training.

FY 95: \$2,930,000

FY 96: \$2,930,000

FY 97:

Populations Served: HIV/AIDS mental health care providers whose client population may include gay and bisexual men, women, racial and ethnic minority groups, injecting drug users and their sex partners, sex workers, children, adolescents, and the sex partners of people with HIV/AIDS.

Constituency Involvement: Health professionals, consumers, and community service providers.

Unmet Need: Additional financial resources and increased collaboration with other Federal agencies would broaden the scope of the training to include all health professionals.

Objective 2: Provide training programs for health care professionals, modifying curricula and strengthening training opportunities in comprehensive care for people with or at risk for substance abuse, mental illness and infectious diseases including HIV and TB.

Action Steps: Train health care professionals to provide comprehensive services and care; and

Enhance curricula by including training for diverse populations with multiple risk factors and illnesses.

Descriptions: AIDS Training Grants.

FY 95: \$2,800,000

FY 96: \$0

FY 97:

Populations Served: People with or at risk for substance abuse, mental illness and/or transmission of HIV.

Constituency Involvement: Health professionals and consumers.

Unmet Need: Additional resources would strengthen the training opportunities for health care professionals and enhance services rendered for people with or at risk for substance abuse, mental illness, HIV, and other STDs.

National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96

Agency: Department of Health and Human Services, the Substance Abuse and Mental Health Services Administration

Goal: To improve the integration of substance treatment and primary medical care.

Objective: To demonstrate the effectiveness of fostering greater services integration by linking substance abuse treatment, primary medical care, mental health services, and HIV/AIDS, STD and TB services.

Action Steps: Develop and foster linkages among service providers; and

Evaluate the efficiency and effectiveness of linked, integrated services.

Descriptions: The Linkage Initiative.

FY 95: \$7,700,000

FY 96:

FY 97:

Populations Served: Injecting drug users and other high risk substance abusers and their sexual partners.

Constituency Involvement: Service providers and consumers

Unmet Need: This collaborative effort serves as catalyst for linking AOD treatment, mental health and primary care services, and services for HIV/AIDS, STDs and TB. Additional resources could join this effort with other agencies to enhance the services rendered.

National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96

Agency: Department of Housing and Urban Development

Goal: To increase the housing supply for persons with disabilities, including persons living with HIV and their families.

Objective 1: Increase the supply of permanent housing units for persons living with HIV.

Action Steps: Encourage HIV housing and program sponsors to apply for funds for projects for persons living with HIV.

Descriptions: Section 811 Supportive Housing Program for Persons with Disabilities.

FY 95: \$376,000,000 (Represents the full program appropriation; no set aside for persons with HIV is made.)

FY 96: \$258,000,000 (Represents the full program appropriation; no set aside for persons with HIV is made. \$25 million for increased contract terms only)

FY 97: \$196,000,000 (Part of Housing for Special Populations fund of \$769 million, i.e. elderly and disabled.)

Populations Served: Disabled person 18 years of age and older.

Constituency Involvement: Input received through local planning groups.

Unmet Need: Program can serve PWAs in project which may include persons with other disabilities; however, with the increasing number of persons living with HIV/AIDS, further housing resources will need to be sought.

Objective 2: Assist communities in providing local comprehensive systems of housing assistance and related services for persons who are homeless by increasing the supply, accessibility and appropriateness of housing and related supportive service options to address the needs of persons who are homeless and living with HIV/AIDS.

Action Steps: Ensure the availability of funds to support community-wide efforts to comprehensively address the needs for emergency, transitional and permanent supportive housing for person with HIV/AIDS.

Descriptions: Continuum of Care Homeless Assistance, including the Supportive Housing Program, Shelter Plus Care program, and

the Section 8 Moderate Rehabilitation for Single Room Occupancy Dwellings for Homeless Individuals program.

FY 95: \$1,100,000,000

FY 96: \$823,000,000

FY 97: \$1,120,000,000

Populations Served: Homeless persons and families, including persons with disabilities, such as persons living with HIV/AIDS.

Constituency Involvement: Communities participating in the development of coordinated and comprehensive systems of housing and care for persons who are homeless, include government agencies, nonprofit organizations, advocates, and consumers.

Unmet Need: In 1995, HUD made the largest ever award of Federal funds to address the needs of persons who are homeless to communities and projects which are part of comprehensive and coordinated systems of housing and care. Although 881 projects were funded with the \$904 million available in the competition, another 1,900 projects were not selected or funded due to the amount of funds available. These additional 1,500 projects requested about \$2 billion in assistance. No measure of the unmet needs of HUD's other programs are made, although programs which support community economic development, the availability of affordable housing and reduce the rent burdens on clients through rental assistance may have considerable amounts of unmet needs for persons living with HIV/AIDS.

National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96

Agency: Department of Housing and Urban Development

Goal: To increase the capacity of AIDS housing and service providers to develop, operate, and evaluate housing programs for persons living with HIV.

Objective: Increase the capacity of AIDS housing and service providers to develop, operate, and evaluate housing programs for persons living with HIV.

Action Steps: Ensure the availability of technical assistance and other support for nonprofit providers.

Authorize technical assistance activities in HUD programs for HIV-related nonprofit providers and grantees.

Descriptions: Technical assistance or other support for the development of program capacity.

FY 95: \$0

FY 96: \$0 (Some funding within homeless assistance grants and HOPWA funding.)

FY 97: \$0 (Some funding within homeless assistance grants and HOPWA funding.)

Populations Served: Homeless persons, including those living with HIV.

Constituency Involvement: HUD program grantees, including State and local governments, housing authorities and finance agencies and non-profit organizations that develop, provide or coordinate services for person receiving housing assistance, as well as advocates and consumers.

Unmet Need: There is a need to broaden and deepen the ability of AIDS housing and service providers and AIDS program grantees to expand the range of housing options, ensure quality and responsive programs and undertake evaluation efforts. This will become increasingly important as additional demands will be made on programs as the epidemic increases the number of persons living with HIV. No additional funds are requested as these activities are part of the functions of existing offices, such as the Office of HIV/AIDS Housing, Fair Housing and Equal Opportunities and other program offices.

National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96

Agency: Department of Housing and Urban Development

Goal: To increase the awareness of staff in public and private organizations to the general and unique needs of persons living with HIV.

Objective: Increase awareness regarding HIV among agency and other staff.

Action Steps: Authorize training activities in HUD programs for HUD staff, HIV-related nonprofit providers and grantees.

Descriptions: Training and support for HIV awareness.

FY 95: \$0

FY 96: \$0

FY 97: \$0

Populations Served: Public and private staff and persons at risk for HIV infection.

Constituency Involvement: HUD program grantees, including State and local governments, housing authorities and finance agencies and non-profit organizations that develop, provide or coordinate services for person receiving housing assistance, as well as advocates and consumers.

Unmet Need: Misinformation, prejudice and non-responsiveness continue in the operation of public and private housing programs and the general awareness of individuals in preventing the spread of HIV. The increasing numbers of persons living with HIV requiring housing assistance, will increase the challenges on service programs to be vigilant in ensuring that information is accurately communicated and efforts are in no manner prejudicial. No additional funds are requested as these activities are part of the functions of existing offices, such as the Office of HIV/AIDS Housing, Fair Housing and Equal Opportunities and other program offices.

Agency: Department of Housing and Urban Development

Goal: To increase the awareness and responsiveness of HUD programs that may target or incidentally assist persons living with HIV.

Objective: Ensure that the needs of persons living with HIV are addressed in HUD programs.

Action Steps: Designate an office with direct responsibility for programs and advocacy on AIDS issues.

Descriptions: Office on HIV/AIDS Housing

FY 95: \$0 (within current efforts)

FY 96: \$0 (within current efforts)

FY 97: \$0 (within current efforts)

Populations Served: Homeless persons, nonprofit organizations, government agencies, and HUD staff.

Constituency Involvement: HUD program grantees, including State and local governments, housing authorities and finance agencies and non-profit organizations that develop, provide or coordinate services for person receiving housing assistance, as well as advocates and consumers.

Unmet Need: Maintaining office functions that promote understanding of AIDS and the needs of persons living with HIV as well as support for programs that support these clients. More staff would allow even greater impact on HUD programs. No additional funds are requested as these activities are part of the functions of existing offices, such as the Office of HIV/AIDS Housing, Fair Housing and Equal Opportunities and other program offices.

National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96

Agency: Department of Justice

Goal: To provide education and training for law enforcement and social services agencies regarding victims of crime.

Objective: To improve trainees' interaction with the populations they serve, especially those who might have been exposed to the HIV virus or those who may be HIV positive.

Action Steps: Provide funds to the National Victims Center (NVC) under a cooperative agreement. (The NVC provides education, and sensitivity training to law enforcement personnel and social service agencies.)

Provide grant funds to the Educational Development Center (EDC) for training regarding hate/bias crimes. (The EDC trains law enforcement and social service agency personnel regarding procedures for identifying and handling hate crimes, including such crimes against those who are HIV positive or living with AIDS.

Descriptions: Provide grants and operate cooperative agreements.

FY 95: \$133,900

FY 96: Although no funds have been budgeted, the training for law enforcement and social services personnel was covered by the FY 95 budget and will continue.

FY 97: The department anticipates allocating additional funds for training.

Populations Served: Law enforcement and social service agencies are directly served. The crime victims who interact with these agencies benefit indirectly.

Constituent Involvement: Victims rights groups were consulted regarding the curriculum development for the training program.

Unmet Need: Additional resources to provide more regional training.

Agency: Department of Justice

Goal: To provide health care for prisoners with HIV/AIDS. Educate and counsel the inmate population about the transmission of HIV/AIDS and for the purpose of reducing the incidence of HIV transmission.

Objective: Provide counseling, education and treatment for prisoners.

Action Steps: Conduct random HIV testing on 10% of newly incarcerated inmates;

Provide pre- and post-test counseling for inmates;

Conduct HIV tests on new inmates where clinically indicated, provide HIV training and education for all newly committed inmates during their admission and orientation;

Provide additional HIV and infectious disease-related training annually to each incarcerated inmate who has a job-related potential exposure to bloodborne pathogens; and

Provide health care for inmates.

Descriptions: Provide testing, counseling, education, and health care for inmates.

FY 95: \$1,000,000 for prevention and \$500,000,000 for medical care

FY 96: \$1,000,000 for prevention and \$500,000,000 for medical care

FY 97: \$1,000,000 for prevention and \$600,000,000 for medical care

Population Served: Bureau of Prisons inmates.

Constituency Involvement: None.

Unmet Need: Funding for counseling and testing of all inmates.

National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96

Agency: Department of Veterans Affairs

Goal: To provide high quality, comprehensive care across the spectrum of HIV disease to all eligible veterans.

Objective 1: Assess and evaluate claims and, if in order, make disability compensation or pension payments to eligible veterans with HIV-related illnesses.

Action Steps: Implement published final regulatory criteria effective March 24, 1992, for evaluating manifestations of HIV-related illnesses.

Publish amendment to portion of Schedule for Rating Disabilities.

Objective 2: Assist Departmental training programs to ensure widespread awareness of VA policies related to HIV/AIDS.

Action Steps: Coordinate with other Departmental offices to facilitate HIV/AIDS training at all Veterans Benefits Administration facilities.

Conduct follow-up training on HIV/AIDS as new information becomes available.

Objective 3: Expand outreach efforts to increase awareness of VA's HIV/AIDS programs.

Action Steps: Include information on VA's HIV/AIDS-related policies and accomplishments at external presentations, i.e., service organization meetings, town meetings.

Objective 4: Provide HIV testing and counseling to high risk groups of patients and/or patients who request testing.

Action Steps: Provide HIV testing and counseling services available at every VA medical center and/or VA outpatient clinic throughout the system;

Train professional health-care staff to serve as HIV counselors and patient educators on HIV prevention and transmission;

Establish quality laboratory standards for HIV testing, including ELISA and Western Blot; and

Ensure implementation of policy prohibiting routine involuntary screening.

Objective 5: Protect patients rights to information and self-determination in HIV testing process.

Action Steps: Ensure that HIV testing is performed only with written informed consent, utilizing standardized written informed consent form, by law and policy.

Provide counseling and patient education on prevention and transmission performed by trained health-care professionals.

Provide patient education pamphlet explaining HIV testing in VA available.

Objective 6: Protect patients rights to confidentiality in HIV testing and/or infection.

Action Steps: Ensure that medical records of veteran tested for or infected with HIV subject to additional confidentiality (beyond Privacy Act), by law, regulation and policy.

Implement safeguards to assure that: veteran HIV testing or status is released only with patient's written authorization with exceptions to disclosure (public health agencies, spouse, sexual partners) only under specified conditions; VA staff's access to medical records only on "need to know" basis; and legal, clinical and administrative staff trained in confidentiality regulations and policy.

Objective 7: Protect patient's rights to non-discrimination in admission to or treatment in VA health-care facilities.

Action Steps: Ensure non-discrimination in admission and treatment on the basis of HIV status, established by law and policy.

Implement safeguards to assure that: access to medical treatment based on clinical judgment, not HIV status; legal, clinical and administrative staff trained in regulations and policy with periodic updates and consultation available; and patient representatives and clinical staff are available in all facilities for patient grievances.

Objective 8: Provide state-of-the-art medical treatment for patients with HIV infection or AIDS through professional health-care staff educated and current in state-of-the-art HIV/AIDS treatment and the availability of appropriate pharmaceuticals and therapeutics at health-care facilities.

Action Steps: Provide FDA approved pharmaceuticals and therapies at local medical centers, outpatient clinics or health-care facilities or referral medical centers in VHA networks.

Provide compassionate use and therapies under research protocols at referral or other medical centers and facilities throughout system.

Promote integration of clinical treatment and research in HIV/AIDS.

Establish and maintain "Centers of Excellence" for the care of HIV/AIDS patients utilizing multidisciplinary models of care.

Facilitate physician and other clinician participation in local and national educational programs, professional societies, local, state and national advisory groups.

Support on-going education and training of health-care and support staff throughout system.

Encourage establishment of formal and informal physician and clinician networks for treatment advice.

Objective 9: Provide full range of medical and psycho-social services to meet comprehensive care needs.

Action Steps: Provide specialty and subspecialty care in medicine, surgery, psychiatry, psychology, rehabilitation in medical centers and/or networks.

At medical center level, provide comprehensive social services and counseling including family, housing and community referrals.

Objective 10: Provide consultation on legal, clinical and policy issues related to the care of HIV-infected patients.

Action Steps: Address and or refer to the appropriate individuals, questions and inquiries from external agencies, field staff, and veterans on issues related to HIV infection and AIDS.

Maintain and establish, as needed, special advisory groups of interdisciplinary field experts to address problems or issues requiring national focus. Include veterans in deliberations, as appropriate.

National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96

Implement, through policy, guidelines and recommendations of CDC, PHS, OSHA and other Federal agencies specific to HIV/AIDS and bloodborne pathogens.

Objective 11: Assess the impact of the HIV/AIDS epidemic on VA health-care system for resource utilization and planning purposes.

Action Steps: Maintain confidential HIV/AIDS Registry of all patients treated in VA health-care facilities.

Evaluate workload distribution by medical center to determine geographical distribution.

Utilize workload information as validation tool in resource allocation process.

In conjunction with the resource allocation group, estimate future workload based on past and present figures.

Include special field advisory group in resource planning and management in the allocation process for HIV/AIDS care.

Objective 12: Participate in interagency planning on issues related to HIV/AIDS. Provide expertise, when requested, on special issues.

Action Steps: Cooperate and collaborate with other agencies such as CDC on special issues such HIV-infected health-care workers, when requested. Provide expertise from field.

Involve other agencies, as appropriate, on special issues in HIV/AIDS.

Utilize OSHA, HHS, CDC, FDA expertise on specific issues, as necessary.

Objective 13: Ensure that Federal, State, County and local officials are aware of Department policies, procedures, treatment of personnel and veterans with HIV/AIDS.

Action Steps: Monitor status of pending legislation for State, County and local officials.

Serve on committees that develop and review Department policies when requested.

Objective 14: Ensure Department policies and procedures comply

***National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96***

with Federal law.

Action Steps: Interpret Federal laws that impact on VA's HIV/AIDS program.

Provide legal advice and counsel to program officials.

Serve on committees that develop and review Department policies when requested.

Review new and updated policy directive on HIV/AIDS.

Descriptions: Medical care and services.

FY 95: \$281,000,000 *

FY 96: \$300,000,000 *

FY 97: \$310,000,000 *

* Resources for HIV/AIDS care are derived from the general Medical Care Budget. FY 1995 figures are reported expenditures. FY 1996 and FY 1997 are based on the projected number of patients by category or stage of disease and estimated resources required. The estimates are those contained in the President's budget.

Populations Served: Eligible HIV positive veterans.

Constituency Involvement: Eligible veterans through local medical centers and facilities.

Unmet Need: Advances in treatment through research and/or changes in prevention activities may require re-assessment of funding levels.

National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96

Agency: Corporation for National Service

Goal: To promote HIV/AIDS awareness and to provide respite care and other services to persons living with HIV and AIDS.

Objective 1: To promote HIV/AIDS awareness through training and other service activities.

Action Steps: Encourage all AmeriCorps programs to provide training in HIV/AIDS to AmeriCorps members and encourage them to become involved in HIV/AIDS service activities.

Program Description: Examples of AmeriCorps programs focusing on AIDS: The National AIDS Fund and the Birmingham AIDS Outreach Program.

FY 95: Part of overall operating cost.

FY 96: Part of overall operating cost.

FY 97: Part of overall operating cost.

Populations Served: Persons living with HIV and AIDS and AmeriCorps Members.

Constituency Involved: AmeriCorps Members and the public at large.

Unmet Needs: Without these programs, HIV/AIDS service providers would not be able to deliver services to as many people with HIV/AIDS.

Objective 2: To match volunteers from the National Senior Service Corps with persons living with HIV and AIDS for respite care and other services.

Action Steps: Through the Foster Grandparent program, provide foster and respite care, as well as counseling and living assistance for children with HIV/AIDS.

Through the Senior Companion Program, provide some persons living with HIV and AIDS with volunteers for respite care and living assistance.

Continue to provide some persons living with HIV and AIDS with health and nutrition services and respite care from the Retired and Senior Volunteer Program.

Program Description: An example of a program provided by senior volunteers include a program in Indianapolis where seniors visit

people living with AIDS that are confined to a hospice.

FY 95: Part of overall operating cost.

FY 96: Part of overall operating cost.

FY 97: Part of overall operating cost.

Populations Served: Persons living with HIV and AIDS.

Constituency Involved: National Senior Service Corps and people living with HIV and AIDS.

Unmet Needs: Without these programs, respite services to persons living with AIDS would be unavailable.

National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96

Agency: Office of Personnel Management

Goal: To implement and improve workplace policies and employee benefits.

Objective 1: Implement and improve workplace guidelines.

Action Steps: Publish and distribute OPM's "HIV/AIDS Policy Guidelines".

Publish and distribute OPM personnel manuals on related HIV/AIDS issues, such as information on accommodations for employees who are HIV positive and on educational resources.

Descriptions: Policy development.

FY 95: \$20,000

FY 96: \$15,000

FY 97: \$0 (Goal achieved)

Populations Served: Federal agencies and employees, including labor organizations.

Constituency Involvement: Federal agencies and employees, including labor organizations.

Unmet Need: None.

Objective 2: Improve life insurance benefits programs.

Action Steps: Distribute guidance on "living benefits" insurance benefits.

Develop and distribute guidance on viatical settlements.

Descriptions: Insurance programs.

FY 95: None.

FY 96: None.

FY 97: None.

Populations Served: Federal agencies and employees and retirees covered by the Federal Employees Group Life Insurance Program.

Constituent Involvement: Federal agencies and employees and retirees covered by the Federal Employees Group Life Insurance Program.

National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96

Unmet Need: None.

National AIDS Strategy, Appendix C: Care and Services
Draft for ONAP Review, 7.22.96

Agency: Social Security Administration

Goal: To provide access to benefits payable under the Social Security Act.

Objective: Expedite and facilitate the processing of all disability claims, including those filed based on an allegation of HIV disease.

Action Steps: Process HIV claims under high priority status using procedures for processing claims where there is an indication of terminal illness.

Revise as necessary SSA's adjudicative policies based on dynamic nature of HIV disease.

Expedite claims processing by streamlining disability claims procedures and help AIDS service providers assist clients applying for SSI.

Descriptions: Disability and Social Insurance Programs and Outreach Demonstration Program (ODP).

FY 95: 1,005,000 plus 433,000 for ODP

FY 96: 1,200,000

FY 97: Use OMB figure

Populations Served: People living with HIV eligible for Title II and/or Title XVI social security benefits.

Constituency Involvement: People living with HIV and AIDS and their caregivers and advocates, the medical community, national AIDS organizations, SSA employees, coordinating federal agencies.

Unmet Need: Outreach programs now reach only four states. Additional funding would expand outreach project.

Agency: Social Security Administration

Goal: To provide information regarding benefits payable under the Social Security Act.

Objective: Provide information to people living with AIDS (PWAs) and to the medical community regarding eligibility requirements and changes in SSA programs as they apply to PWAs.

Action Steps: Inform PWAs about disability programs and eligibility requirements through mass mailings, electronic bulletin boards and community based organizations.

Participate and exhibit at national conventions.

Train on disability programs.

Coordinate public information campaigns among Federal agencies and non-governmental organizations to disseminate information to more people more rapidly.

Descriptions: Public information campaigns.

FY 95: NA

FY 96: NA

FY 97: NA

Populations Served: Persons living with HIV and their caregivers and advocates, the medical community and federal agencies.

Constituent Involvement: PLAs, their caregivers and advocates; the medical community; national- and community-based AIDS organizations; coordinating federal agencies and SSA employees.

Unmet Need: Additional technical, clerical support to disseminate information to more people.

Agency: Department of Housing and Urban Development

Goal: Provide support and encourage the development of local programs that provide a comprehensive range of housing and related services for persons living with HIV.

Objective: Provide states and localities with resources to provide housing and related services under long-term comprehensive strategies for meeting the needs of persons living with HIV/AIDS.

Action Steps: Award grants, both formula-based and competitively-selected grants to support a broad range of housing and services to prevent homelessness of persons living with HIV/AIDS. Unmet need, see above.

Descriptions: Housing Opportunities for Persons with AIDS (HOPWA) Program, in coordination with other HUD resources (see other HUD goals).

FY 95: \$171,000,000

FY 96: \$171,000,000

FY 97: \$171,000,000

Populations Served: Low income persons living with HIV and their families.

Constituency Involvement: Communities participating in the Consolidated Planning Process will involve HIV/AIDS housing and services providers, advocates, and persons living with HIV.

Unmet Need: The HOPWA program can be estimated to serve about 50,000 persons living with HIV and their families. This includes about 35,000 units of housing assistance, mostly in the form of short-term payments and rental assistance. Up to 50 percent of persons living with HIV/AIDS are expected to need housing assistance of some kind during their lifetime; given that over 300,000 persons are living with AIDS, approximately 150,000 persons are expected to require housing assistance.

***The National AIDS Strategy, Appendix D: International Activities
Draft for ONAP Review: 7.22.96***

Agency: Department of Defense

Goal: To support leadership in the international community by sharing research methodologies and findings, observing host nation requirements for HIV testing and reporting, and supporting research at international sites with high prevalence or incidence of HIV and AIDS.

Objective: Participate in global surveillance initiatives and maintain current knowledge of host nation HIV screening and reporting requirements.

Action Steps: Determine the prevalence of HIV initiative, infections, and genotypes in geographic areas of military activity.

Coordinate with Department of State.

Descriptions: International efforts including the study of geographic distribution of genotypes at DoD overseas laboratories. Support for basic research on diagnostic tests and vaccines.

FY 95: \$1,500,000

FY 96: \$1,500,000

FY 97: \$1,200,000

Populations Served: Foreign national and active duty U.S. military personnel.

Constituent Involvement: Active duty military and foreign service national of DoD overseas laboratories.

Unmet Need: None.

***The National AIDS Strategy, Appendix D: International Activities
Draft for ONAP Review: 7.22.96***

Agency: Department of Health and Human Services, the Office of International Affairs

Goal: To support U.S. interests globally by serving as a policy and coordinating body for international activities supported by HHS, a liaison with other U.S. departments and agencies supporting international activities, and a liaison with foreign governments working with U.S.

Objective: Improve coordination among HHS and other Federally-supported international activities.

Action Steps: Establish and maintain communications with other departments and agencies supporting international activities.

Develop mechanism for tracking HHS-related international activities.

Descriptions: International activities mapping project.

FY 95: NA - HIV activities integrated into overall budget

FY 96: NA - HIV activities integrated into overall budget

FY 97: NA - HIV activities integrated into overall budget

Populations Served: Program planners and policy makers.

Constituency Involvement: ?????

Unmet Need: Staff to initiate and complete project.

The National AIDS Strategy, Appendix D: International Activities
Draft for ONAP Review: 7.22.96

Agency: U.S. Department of State

Goal: To promote more active involvement on HIV/AIDS issues by foreign governments.

Objective: Persuade foreign governments to increase national and global activities to stem the spread of HIV/AIDS and to mitigate its impact.

Action Steps: Overseas posts will communicate the major objectives of the U.S. International Strategy on HIV/AIDS to host country officials.

Description: Initiative to increase commitment of foreign leaders.

FY 95: Not applicable.

FY 96: Not applicable.

FY 97: Not applicable.

Population Served: Nations affected by HIV/AIDS, PWAs globally and populations threatened by HIV/AIDS.

Constituency Involved: U.S. State Department, foreign governments, NGOs and business groups.

Unmet Needs: Budget and personnel constraints limit the Department's ability to coordinate actions identified in the International Strategy on HIV/AIDS document.

***The National AIDS Strategy, Appendix D: International Activities
Draft for ONAP Review: 7.22.96***

Agency: U.S. Department of State

Goal: To enhance U.S. participation on HIV/AIDS issues internationally.

Objective 1: Address HIV/AIDS in all appropriate international fora.

Action Steps: Ensure that the U.S. International Strategy is promoted at relevant international meetings of the U.N. and other bodies. Convene interagency meetings to discuss the international calendar and to develop cohesive approaches to AIDS issues.

Description: Implementation of the U.S. International Strategy on HIV/AIDS.

FY 95: Not applicable.

FY 96: Not applicable.

FY 97: Not applicable.

Population Served: Nations affected by HIV/AIDS, PWAs globally and populations threatened by HIV/AIDS.

Constituency Involved: U.S. State Department and other federal agencies.

Unmet Needs: Budget and personnel constraints limit the Department's ability to coordinate actions identified in the International Strategy on HIV/AIDS document.

Objective 2: Assist U.S. agencies in improving responsiveness to a range of HIV/AIDS-related issues.

Action Steps: Address the issue of the spread of AIDS in international peacekeeping and humanitarian missions. Explore possibilities for closer collaboration with MDBs to stem the spread of AIDS.

Description: Improving U.S. responsiveness.

FY 95: Not applicable.

FY 96: Not applicable.

FY 97: Not applicable.

Population Served: Nations affected by HIV/AIDS, PWAs around the world and populations threatened by HIV/AIDS.

Constituency Involved: U.S. State Department and MDBs.

Unmet Needs: Budget and personnel constraints limit the Department's ability to coordinate actions identified in the International Strategy on HIV/AIDS document.

The National AIDS Strategy, Appendix D: International Activities
Draft for ONAP Review: 7.22.96

Agency: U.S. Department of State

Goal: To enhance awareness of implications of HIV/AIDS worldwide.

Objective 1: Heighten awareness of Congress as to implications of global HIV/AIDS on U.S. foreign policy.

Action Steps: Communicate to Congress the implications of global HIV/AIDS for foreign policy initiatives. Support biomedical research and international prevention efforts as means of reducing potential impact.

Description: Communicate implications of U.S. International Strategy on HIV/AIDS to Congress.

FY 95: Not applicable.

FY 96: Not applicable.

FY 97: Not applicable.

Population Served: Nations affected by HIV/AIDS, PWAs globally, populations threatened by HIV/AIDS and the U.S. Congress.

Constituency Involved: U.S. State Department.

Unmet Needs: Budget and personnel constraints limit the Department's ability to coordinate actions identified in the International Strategy on HIV/AIDS document.

Objective 2: Heighten awareness within the U.S. foreign service community and other U.S. agencies of the foreign policy implications of global HIV/AIDS.

Action Steps: Distribute International Strategy on HIV/AIDS to embassy personnel;

Hold workshop on the global implications of HIV/AIDS;

Use training sessions and individual briefings of foreign service personnel to discuss HIV/AIDS as a foreign policy concern;

Work with U.S.-based international businesses to gain a better understanding of the economic impact of global HIV/AIDS on U.S. business; and

Continue to include HIV/AIDS-related discrimination and human rights abuses in regular embassy reporting.

Description: Inform and educate U.S. foreign service personnel.

The National AIDS Strategy, Appendix D: International Activities
Draft for ONAP Review: 7.22.96

FY 95: Not applicable.

FY 96: Not applicable.

FY 97: Not applicable.

Population Served: Nations affected by HIV/AIDS, PWAs globally, populations threatened by HIV/AIDS and State Department foreign service personnel.

Constituency Involved: U.S. State Department.

Unmet Needs: Budget and personnel constraints limit the Department's ability to coordinate actions identified in the International Strategy on HIV/AIDS document.

The National AIDS Strategy, Appendix D: International Activities
Draft for ONAP Review: 7.22.96

Agency: U.S. Department of State

Goal: To support U.S. technical agencies.

Objective: Support U.S. technical agencies in fulfilling the international HIV/AIDS objectives as appropriate to their individual agency mandates.

Action Steps: Assist USG agencies in strengthening or establishing international research and training collaborations and in gaining approval for HIV/AIDS vaccine trials and other research efforts.

Description: Support for international research.

FY 95: Not applicable.

FY 96: Not applicable.

FY 97: Not applicable.

Population Served: Nations affected by HIV/AIDS, PWAs globally, populations threatened by HIV/AIDS, researchers and USG agencies.

Constituency Involved: U.S. State Department, USG agencies and researchers.

Unmet Needs: Budget and personnel constraints limit the Department's ability to coordinate actions identified in the International Strategy on HIV/AIDS document.

***The National AIDS Strategy, Appendix D: International Activities
Draft for ONAP Review: 7.22.96***

Agency: Department of the Treasury

Goal: To support developing international health programs, including HIV-related programs.

Objective: Work with the multilateral development banks (MDBs) to provide large-scale assistance for health projects, including HIV-related projects.

Action Steps: Through the Department's oversight authority over the multilateral development banks, assist in the provision of external financing for primary health and AIDS programs in the developing world.

Descriptions: Multilateral development bank provision of direct finance, technical assistance and policy advice, and MDB coordination of bilateral assistance efforts.

FY 95: Not applicable.

FY 96: Not applicable.

FY 97: Not applicable.

Populations Served: Developing countries.

Constituent Involvement: Recipient countries are actively involved in the preparation and implementation of MDB lending and technical assistance programs.

Unmet Need: ???

***The National AIDS Strategy, Appendix D: International Activities
Draft for ONAP Review: 7.22.96***

Agency: Peace Corps

Goal: To prevent transmission of HIV infection for Peace Corps Trainees and Volunteers.

Objective 1: Provide all trainees with comprehensive HIV/AIDS training during the preservice training period.

Action Steps: Develop training modules, train overseas medical staff, and educate trainees.

Descriptions: HIV/AIDS prevention training for Peace Corps Volunteers/Trainees.

Objective 2: Provide continued HIV education and counseling for Peace Corps Volunteers and Medical Staff.

Action Steps: Train OMS staff on communication and counseling skills;

Continue to educate volunteers about HIV/AIDS during inservice trainings and conferences;

Develop and distribute health newsletters;

Provide one-on-one counseling for volunteers on an as needed basis;

Disseminate videos, pamphlets, education material on HIV/AIDS prevention; and

Follow CDC guidelines on prevention of transmission in a medical setting.

Descriptions: Follow-up HIV training for volunteers and medical staff. Make condoms available and easily accessible for all volunteers.

FY 95: \$300,000

FY 96: \$100,000

FY 97: \$100,000

Populations Served: Peace Corps Volunteers/Trainees and medical staff.

Constituency Involvement: Peace Corps Volunteers/Trainees and Peace Corps Medical Staff.

Unmet Need: Due to budget constraints, Office of Medical Services (OMS) will only be able to provide courses for in-country Medical Staff every other year.

***The National AIDS Strategy, Appendix D: International Activities
Draft for ONAP Review: 7.22.96***

Agency: Peace Corps

Goal: To enhance the understanding of HIV/AIDS and transfer skills for prevention to the communities and countries in which Peace Corps Volunteers serve.

Objective: Provide quality programming and training on HIV/AIDS prevention as a primary project in six countries.

Provide quality programming and training to ten percent of all Volunteers to work in HIV/AIDS as a secondary activity.

Support on-going education and training of Associate Peace Corps Directors (APCD) in charge of programming at country level.

Liaison with other organizations working in HIV/AIDS both internationally and domestically.

Action Steps: Recruit 50 Volunteers to work in HIV/AIDS as their primary job;

Train 50 new Volunteers and 45 second year Volunteers in HIV/AIDS, language and cross-cultural skills;

Support 100 Volunteers to work in HIV/AIDS as their primary assignment;

Support the development of projects and training curriculum;

Support workshops for APCDs in three regions;

Provide expert consultants for the development of projects and training; and

Support attendance at international and national conferences and workshops on HIV/AIDS and share information.

Descriptions: HIV/AIDS prevention activities in developing countries around the world.

FY 95: \$4,500,000

FY 96: \$5,000,000

FY 97: \$5,000,000

Populations Served: Communities in developing countries, women and youth.

Constituency Involvement: Peace Corps designs all programs in

conjunction with the beneficiary population.

Unmet Need: There is higher demand for Peace Corps Volunteers than the agency can meet, and this is particularly true for program areas such as HIV/AIDS.

Agency: U.S. Agency for International Development

Goal: To achieve sustainable reduction in sexually transmitted infections (STIs)/HIV transmission among key populations.

Objective 1: Develop and test new interventions and methods to prevent transmission and mitigate impact of the epidemic.

Action Steps: Support research to identify activities that immediately and directly influence the effectiveness of existing programs.

Undertake activities that enable women to reduce the risk of HIV infection.

Undertake pilot projects and research to mitigate the impact of HIV in severely affected areas.

Undertake activities that support the public health infrastructure and utilization of HIV vaccines.

Description: Development and improvement of women's access to female controlled barrier methods. Improvement of STD/HIV prevention interventions and technologies for STD management. Support of studies that enhance understanding of behaviors and epidemiology, mitigate the impact of HIV/AIDS on communities. Facilitate opportunities for international field trials of promising vaccines.

Population Served: Persons living in USAID's HIV/AIDS emphasis countries.

Constituency Involvement: USAID agency employees, developing country representatives, community representatives, PVO/NGO donors, multilateral donors, and bilateral donors.

Unmet Needs: Given the limited resources available for international development assistance, it is not possible for USAID to meet all the needs in this area.

Objective 2: Policy reform addressing social, cultural, regulatory and economic issues related to HIV/AIDS and other STIs.

Action Steps: Conduct policy dialogue with decision makers to encourage a high-level multi-sectoral coordinated response to HIV/AIDS.

Address resource issues and long-term sustainability at all levels.

Address the social and cultural impediments to the successful implementation of HIV/AIDS programs.

Develop tools and complete research to serve policy dialogue and reform.

Description: Increase the use of methods aimed at reducing perinatal and parenteral HIV transmission. Coordinate effective donor responses and leveraged funding. Support international and regional multi-sectoral approaches and mobilize the private sector. Support decision-makers addressing difficult social, cultural, and religious issues. Continue to develop and use tools such as simulation modelling to describe the socio-economic impact of the epidemic.

Population Served: Persons living in USAID's HIV/AIDS emphasis countries.

Constituency Involved: USAID agency employees, developing country representatives, community representatives, PVO/NGO partners, multilateral donors and other bilateral donors.

Unmet Needs: Given the limited resources available for international development assistance, it is not possible for USAID to meet all the needs in this area.

Objective 3: Develop and implement HIV/AIDS prevention programs that utilize proven interventions to prevent transmission.

Action Steps: Promote safer sexual behavior through information, education, and communication.

Increase the demand for, access to, and use of condoms.

Control STIs by improving STI with diagnosis and treatment services and by education of persons with STIs.

Description: Improvement of social and cultural commitment to HIV/AIDS prevention. Strengthening programs to create a more supportive environment for behavior change, improving the quality of diagnosis and treatment, and increasing access to services including counseling and training for care providers, and facilitating the procurement of therapies.

Population Served: Persons living with AIDS in USAID HIV/AIDS

emphasis countries.

Constituency Involved: USAID agency employees, developing country representatives, community representatives, PVO/NGO partners, multilateral donors and other bilateral donors.

Unmet Needs: Given the limited resources available for international development assistance, it is not possible for USAID to meet all the needs in this area.

Objective 4: Enhance capacity of public, private NGO and community based organizations to design, implement and evaluate effective HIV/STI prevention and care programs.

Action Steps: Improve policy reform, research capability, logistics systems, and use of local and regional NGO networks.

Enhance the technical and managerial capability of indigenous NGOs and PVOs to design, implement and evaluate HIV/STI projects in all HIV/AIDS emphasis countries.

Strengthen local and regional networks of NGOs involved in HIV prevention, care and advocacy in at least six countries.

Assess and strengthen host country capacity for HIV/STI prevention research.

Disseminate models of home and community based delivery of HIV/STI care.

Description: Support for USAIDS' response to HIV/AIDS in developing countries, the Paris Summit Initiative, and the Greater Involvement of Persons Infected and Affected by HIV/AIDS (GIPA). Provide support for and strengthen linkages between indigenous NGOs and U.S. domestic PVOs, NGOs, and ASOs. Concentrate bilateral and care resources on selected emphasis countries to assure comprehensive programs; strengthen trans-national and regional activities in prevention and research through the "areas of affinity" concept. Continue collaboration with and support for efforts of multi-lateral organizations such as UNAIDS, WHO, UNDP, ENFPA, UNICEF, and the U.S.-Japan Common Agenda for HIV/AIDS prevention.

FY 95: \$119,000

FY 96: \$114,000

FY 97: \$114,000

Population Served: Persons living in USAID's HIV/AIDS emphasis

countries.

Constituency Involved: USAID agency employees, developing country representatives, community representatives, PVO/NGO partners, multilateral donors and other bilateral donors.

Unmet Needs: Given the limited resources available for international development assistance, it is not possible for USAID to meet all the needs in this area.

***The National AIDS Strategy, Appendix D: International Activities
Draft for ONAP Review: 7.22.96***

Agency: U. S. Information Agency

Goal: To increase understanding of and support for U.S. Government (USG) policies and programs on HIV/AIDS among foreign publics.

Objective 1: To provide accurate information on USG policy and programs to key foreign audiences.

Action Steps: Disseminate information via multi-language television, radio and texts distributed directly and through overseas posts and reference centers, tours and briefings for foreign journalists and health policy officials, and public affairs campaigns that support specific USG initiatives in foreign countries.

Description: Information on USG policy and programs.

FY 95: \$350,000

FY 96: \$325,000

FY 97: \$325,000

Population Served: Policy makers, academics, journalists, researchers and Non-governmental Organizations (NGO) leaders.

Constituency Involvement: USG officials, academics/researchers and NGO leaders.

Unmet Needs: Lack of technology in many underdeveloped countries may prohibit information from reaching key audiences.

Objective 2: To give foreign decision makers a first-hand experience with U.S. policy and programs - public and private, national and local - to address the HIV/AIDS pandemic and encourage exchange with their U.S. counterparts.

Action Steps: Sponsor multi-regional, regional and individual International Visitor Programs, focusing specifically on HIV/AIDS issues and as part of programs on substance abuse, civil society, human rights and community health.

Description: International Visitors Program.

FY 95: \$240,000

FY 96: \$200,000

FY 97: \$200,000

Population Served: Health policy makers and NGO leaders.

Constituency Involvement: U.S. NGOs, state, local and federal agencies and academic/research institutions.

Unmet Needs: The program is currently very limited, only allowing for 31 health policy officials and community leaders from 24 countries to visit the United States.

**National AIDS Strategy,
Appendix E: Translation of Research into Practice
Draft for ONAP Review, 7.22.96**

Agency: Department of Health and Human Services, the Agency for Health Care Policy and Research

Goal: To expedite the dissemination of data from research.

Objective 1: To provide accurate information concerning current Federally approved treatments for HIV-related conditions.

Action Steps: Through the use of reference specialists, provide appropriate treatment information to callers, drawing on NLM's database of AHCPR guidelines, in addition to NIH, CDC and other Federal agency guidelines and consensus statements.

Descriptions: AIDS Treatment Information Service

FY 95: \$75,000

FY 96: \$0

FY 97: \$0

Populations Served: HIV-positive individuals, primary care practitioners, case managers, and allied health professionals.

Constituency Involvement: HIV-positive individuals and advocacy groups as well as health care professionals.

Unmet Need: N/A

Objective 2: To provide accurate information to service providers and consumers concerning management of early HIV infection.

Action Steps: A panel of experts reviewed relevant literature and summarized findings into specific clinical practice guidelines, which stress the importance of preventing HIV-related opportunistic infections and the link between prevention and early diagnosis. Approximately 2.7 million copies of guideline-related documents have been distributed.

Descriptions: Dissemination of AHCPR's HIV-Related Clinical Guidelines.

FY 95: \$60,000

FY 96: \$0

FY 97: \$0

Populations Served: Clinical practitioners, individuals with HIV infection, and those persons caring for persons with HIV.

**National AIDS Strategy,
Appendix E: Translation of Research into Practice
Draft for ONAP Review, 7.22.96**

Constituency Involvement: Clinicians, HIV positive persons, and caregivers.

Unmet Need: N/A

Objective 3: To assess effective and ineffective dissemination strategies employed by community-based HIV education programs.

Action Steps: Examined organizational strategies used by several community-based HIV education agencies. Completed in FY 96.

Descriptions: Effective Strategies of AIDS Programs in San Francisco.

FY 95: \$0

FY 96: \$0

FY 97: \$0

Populations Served: Community-based HIV education agencies in San Francisco

Constituency Involvement: Advocacy organizations and persons with HIV were included in the research.

Unmet Need: N/A

Objective 4: This guide and related materials will inform pregnant women with HIV about the use of zidovudine (AZT) for the prevention of perinatal HIV infection.

Action Steps: Developed guide and related materials which describe the recommendations of the PHS Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of HIV, based on results of AIDS Clinical Trials Group 076. Provided the information in a format and reading level that consumers can comprehend.

Descriptions: Development of Consumer Guide on Use of Zidovudine for the Prevention of Perinatal HIV Infection (076 Guide).

FY 95: \$15,000

FY 96: \$0

FY 97: \$0

Populations Served: Pregnant women and women of child-bearing age who have HIV.

*National AIDS Strategy,
Appendix E: Translation of Research into Practice
Draft for ONAP Review, 7.22.96*

Constituency Involvement: HIV infected individuals and advocacy groups are involved in the development and review of the guide. The guide is cosponsored by multiple Federal and non-Federal agencies.

Unmet Need: N/A

**National AIDS Strategy,
Appendix E: Translation of Research into Practice
Draft for ONAP Review, 7.22.96**

Agency: National Institutes of Health

Goal: To support the dissemination and transfer of HIV-related research information to researchers, health care providers, HIV-related service providers, and HIV-infected individuals and their advocates.

Objective 1: Support the effective dissemination and utilization of HIV/AIDS information to all constituent communities of NIH.

Description: Effective Communication: Exchange of information about basic, clinical, and behavioral HIV/AIDS research finds is essential to progress in research and ultimately to improved care and treatment for HIV-infected people. The traditional methods of reporting ongoing studies and research results in peer-reviewed journals and at scientific meetings may be slow and may reach only limited audience. Health educators, health care providers, and patients, particularly those in underserved communities, need to know the results of clinical and prevention intervention studies, state-of-the-art recommendations, and the most up-to-date standards of health care. This information should be timely, include discussion of the potential implications of research findings for patient care, and should be in a form that audiences can use. The latest computer and information technologies should be exploited whenever appropriate. The findings resulting from communications research should be incorporated into the strategies to carry out this objective.

Objective 1: Rapidly disseminate new research findings with information on their potential implications on prevention, care, and treatment of HIV-infected individuals.

Expand access to current treatment and patient management guidelines including state-of-the-art care and information on clinical trials using multiple technologies such as, but not limited to, on-line access AIDSTRIALS and AIDSDRUGS data bases) and voice access (HIV/AIDS Treatment Information Service and the AIDS Clinical Trials Information Service).

Improve current and develop and evaluate new techniques for the two-way communication of information to scientific and lay audiences, particularly to hard-to-reach populations.

Support community groups to access HIV/AIDS information resources in their development of educational materials.

*National AIDS Strategy,
Appendix E: Translation of Research into Practice
Draft for ONAP Review, 7.22.96*

Develop and disseminate educational information. Enhance understanding of HIV and basic and clinical research processes by health care providers, community-based HIV/AIDS service organizations, and persons with HIV/AIDS.

Develop mechanisms for rapidly disseminating information on research in progress to the research community in order to increase collaboration, reduce duplication of effort, and enhance the discovery process.

Enhance communication with the pharmaceutical industry concerning research on the development of therapeutics and vaccines.

Communicate and exchange information internationally on topics such as prevention and treatment information, patient management guidelines, and research results that impact on the care of HIV-infected individuals, particularly in developing countries.

Support the exchange of basic, clinical, and behavioral research information at community, regional, national, and international conferences and workshops.

Provide on-line, in advance when possible, the full text of abstracts and other information from scientific meetings.

Collect, archive, and make available existing data from NIH-supported basic and applied research for secondary data analysis.

Disseminate widely information concerning specimen repositories, including existing repositories, specimens available and relevant information concerning cohorts, contact people, and the process for obtaining access to samples.

Evaluate the effectiveness of communication efforts by appropriate means, including obtaining feedback from target audience members and information dissemination intermediaries.

Objective 2: Support research to identify existing gaps in communications approaches, identify existing strategies that are effective, and develop and test new and innovative communication strategies that will improve access to and use of state-of-the-art HIV information by all relevant audiences.

Description: Research: Past assessments have identified important information needs and barriers for relevant target audiences such as health care providers, service providers, people with HIV and their advocates, at-risk populations, basic and applied

**National AIDS Strategy,
Appendix E: Translation of Research into Practice
Draft for ONAP Review, 7.22.96**

researchers, and the general public, and although significant communications efforts have been initiated, some communities still may not be (1) receiving needed information, (2) receiving information in a context appropriate for the audience, (3) comprehending the information, or (4) translating the information into action. New approaches are needed to ensure that the communication of information resulting from research is optimally effective.

Action Steps: Develop, test and evaluate innovative strategies for effectively reaching scientific audiences with relevant HIV information.

Investigate how and under what circumstances different communication and dissemination strategies influence the adoption of scientifically based HIV behavior change interventions and clinical practice activities in various populations.

Identify obstacles to information dissemination and develop and test possible ways to overcome these obstacles.

Assess the information needs of, and sources of information used by, various audiences, including biomedical and behavioral research communities, health care providers, service providers, people with HIV and their advocates, at-risk populations, and the general public.

Investigate the adoption of new technologies for disseminating basic and applied research findings.

Develop, improve, and evaluate the interface between human factors and emerging technologies for information exchange in HIV/AIDS.

Objective 3: Develop, implement, and evaluate mechanisms that promote coordination and collaboration on all current HIV/AIDS communication activities among NIH ICDs and with other Federal and non-Federal groups.

Description: Coordination: The scientific and lay communities look to the NIH as a central source of information on HIV/AIDS. Since multiple NIH ICDs disseminate HIV/AIDS information to these communities, coordination of efforts is essential. In order to make more effective use of limited Federal dollars, increase efficiency, make better use of new technologies, and ensure credibility with the scientific and lay communities, there must be more collaboration and better coordination of communication

**National AIDS Strategy,
Appendix E: Translation of Research into Practice
Draft for ONAP Review, 7.22.96**

activities within the NIH and between the NIH and other Federal Agencies, community groups, universities, and the private sector.

Action Steps: Build ongoing partnerships between community-based organizations and basic, clinical, and behavioral researchers through both the intramural and extramural research programs to encourage exchange of information and experience throughout the research process to enhance research, treatment, and prevention efforts. For example, this could be accomplished through requirements in appropriate funding proposals to establish appropriate communication and coordination.

Promote closer interagency collaboration within PHS on information dissemination programs.

Coordinate collaboration among all ICDs in the provision of information about their clinical trials for HIV/AIDS to the AIDS Clinical Trial Information Service.

Maintain an interface with the Cancer Information Service and PDQ to provide information on clinical trials for AIDS-related malignancies.

Expand the development and use of HIV/AIDS resource on the Internet to facilitate domestic (NIH and non-NIH) and international research collaboration and data sharing.

Continue collaborations with the United Nations/World Health Organization (WHO) AIDS program, the Pan American Health Organization (PAHO), and international AIDS agencies or societies to obtain and disseminate information about international clinical trials.

Collaborate with public and health sciences libraries to facilitate community group access to needed information.

Work within HHS, including HCFA, and with the private sector in the development of medical standards of care for determining guidelines for reimbursement.

FY 95: \$16,153,000

FY 96: \$17,912,000

FY 97: \$17,694,000

Populations Served: All populations.

Constituency Involvement: Researchers, clinicians, community and

*National AIDS Strategy,
Appendix E: Translation of Research into Practice
Draft for ONAP Review, 7.22.96*

patient representatives, and NIH-affiliated advisory councils and committees.

Unmet Needs: The NIH FY 1996 Plan and Budget Estimate for Scientific Opportunities in HIV-Related Research identified areas for further productive research in this area in the amount of \$833,000 over the FY 97 figure.

The National AIDS Strategy, Appendix F: Civil Rights
Draft for ONAP Review: 7.22.96

Agency: Department of Justice

Goal: To enforce HIV-related civil rights laws and heighten issue awareness.

Objectives: Prevent discrimination on the basis of real or perceived HIV status.

Action Steps: Enforce civil rights laws and inform and educate the public.

Descriptions: Litigate HIV-related civil rights cases involving housing discrimination and discrimination in the provision of services.

Provide information via the Americans with Disabilities Act (ADA) information line and provide technical assistance to state and local governments, Federal agencies and other entities and individuals having rights and responsibilities under Titles II and III of the ADA.

Developed and disseminated ADA questions and answers intended for persons who are HIV positive or living with AIDS to 5,000 HIV/AIDS service providers.

FY 95: Information line \$350,000; other activities part of overall operating budget.

FY 96: Information line \$350,000; other activities part of overall operating budget.

FY 97: The President's 1997 budget requests a 3.9% increase for ADA enforcement. Baseline number?

Populations Served: Victims of HIV/AIDS discrimination, Federal, state and local agencies, businesses and general populace.

Constituency Involvement: In addition to having access to the ADA information line, AIDS-related disability groups are sent the Justice Department's quarterly update on ADA enforcement activities and any relevant press releases on the Department's HIV-related anti-discrimination activities.

Unmet Need: Funds for attorneys for additional litigation. Public education and technical assistance for health care and day care providers regarding their ADA obligations to persons with HIV.

The National AIDS Strategy, Appendix F: Civil Rights
Draft for ONAP Review: 7.22.96

Agency: Department of Labor

Goal: To provide protection for people living with HIV and AIDS from discrimination in the workplace.

Objective: Under the Rehabilitation Act of 1973 provide protection for persons living with HIV and AIDS from discrimination in the workplace.

Action Steps: Establish policies under Section 503 of the Rehabilitation Act of 1973 providing for processing and investigating complaints filed by persons living with HIV and AIDS.

Descriptions: Protection from discrimination in workplace.

FY 95: Part of overall operating budget.

FY 96: Part of overall operating budget.

FY 97: Part of overall operating budget.

Populations Served: Persons living with HIV and AIDS.

Constituency Involvement: Persons living with HIV and AIDS and Department of Labor staff.

Unmet Need: Current resource levels permit satisfactory processing of received cases.

Agency: U.S. Equal Employment Opportunity Commission

Goal: As part of EEOC's overall enforcement goal to eliminate employment discrimination against persons with HIV disease.

Objective: Enforce Title I of the Americans with Disabilities Act (ADA), which protects job applicants and employees with HIV disease from employment discrimination.

Action Steps: Receive, investigate, and resolve ADA discrimination complaints from job applicants and employees with HIV disease;

Litigate select cases involving employment discrimination against persons with HIV disease; and

Educate the public regarding ADA's protections for job applicants and employees with HIV disease.

Descriptions: Enforcement of Title I of the ADA.

FY 95: Part of EEOC's general operating budget.

FY 96: Part of EEOC's general operating budget.

FY 97: Part of EEOC's general operating budget.

Populations Served: Job applicants and employees with HIV disease.

Constituency Involvement: Ongoing communication with AIDS-related disability groups.

Unmet Need: An increase in the Commission's investigative and legal staff would provide for quicker resolution of all EEOC complaints, including HIV-related complaints brought under the ADA.


The National Strategy for HIV and AIDS

Draft for Department of Health and Human Services Review: 6.11.96

***IV. FIGURES, ACRONYMS, AND MEMBERS OF THE INTERDEPARTMENTAL TASK
FORCE ON HIV AND AIDS***

Figure 1 Death Rates from Leading Causes of Death in Persons Aged 25-44 Years,
USA, 1982 -1993

Death Rates from Leading Causes of Death in Persons Aged 25-44 Years, USA, 1982-1993



National Vital Statistics

*Provisional data

CDC

The National Strategy for HIV and AIDS
Draft for Department of Health and Human Services Review: 6.11.96

Figure 2 Cumulative U.S. AIDS Cases: 2/83 through 12/94

Cumulative U.S. AIDS Cases as of 2/83 N~1,000




Each point = 30 cases

Cumulative U. S. AIDS Cases as of 5/85 N~10,000




Each point = 30 cases

Cumulative U.S. AIDS Cases as of 7/89 N~100,000



Each point = 30 cases

Cumulative U. S. AIDS Cases as of 12/94 N~440,878



Each point = 30 cases

The National Strategy for HIV and AIDS
Draft for Department of Health and Human Services Review: 6.11.96

Acronym List

ACTG	AIDS Clinical Trial Group
ADA	Americans with Disabilities Act of 1990
ADC	AIDS Dementia Complex
ACTIS	AIDS Clinical Trials Information Service
ADAP	AIDS Drug Assistance Programs
AETC	AIDS Education Training Center
AHCPR	Agency for Health Care Policy and Research
AIDS	Acquired Immune Deficiency Syndrome
AOD	Alcohol and other drugs
ASO	AIDS Service Organization
ATIS	HIV/AIDS Treatment Information Service
ATOD	Alcohol, tobacco, and other drugs
AZT	
BOP	Bureau of Prisons
BRTA	Business Responds to AIDS
CARE	Ryan White Comprehensive AIDS Resources Emergency Act
CDBG	Community Development Block Grant
CDC	The Centers for Disease Control and Prevention
CMV	Cytomegalovirus
CNS	Central Nervous System
CPCRA	Terry Bein Community Programs for Clinical Research on AIDS
DEA	Drug Enforcement Agency
DHHS	Department of Health and Human Services
DOD	Department of Defense
DOJ	Department of Justice
DOL	Department of Labor
EDC	Educational Development Center
EEOC	Equal Employment Opportunity Commission
ENFPA	
FDA	Food and Drug Administration
FBI	Federal Bureau of Investigation
GCRC	General Clinical Research Centers Program
GIPA	Greater Involvement of Persons Infected and Affected by HIV/AIDS

The National Strategy for HIV and AIDS

Draft for Department of Health and Human Services Review: 6.11.96

HCFA	Health Care Financing Administration
HIV	Human Immunodeficiency Virus
HOPWA	Housing Opportunities for Persons with AIDS
HRSA	Health Resources and Services Administration
HSV	Herpes Simplex Virus
HUD	Department of Housing and Urban Development
ICD	Institute(s), Center(s), Division(s)
IDTF	Interdepartmental Task Force on HIV and AIDS
IHS	Indian Health Service
INS	Immigration and Naturalization Service
IOM	Institute of Medicine
JMD	Justice Management Division
LRTA	Labor Responds to AIDS
MAC	<i>Mycobacterium Avium</i> Complex
NCRR	National Center for Research Resources
NGO	Non-governmental Organization
NIDA	National Institute on Drug Abuse
NIH	National Institutes of Health
NREN	National Research and Education Network
NVC	National Victims Center
OAR	Office of AIDS Research
OI	Opportunistic Infection
OMB	Office of Management and Budget
ONAP	Office of National AIDS Policy
PAC	Presidential Advisory Council on HIV and AIDS
PCP	<i>Pneumocystis carinii</i> pneumonia
PHS	Public Health Service
PLWH	Persons living with HIV
PSA	Public Service Announcement
PVO	Private Voluntary Organization
PWA	Person with AIDS
RFIP	Research Facilities Infrastructure Program (NIH)
RPRC	Regional Primate Research Center (NIH)
RWCA	Ryan White Comprehensive AIDS Resources Emergency (CARE) Act

The National Strategy for HIV and AIDS

Draft for Department of Health and Human Services Review: 6.11.96

SAMHSA	Substance Abuse and Mental Health Services Administration
SPF	Specific Pathogen-Free
SPNS	Special Projects of National Significance
SSA	Social Security Administration
SSI	Supplemental Security Income
STD	Sexually transmitted disease
STI	Sexually transmitted infection
TA	Technical Assistance
TB	<i>Mycobacterium tuberculosis</i>
UNAIDS	United Nations Programme on AIDS
UNDP	
UNICEF	
USAID	U.S. Agency for International Development
USIA	U.S. Information Agency
USMS	U.S. Marshals Service
VA	Department of Veterans Affairs
WHO	World Health Organization

III. APPENDICES

DHHS Appendices:

The Administration for Children and Families (ACF)
The Agency for Health Care Policy and Research (AHCPR)
The Centers for Disease Control and Prevention (CDC)
The Food and Drug Administration (FDA)
The Health Care Financing Administration (HCFA)
The Health Resources and Services Administration (HRSA)
The Indian Health Service (IHS)
The National Institutes of Health (NIH)
The Office of International Affairs (OIA)
The Office of Population Affairs (OPA)
The Substance Abuse and Mental Health Services Administration (SAMSHA)